[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Axcentria Pharmaceuticals, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":402},{"warningLetters":4,"total":401},[5,32,52,71,93,115,134,154,172,193,213,226,249,267,289,309,330,351,370,386],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},870,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-27T04:00:00Z\">05\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-13T04:00:00Z\">05\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faace-pharmaceuticals-inc-701310-05132025\">AACE Pharmaceuticals, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-72\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Atul B. Mehta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President, Co-Chairman, and Co-Founder \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AACE Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15 Gardner Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fairfield\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-72\u003C\u002Fp>\u003Cp>May 13, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Mehta:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AACE Pharmaceuticals, Inc., FEI 3013433273, at 15 Gardner Road, Fairfield, from November 12 to 22, 2024, after an FDA inspection revealed violative conditions at Brassica Pharma Private Limited, a contract manufacturing organization (CMO) used to manufacture ophthalmic drugs for AACE Pharmaceuticals, Inc.\u003C\u002Fp>\u003Cp>The FDA inspection of this foreign facility revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21, Code of Federal Regulations, Parts 210 and 211 (21 CFR Parts 210 and 211), causing these drug products to be adulterated, including within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>The inspection of your facility revealed that you operated as a distributor of AACE Pharmaceuticals brand name products, including Lubricant PM Ointment. Your receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c), and your introduction into interstate commerce of adulterated drugs violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Inspection of Your CMO\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>An inspection of Brassica Pharma Private Limited (“Brassica”), FEI 3014129013, conducted from January 15 to 19, 2024, revealed multiple CGMP violations, including but not limited to poor aseptic practices for the manufacture of sterile drugs; fabrication of microbiology laboratory records; microbial recoveries of incubating samples from ISO 5 manufacturing areas and sterility tests exhibiting turbidity during incubation; inadequate media fill program and airflow visualization studies; and use of ripped and visibly dirty gowning in the aseptic processing areas. These CGMP violations render the products manufactured by Brassica adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>On January 30, 2024, Brassica was placed on Import Alert 66-40 and recalled all drug products within expiry on February 22, 2024. On July 11, 2024, Brassica received a warning letter (Warning Letter #320-24-52).\u003C\u002Fp>\u003Cp>\u003Cstrong>Receipt and Distribution of Adulterated Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection of your firm and review of your import records indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipments of AACE Pharmaceuticals Lubricant PM Ointment were imported from a third-party, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured by your CMO Brassica Pharma Private Limited, received by AACE Pharmaceuticals, and further distributed to customers. Your receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c), and your introduction into interstate commerce of adulterated drugs violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Inspection of AACE Pharmaceuticals, Inc.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your December 11, 2024, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your ophthalmic drug product, Lubricant PM Ointment, is intended to be sterile. Your firm utilized a CMO to manufacture your ophthalmic drug products. However, your quality unit failed to have adequate supplier qualification procedures to ensure that the drug products received from your CMO were manufactured in compliance with CGMP prior to being distributed in the United States.\u003C\u002Fp>\u003Cp>For example, our investigators observed that your firm identified several CGMP deficiencies with Brassica in September 2020, such as a failure to maintain raw testing data. Despite identifying these deficiencies, your firm qualified Brassica as an approved CMO. Furthermore, you requalified Brassica in 2023, without evaluating whether subsequent corrective actions and preventive actions adequately addressed the identified deficiencies.\u003C\u002Fp>\u003Cp>Your firm’s quality unit released Lubricant PM Ointment for distribution without adequate procedures to ensure that the ophthalmic drug products produced for your firm met appropriate quality attributes.\u003C\u002Fp>\u003Cp>In your response, you state that your procedures have been revised to assess CGMP findings of your CMOs, and that your Quality Assurance must evaluate corrective action and preventive action (CAPA) plans implemented by CMOs.\u003C\u002Fp>\u003Cp>Your response is inadequate. While you have revised your procedures, you did not provide sufficient details on how you will assess findings that include CGMP deficiencies. Your procedure lacks a process for disqualifying CMOs or maintaining disqualification across product lines. Also, you did not propose evaluating the qualification status of your other CMOs.\u003C\u002Fp>\u003Cp>In addition, you state that you will be comparing the data reported on the certificate of analysis (COA) against the pre-approved specification before releasing finished product. We note that your quality unit is ultimately responsible for ensuring that your drug products are manufactured in accordance with CGMP. Comparing a COA from a CMO to pre-approved specifications does not overcome your responsibility to evaluate, qualify, audit, and monitor your contract manufacturers. The suitability and competence of potential contractors should be assessed, based on quality risk management principles, before outsourcing operations, and should implement any needed improvements. Your firm should have a robust qualification process of your CMOs, commensurate with risk, ahead of making product disposition determinations based on a COA.\u003C\u002Fp>\u003Cp>You are responsible for ensuring that the drugs you distribute are not adulterated and are manufactured in accordance with CGMP requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide a detailed plan to ensure you do not receive or deliver adulterated drugs in interstate commerce, in violation of sections 301(a) and 301(c) of the FD&amp;C Act, 21 U.S.C. 331(a) and 331(c). Items in your plan should minimally include the following:\u003C\u002Fp>\u003Cul>\u003Cli>A thorough evaluation of your current CMOs’ qualification. If gaps are identified, include your plan for remediation or discontinuation of use of that CMO.\u003C\u002Fli>\u003Cli>A description of improvements to your procedures for qualifying your contract manufacturers to ensure that they operate in compliance with CGMP, including a plan to conduct periodic audits of your CMOs.\u003Cbr>o Provide sufficient details on how you will assess findings that include CGMP deficiencies or disqualification from use.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ophthalmic Drug Product Recall and Distribution Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On January 30, 2024, you notified your customers that Brassica recalled Lubricant PM Ointment batches A2G01, A2G02, A3F08, A3F09, A3J17, and A3J18. We acknowledge that as of January 31, 2024, you commit to discontinue distributing AACE Pharmaceuticals Lubricant PM Ointment manufactured by Brassica. In response to this letter, clarify whether you intend to distribute ophthalmic or sterile drugs for the U.S. market.\u003C\u002Fp>\u003Cp>If you plan to distribute ophthalmic or sterile products regulated under the FD&amp;C Act, notify this office. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm and CMOs are capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that the drugs you deliver into interstate commerce are not adulterated. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013433273 and ATTN: Sena G. Dissmeyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-72\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Atul B. Mehta\n\nRecipient Title\n\nPresident, Co-Chairman, and Co-Founder\n\nAACE Pharmaceuticals, Inc.\n\n15 Gardner Road\n\nFairfield, NJ 07004\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-72\nMay 13, 2025\nDear Mr. Mehta:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AACE Pharmaceuticals, Inc., FEI 3013433273, at 15 Gardner Road, Fairfield, from November 12 to 22, 2024, after an FDA inspection revealed violative conditions at Brassica Pharma Private Limited, a contract manufacturing organization (CMO) used to manufacture ophthalmic drugs for AACE Pharmaceuticals, Inc.\nThe FDA inspection of this foreign facility revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21, Code of Federal Regulations, Parts 210 and 211 (21 CFR Parts 210 and 211), causing these drug products to be adulterated, including within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nThe inspection of your facility revealed that you operated as a distributor of AACE Pharmaceuticals brand name products, including Lubricant PM Ointment. Your receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c), and your introduction into interstate commerce of adulterated drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nInspection of Your CMO\nAn inspection of Brassica Pharma Private Limited (“Brassica”), FEI 3014129013, conducted from January 15 to 19, 2024, revealed multiple CGMP violations, including but not limited to poor aseptic practices for the manufacture of sterile drugs; fabrication of microbiology laboratory records; microbial recoveries of incubating samples from ISO 5 manufacturing areas and sterility tests exhibiting turbidity during incubation; inadequate media fill program and airflow visualization studies; and use of ripped and visibly dirty gowning in the aseptic processing areas. These CGMP violations render the products manufactured by Brassica adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act.\nOn January 30, 2024, Brassica was placed on Import Alert 66-40 and recalled all drug products within expiry on February 22, 2024. On July 11, 2024, Brassica received a warning letter (Warning Letter #320-24-52).\nReceipt and Distribution of Adulterated Drugs\nOur inspection of your firm and review of your import records indicated that (b)(4) shipments of AACE Pharmaceuticals Lubricant PM Ointment were imported from a third-party, (b)(4), manufactured by your CMO Brassica Pharma Private Limited, received by AACE Pharmaceuticals, and further distributed to customers. Your receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c), and your introduction into interstate commerce of adulterated drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nInspection of AACE Pharmaceuticals, Inc.\nWe reviewed your December 11, 2024, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\nYour ophthalmic drug product, Lubricant PM Ointment, is intended to be sterile. Your firm utilized a CMO to manufacture your ophthalmic drug products. However, your quality unit failed to have adequate supplier qualification procedures to ensure that the drug products received from your CMO were manufactured in compliance with CGMP prior to being distributed in the United States.\nFor example, our investigators observed that your firm identified several CGMP deficiencies with Brassica in September 2020, such as a failure to maintain raw testing data. Despite identifying these deficiencies, your firm qualified Brassica as an approved CMO. Furthermore, you requalified Brassica in 2023, without evaluating whether subsequent corrective actions and preventive actions adequately addressed the identified deficiencies.\nYour firm’s quality unit released Lubricant PM Ointment for distribution without adequate procedures to ensure that the ophthalmic drug products produced for your firm met appropriate quality attributes.\nIn your response, you state that your procedures have been revised to assess CGMP findings of your CMOs, and that your Quality Assurance must evaluate corrective action and preventive action (CAPA) plans implemented by CMOs.\nYour response is inadequate. While you have revised your procedures, you did not provide sufficient details on how you will assess findings that include CGMP deficiencies. Your procedure lacks a process for disqualifying CMOs or maintaining disqualification across product lines. Also, you did not propose evaluating the qualification status of your other CMOs.\nIn addition, you state that you will be comparing the data reported on the certificate of analysis (COA) against the pre-approved specification before releasing finished product. We note that your quality unit is ultimately responsible for ensuring that your drug products are manufactured in accordance with CGMP. Comparing a COA from a CMO to pre-approved specifications does not overcome your responsibility to evaluate, qualify, audit, and monitor your contract manufacturers. The suitability and competence of potential contractors should be assessed, based on quality risk management principles, before outsourcing operations, and should implement any needed improvements. Your firm should have a robust qualification process of your CMOs, commensurate with risk, ahead of making product disposition determinations based on a COA.\nYou are responsible for ensuring that the drugs you distribute are not adulterated and are manufactured in accordance with CGMP requirements.\nIn response to this letter, provide a detailed plan to ensure you do not receive or deliver adulterated drugs in interstate commerce, in violation of sections 301(a) and 301(c) of the FD&C Act, 21 U.S.C. 331(a) and 331(c). Items in your plan should minimally include the following:\nA thorough evaluation of your current CMOs’ qualification. If gaps are identified, include your plan for remediation or discontinuation of use of that CMO.\nA description of improvements to your procedures for qualifying your contract manufacturers to ensure that they operate in compliance with CGMP, including a plan to conduct periodic audits of your CMOs.\no Provide sufficient details on how you will assess findings that include CGMP deficiencies or disqualification from use.\nOphthalmic Drug Product Recall and Distribution Ceased\nOn January 30, 2024, you notified your customers that Brassica recalled Lubricant PM Ointment batches A2G01, A2G02, A3F08, A3F09, A3J17, and A3J18. We acknowledge that as of January 31, 2024, you commit to discontinue distributing AACE Pharmaceuticals Lubricant PM Ointment manufactured by Brassica. In response to this letter, clarify whether you intend to distribute ophthalmic or sterile drugs for the U.S. market.\nIf you plan to distribute ophthalmic or sterile products regulated under the FD&C Act, notify this office. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm and CMOs are capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nUse of Contract Manufacturers\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that the drugs you deliver into interstate commerce are not adulterated. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013433273 and ATTN: Sena G. Dissmeyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","AACE Pharmaceuticals, Inc.","aace-pharmaceuticals-inc-701310-05132025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faace-pharmaceuticals-inc-701310-05132025","2026-10-26T08:07:48.493571+00:00","Warning Letter","Issued","2025-05-27","701310","Drugs","Mr. Atul B. Mehta","2026-08-19T16:43:54.801+00:00","VIA UPS","320-25-72","2025-05-13",{"id":33,"raw":34,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":11,"recipient_name":49,"body_fetched_at":50,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},1149,[35,36,37,11,38,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-15T05:00:00Z\">11\u002F15\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentura-pharmaceuticals-inc-684733-11152024\">Centura Pharmaceuticals Inc\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rahul Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Centura Pharmaceuticals Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>24718 State Road 54C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lutz\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33559\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:centurapharma@gmail.com\"> centurapharma@gmail.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 15, 2024\u003Cbr>\n\u003Cbr>\nRe: 684733\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that in April 2024, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet addresses www.centurapharma.com and centurabltcream.com, where your “BLT 1-2-3 Cream” drug product is available for purchase in the United States without a prescription.\u003C\u002Fp>\n\n\u003Cp>“BLT 1-2-3 Cream” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the Federal Food, Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>FDA has safety concerns about your external analgesic drug product because it is intended to be used before certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of this product before and\u002For during a cosmetic procedure may not always be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in a recent press announcement\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and multiple public health advisories\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when used in conjunction with methods that increase skin temperature such as warming the skin before application and\u002For covering the skin after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“BLT 1-2-3 Cream” is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples from the “BLT 1-2-3 Cream” product labeling, including the websites listed above, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>DRUG FACTS Active Ingredient:\u003C\u002Fstrong> Benzocaine 20% Topical Anesthetic…For the temporary relief of pain and itching.” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>DRUG FACTS Active Ingredient:\u003C\u002Fstrong> Lidocaine HCL 4% Topical Anesthetic…For the temporary relief of pain and itching.” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>DRUG FACTS Active Ingredient:\u003C\u002Fstrong> Tetracaine 2%...Topical Anesthetic…For the temporary relief of pain and itching.” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“BLT numbing creams are topical anesthetics consisting of benzocaine, lidocaine, and tetracaine as local analgesics for mild pain control. In cosmetic settings, topical anesthetics are widely used to alleviate pain and minimize discomfort associated with procedures like filler injectables, laser hair removal, skin resurfacing with laser and light-based devices.…BLT numbing cream packets provide the best over-the-counter numbing cream for minimizing pain and discomfort associated with cosmetic and esthetic procedures. [from your “BLT 1-2-3 Cream” product website]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>How Centura BLT Numbing Creams Work?\u003C\u002Fstrong>…When mixed before use, BLT numbing creams provide a maximum analgesic effect on the skin by keeping it numb for up to 30 minutes.” [from your “BLT 1-2-3 Cream” product website]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Potential Applications\u003C\u002Fstrong>…The Centura Pharmaceuticals BLT Cream is potentially useful for a wide range of cosmetic and esthetic procedures, including: ∙ Dermal fillers used on small areas of skin such as hyaluronic acid (Juvederm, Restylane, Belotero Balance, Revanesse Versa) ∙ Injectable toxins (Botox, Dysport, and Xeomin injections) ∙ Esthetic facial treatments (chemical peels, laser hair removal, collagen induction therapy, eyebrow microblading, and tattoo removal).” [from your “BLT 1-2-3 Cream” product website]\u003C\u002Fp>\n\n\u003Cp>“Centura Pharma’s packaging separates each medication into its own sachet. Each sachet is 5gm in size, and is mixed just prior to application. Specifically formulated for minimally invasive surgeries such as microneedling Minimizes the pain of many procedures for patients.” [from your “BLT 1-2-3 Cream” product website]\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling, “BLT 1-2-3 Cream” is intended for use as an external analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug product identified above.\u003C\u002Fp>\n\n\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as, “BLT 1-2-3 Cream,” in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph(s), here Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesic monograph”).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your “BLT 1-2-3 Cream” product does not conform to the conditions specified in M017 for the reasons described below.\u003C\u002Fp>\n\n\u003Cp>Your “BLT 1-2-3 Cream” is distributed as a combination of three packets containing benzocaine 20%, lidocaine HCl 4%, and tetracaine 2%, respectively. Your website states, “Empty the contents of each sachet gradually and mix them thoroughly to ensure even distribution of the pack contents” and includes a video instructing users to mix the three packets together prior to use as well. While benzocaine at a concentration range of 5% to 20%, lidocaine HCl from 0.5% to 4%, and tetracaine from 1% to 2% are permitted active ingredients in M017, the monograph does not permit a combination of more than one “-caine” type active ingredient in a single drug product.\u003C\u002Fp>\n\n\u003Cp>Furthermore, labeling for your “BLT 1-2-3 Cream” includes indications that are not consistent with the permitted indications for an external analgesic drug product in M017. For example, claims on your product identified above describe its use for sensitive cosmetic procedures, such as laser hair removal and tattoo removal treatments, go beyond merely describing the general intended uses for an external analgesic drug product as set forth in M017.50(b).\u003C\u002Fp>\n\n\u003Cp>Thus, your “BLT 1-2-3 Cream” drug product does not comply with the applicable conditions specified in M017 and has not otherwise been found GRASE.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no evident basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of this unapproved new drug into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Your “BLT 1- 2-3 Cream” is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Refer to FDA Press announcement FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Refer to public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions as set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “BLT Cream” is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nRahul Patel\n\nRecipient Title\n\nPresident\n\nCentura Pharmaceuticals Inc\n\n24718 State Road 54C\n\nLutz, FL 33559\n\nUnited States\n\ncenturapharma@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nNovember 15, 2024\n\nRe: 684733\n\nDear Mr. Patel:\n\nThis letter is to advise you that in April 2024, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet addresses www.centurapharma.com and centurabltcream.com, where your “BLT 1-2-3 Cream” drug product is available for purchase in the United States without a prescription.\n\n“BLT 1-2-3 Cream” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the Federal Food, Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nFDA has safety concerns about your external analgesic drug product because it is intended to be used before certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of this product before and\u002For during a cosmetic procedure may not always be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in a recent press announcement1 and multiple public health advisories2 about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when used in conjunction with methods that increase skin temperature such as warming the skin before application and\u002For covering the skin after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\n\nUnapproved New Drug and Misbranded Drug Violations\n\n“BLT 1-2-3 Cream” is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\n\nExamples from the “BLT 1-2-3 Cream” product labeling, including the websites listed above, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\n\n“DRUG FACTS Active Ingredient: Benzocaine 20% Topical Anesthetic…For the temporary relief of pain and itching.” [from your product label]\n\n“DRUG FACTS Active Ingredient: Lidocaine HCL 4% Topical Anesthetic…For the temporary relief of pain and itching.” [from your product label]\n\n“DRUG FACTS Active Ingredient: Tetracaine 2%...Topical Anesthetic…For the temporary relief of pain and itching.” [from your product label]\n\n“BLT numbing creams are topical anesthetics consisting of benzocaine, lidocaine, and tetracaine as local analgesics for mild pain control. In cosmetic settings, topical anesthetics are widely used to alleviate pain and minimize discomfort associated with procedures like filler injectables, laser hair removal, skin resurfacing with laser and light-based devices.…BLT numbing cream packets provide the best over-the-counter numbing cream for minimizing pain and discomfort associated with cosmetic and esthetic procedures. [from your “BLT 1-2-3 Cream” product website]\n\n“How Centura BLT Numbing Creams Work?…When mixed before use, BLT numbing creams provide a maximum analgesic effect on the skin by keeping it numb for up to 30 minutes.” [from your “BLT 1-2-3 Cream” product website]\n\n“Potential Applications…The Centura Pharmaceuticals BLT Cream is potentially useful for a wide range of cosmetic and esthetic procedures, including: ∙ Dermal fillers used on small areas of skin such as hyaluronic acid (Juvederm, Restylane, Belotero Balance, Revanesse Versa) ∙ Injectable toxins (Botox, Dysport, and Xeomin injections) ∙ Esthetic facial treatments (chemical peels, laser hair removal, collagen induction therapy, eyebrow microblading, and tattoo removal).” [from your “BLT 1-2-3 Cream” product website]\n\n“Centura Pharma’s packaging separates each medication into its own sachet. Each sachet is 5gm in size, and is mixed just prior to application. Specifically formulated for minimally invasive surgeries such as microneedling Minimizes the pain of many procedures for patients.” [from your “BLT 1-2-3 Cream” product website]\n\nUnapproved New Drug Violations\n\nBased on the above labeling, “BLT 1-2-3 Cream” is intended for use as an external analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug product identified above.\n\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as, “BLT 1-2-3 Cream,” in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph(s), here Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesic monograph”).3 However, your “BLT 1-2-3 Cream” product does not conform to the conditions specified in M017 for the reasons described below.\n\nYour “BLT 1-2-3 Cream” is distributed as a combination of three packets containing benzocaine 20%, lidocaine HCl 4%, and tetracaine 2%, respectively. Your website states, “Empty the contents of each sachet gradually and mix them thoroughly to ensure even distribution of the pack contents” and includes a video instructing users to mix the three packets together prior to use as well. While benzocaine at a concentration range of 5% to 20%, lidocaine HCl from 0.5% to 4%, and tetracaine from 1% to 2% are permitted active ingredients in M017, the monograph does not permit a combination of more than one “-caine” type active ingredient in a single drug product.\n\nFurthermore, labeling for your “BLT 1-2-3 Cream” includes indications that are not consistent with the permitted indications for an external analgesic drug product in M017. For example, claims on your product identified above describe its use for sensitive cosmetic procedures, such as laser hair removal and tattoo removal treatments, go beyond merely describing the general intended uses for an external analgesic drug product as set forth in M017.50(b).\n\nThus, your “BLT 1-2-3 Cream” drug product does not comply with the applicable conditions specified in M017 and has not otherwise been found GRASE.4 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no evident basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\n\nThe introduction or delivery for introduction of this unapproved new drug into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nMisbranded Drug Violations\n\nYour “BLT 1- 2-3 Cream” is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n____________________________\n\n1 Refer to FDA Press announcement FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects.\n\n2 Refer to public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\n\n3 M017 reflects the conditions as set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf].\n\n4 FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “BLT Cream” is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.","Centura Pharmaceuticals Inc","centura-pharmaceuticals-inc-684733-11152024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentura-pharmaceuticals-inc-684733-11152024","2026-10-26T08:08:13.203086+00:00","2024-11-26","684733","Drugs Over-the-Counter Drugs","Rahul Patel","2026-08-19T17:58:12.589+00:00","2024-11-15",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":18,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":68,"body_fetched_at":69,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":70,"medical_device_id":19,"response_letter_date":19},660,[55,56,57,11,58,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falora-pharmaceuticals-716591-09092025\">Alora Pharmaceuticals\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Harold A. Deas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Alora Pharmaceuticals\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1880 McFarland Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alpharetta\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30005\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>RE: &nbsp;NDA 216117\u003Cbr>RELEXXII® (methylphenidate hydrochloride extended-release tablets) for oral use, CII MA 38\u003C\u002Fp>\u003Cp>\u003Cbr>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cbr>Dear Harold A. Deas:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, Alora Pharmaceuticals, LLC’s (Alora) sponsored links\u003Ca id=\"footnoteref1_lpn6jd3\" href=\"#footnote1_lpn6jd3\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>\u003Ca id=\"footnoteref2_4mt7305\" href=\"#footnote2_4mt7305\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>&nbsp;(3342-v2.1) for RELEXXII® (methylphenidate hydrochloride extended-release tablets) for oral use, CII (Relexxii), submitted by Osmotica Pharmaceutical US LLC (Osmotica) under cover of Form FDA 2253. FDA has determined that the sponsored links are false or misleading. Thus, the sponsored links misbrand Relexxii and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5). These violations are especially concerning from a public health perspective because the promotional communications create a misleading impression about the safety of Relexxii, a Schedule II controlled substance that bears a boxed warning due to the high potential for abuse and misuse, which can lead to overdose, death, and the development of a substance use disorder, including addiction.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Relexxii.\u003Ca id=\"footnoteref3_hty6udk\" href=\"#footnote3_hty6udk\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa>&nbsp;According to the INDICATIONS AND USAGE section of the FDA-approved Prescribing Information (PI):\u003C\u002Fp>\u003Cp>RELEXXII is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older.\u003C\u002Fp>\u003Cp>The PI for Relexxii contains a boxed warning regarding a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Relexxii is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Relexxii and in patients receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI. In addition, the PI for Relexxii includes warnings and precautions regarding risks to patients with serious cardiac disease; increased blood pressure and heart rate; psychiatric adverse reactions; priapism; peripheral vasculopathy, including Raynaud’s phenomenon; long-term suppression of growth in pediatric patients; potential for gastrointestinal obstruction; acute angle closure glaucoma; increased intraocular pressure and glaucoma; and motor and verbal tics, and worsening of Tourette’s syndrome. The most common adverse reactions associated with Relexxii in adults are decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, and hyperhidrosis. The most common adverse reaction in pediatric patients 6 to 17 years is abdominal pain upper.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\u003C\u002Fp>\u003Cp>The sponsored links are misleading because they include representations about the efficacy of Relexxii but fail to communicate any risk information. For example, the sponsored links appearing in searches include the statements, “Once-Daily ADHD Treatment” or “Tailored Treatment for ADHD” in the headline, in conjunction with “RELEXXII (methylphenidate ER).” In addition, the sitelink extension “Bring Life Into Focus” appears with these representations in some variations of the sponsored links.\u003C\u002Fp>\u003Cp>We note the sponsored links include the statement, “See Boxed Warning, Full PI and Safety Information on relexxii.com”; however, this statement does not mitigate the misleading omission of risk information. By omitting risk information associated with Relexxii, the sponsored links fail to provide material information about the consequences that may result from the use of the drug and create a misleading impression about the drug’s safety.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, the sponsored links misbrand Relexxii and make the distribution of the drug in violation of the FD&amp;C Act. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5).\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Relexxii that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Relexxii.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Relexxii; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\u003Cp>Please direct your response to the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 38 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Additionally, the response submission should be coded as an Amendment to eCTD Sequence 0051 under NDA 216117. Questions related to the submission of your response letter should be emailed to CDER-OPDP-RPM@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>CARTER M BEACH 09\u002F09\u002F2025 05:14:50 PM\u003Cbr>On behalf of George Tidmarsh, M.D., Ph.D\u003C\u002Fp>\u003Ch6>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia-base\u002F188769\">Promotional Material\u003C\u002Fa>\u003C\u002Fh6>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_lpn6jd3\">\u003Ca href=\"#footnoteref1_lpn6jd3\">1\u003C\u002Fa>The sponsored link materials submitted by Osmotica under Form FDA 2253 were titled “Alora Pharmaceuticals Relexxii Paid Search Campaign.” Alora is the parent company of Osmotica.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_4mt7305\">\u003Ca href=\"#footnoteref2_4mt7305\">2\u003C\u002Fa>Available at https:\u002F\u002Fwww.google.com (Last accessed September 5, 2025). These communications are responsive to searches of consumers seeking information about Relexxii.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_hty6udk\">\u003Ca href=\"#footnoteref3_hty6udk\">3\u003C\u002Fa>This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nHarold A. Deas\n\nRecipient Title\n\nChief Executive Officer\n\nAlora Pharmaceuticals\n\n1880 McFarland Parkway\n\nAlpharetta, GA 30005\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nRE: NDA 216117\nRELEXXII® (methylphenidate hydrochloride extended-release tablets) for oral use, CII MA 38\n\nWARNING LETTER\n\nDear Harold A. Deas:\nThe U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, Alora Pharmaceuticals, LLC’s (Alora) sponsored links12 (3342-v2.1) for RELEXXII® (methylphenidate hydrochloride extended-release tablets) for oral use, CII (Relexxii), submitted by Osmotica Pharmaceutical US LLC (Osmotica) under cover of Form FDA 2253. FDA has determined that the sponsored links are false or misleading. Thus, the sponsored links misbrand Relexxii and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5). These violations are especially concerning from a public health perspective because the promotional communications create a misleading impression about the safety of Relexxii, a Schedule II controlled substance that bears a boxed warning due to the high potential for abuse and misuse, which can lead to overdose, death, and the development of a substance use disorder, including addiction.\nBackground\nBelow are the indication and summary of the most serious and most common risks associated with the use of Relexxii.3 According to the INDICATIONS AND USAGE section of the FDA-approved Prescribing Information (PI):\nRELEXXII is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older.\nThe PI for Relexxii contains a boxed warning regarding a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Relexxii is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Relexxii and in patients receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI. In addition, the PI for Relexxii includes warnings and precautions regarding risks to patients with serious cardiac disease; increased blood pressure and heart rate; psychiatric adverse reactions; priapism; peripheral vasculopathy, including Raynaud’s phenomenon; long-term suppression of growth in pediatric patients; potential for gastrointestinal obstruction; acute angle closure glaucoma; increased intraocular pressure and glaucoma; and motor and verbal tics, and worsening of Tourette’s syndrome. The most common adverse reactions associated with Relexxii in adults are decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, and hyperhidrosis. The most common adverse reaction in pediatric patients 6 to 17 years is abdominal pain upper.\nFalse or Misleading Risk Presentation\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\nThe sponsored links are misleading because they include representations about the efficacy of Relexxii but fail to communicate any risk information. For example, the sponsored links appearing in searches include the statements, “Once-Daily ADHD Treatment” or “Tailored Treatment for ADHD” in the headline, in conjunction with “RELEXXII (methylphenidate ER).” In addition, the sitelink extension “Bring Life Into Focus” appears with these representations in some variations of the sponsored links.\nWe note the sponsored links include the statement, “See Boxed Warning, Full PI and Safety Information on relexxii.com”; however, this statement does not mitigate the misleading omission of risk information. By omitting risk information associated with Relexxii, the sponsored links fail to provide material information about the consequences that may result from the use of the drug and create a misleading impression about the drug’s safety.\nConclusion and Requested Action\nFor the reasons discussed above, the sponsored links misbrand Relexxii and make the distribution of the drug in violation of the FD&C Act. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5).\nThis letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Relexxii that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Relexxii.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Relexxii; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\nPlease direct your response to the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 38 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Additionally, the response submission should be coded as an Amendment to eCTD Sequence 0051 under NDA 216117. Questions related to the submission of your response letter should be emailed to CDER-OPDP-RPM@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\nCARTER M BEACH 09\u002F09\u002F2025 05:14:50 PM\nOn behalf of George Tidmarsh, M.D., Ph.D\nPromotional Material\n\n1The sponsored link materials submitted by Osmotica under Form FDA 2253 were titled “Alora Pharmaceuticals Relexxii Paid Search Campaign.” Alora is the parent company of Osmotica.\n\n2Available at https:\u002F\u002Fwww.google.com (Last accessed September 5, 2025). These communications are responsive to searches of consumers seeking information about Relexxii.\n\n3This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.","Alora Pharmaceuticals","alora-pharmaceuticals-716591-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falora-pharmaceuticals-716591-09092025","2026-10-26T08:07:53.264331+00:00","2025-09-16","716591","Harold A. Deas","2026-08-19T16:18:44.044+00:00","2025-09-09",{"id":72,"raw":73,"subject":59,"body_html":79,"body_text":80,"firm_name":81,"letter_id":82,"created_at":83,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":86,"posted_date":87,"marcs_cms_no":88,"product_type":26,"closeout_date":89,"issuing_office":77,"recipient_name":90,"body_fetched_at":91,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},3531,[74,75,76,77,58,13,78,13],"\u003Ctime datetime=\"2021-02-16T15:00:00Z\">02\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-11T05:00:00Z\">02\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Facelrx-pharmaceuticals-inc-613257-02112021\">AcelRx Pharmaceuticals, Inc.\u003C\u002Fa>","The Office of Prescription Drug Promotion (OPDP)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Facelrx-pharmaceuticals-inc-613257-03282022\">\u003Ctime datetime=\"2022-06-22T04:00:00Z\">06\u002F22\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vincent J. Angotti\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AcelRx Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>351 Galveston Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Redwood City\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>The Office of Prescription Drug Promotion (OPDP)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>RE: \u003Cstrong>NDA 209128\u003C\u002Fstrong>\u003Cbr>\nDSUVIA (sufentanil) sublingual tablet, CII MA 18, 23\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Angotti:\u003C\u002Fp>\n\n\u003Cp>The Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed an “SDS Banner Ad” (banner) (PM-US-DSV-0018) and a tabletop display (PM-US-DSV-0049) (display) for DSUVIA (sufentanil) sublingual tablet, CII (Dsuvia) submitted by AcelRx Pharmaceuticals, Inc. (AcelRx) under cover of Form FDA 2253. The promotional communications, the banner and display, make false or misleading claims and representations about the risks and efficacy of DSUVIA. Thus, the banner and display misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii); (e)(5); (e)(7)(viii). Oral opioids, such as Dsuvia, include risks for accidental ingestion, which may lead to fatal respiratory depression. To address such concerns associated with DSUVIA, the drug is subject to a Risk Evaluation and Mitigation Strategy (REMS) that restricts its use to certain healthcare settings, and the drug’s labeling includes strong limitations on its use and detailed administration instructions. These violations are especially concerning from a public health perspective given the importance of the administration instructions intended to protect from the serious and potentially life-threatening risks that may result from the accidental exposure to misplaced tablets of Dsuvia or overdosage with Dsuvia.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Dsuvia.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> According to the FDA-approved product labeling (PI):\u003C\u002Fp>\n\n\u003Cp>DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.\u003C\u002Fp>\n\n\u003Cp>Limitations of Use:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting.\u003C\u002Fli>\n\t\u003Cli>Not for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied.\u003C\u002Fli>\n\t\u003Cli>Only to be administered by a healthcare provider.\u003C\u002Fli>\n\t\u003Cli>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve DSUVIA for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>- Have not been tolerated, or are not expected to be tolerated,\u003Cbr>\n- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.\u003C\u002Fp>\n\n\u003Cp>The PI for Dsuvia contains boxed warnings regarding: accidental exposure and the Dsuvia Risk Evaluation and Mitigation Strategy (REMS) Program; life-threatening respiratory depression; addiction, abuse and misuse; Cytochrome P450 3A4 interactions; and risks from concomitant use with benzodiazepines or other CNS Depressants. Dsuvia is contraindicated in patients with significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and known hypersensitivity to sufentanil or components of Dsuvia. In addition, the PI for Dsuvia includes warnings and precautions regarding life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients; serotonin syndrome with concomitant use of serotonergic drugs; adrenal insufficiency; severe hypotension; risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness; risks of use in patients with gastrointestinal conditions; increased risk of seizures in patients with seizure disorders; bradycardia and neonatal opioid withdrawal syndrome. The most common adverse reactions reported with Dsuvia were nausea, headache, vomiting, dizziness, and hypotension.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>False or Misleading Risk and Benefit Presentations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Promotional materials misbrand a drug if they are false or misleading with respect to risk or benefits. The determination of whether promotional materials are misleading includes, among other things, not only representations made or suggested in promotional materials, but also failure to reveal facts that are material in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\u003C\u002Fp>\n\n\u003Cp>The banner includes the claim, “DSUVIA® comes in one strength for acute pain. . . \u003Cstrong>TONGUE AND DONE.”\u003C\u002Fstrong> (bolded emphasis original; reference omitted) in conjunction with an image of the single-dose applicator device. Similarly, the display prominently includes the claim&nbsp;\u003Cstrong>“TONGUE AND DONE”\u003C\u002Fstrong> (bolded emphasis original). These presentations are misleading because they imply that the administration of Dsuvia consists of a simple, one-step process, when this is not the case. In fact, there are numerous administration steps outlined in the PI, including a separate, distinct step to visually confirm tablet placement in the patient’s sublingual space of the mouth. For example, according to the DOSAGE AND ADMINISTRATION section of the PI, step 7 of the \u003Cem>Administration Instructions\u003C\u002Fem> specifically states (underlined emphasis added):\u003C\u002Fp>\n\n\u003Cp>VISUALLY CONFIRM tablet placement in the sublingual space. See \u003Cem>Figure 4\u003C\u002Fem>. NOTE: If the tablet is NOT in the patient’s mouth, it is important to retrieve and dispose of the tablet according to institutional CII waste procedures.\u003C\u002Fp>\n\n\u003Cp>The multiple steps involved in the administration of Dsuvia reflect the complexity of use of Dsuvia. Given the potency and the small size of the tablet, the risk of misplaced tablets is a serious safety concern to the patient and others. Risks include overdose and death due to accidental ingestion or exposure, improper dosing (i.e., over- or under-dosing and their associated risks), and the risk of diversion and its associated public health consequences. This is critical information for healthcare providers to know. Therefore, by oversimplifying the administration process, these presentations create a misleading impression about the safe administration of Dsuvia. These presentations are particularly concerning considering a REMS program was required for Dsuvia to ensure that the benefits of the drug outweigh the risk of respiratory depression that can result from accidental exposure.\u003C\u002Fp>\n\n\u003Cp>In addition, the banner includes the following claims (emphasis original, references omitted):\u003C\u002Fp>\n\n\u003Cp>• “Minimum redosing interval \u003Cstrong>1 hour\u003C\u002Fstrong>”\u003Cbr>\n• “Average redosing interval \u003Cstrong>3 hours*\u003C\u002Fstrong>…\u003Cbr>\n*Shown over a 12-hour period in the pivotal trial.”\u003C\u002Fp>\n\n\u003Cp>These claims create a misleading impression about the use of Dsuvia because the banner omits the following material information from the DOSING AND ADMINISTRATION section of the PI: “Do not exceed 12 tablets in 24 hours.” By omitting this material information about the maximum daily dosage, the banner creates a misleading impression about the safe use of Dsuvia. These omissions are concerning from a public health perspective due to the serious risks associated with overdose with Dsuvia, including respiratory depression and death, that should be considered when prescribing the product.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the banner includes the claim, “DSUVIA® comes in one strength for acute pain. . .” (reference omitted). Thus, the banner makes representations about the indication and use of the drug but fails to adequately convey material information regarding Dsuvia’s limitations of use, thereby creating a misleading impression about the drug.\u003C\u002Fp>\n\n\u003Cp>OPDP acknowledges that the banner states “DSUVIA is for use only in a certified medically supervised healthcare setting” and that the full indication including limitations of use are included farther down on the banner under the header \u003Cstrong>“IMPORTANT SAFETY INFORMATION”\u003C\u002Fstrong> (ISI), (bolded emphasis added). However, unlike the benefit claims in the banner, which utilized a color background and large font, the full indication with the limitations of use are intermingled with risk information in a paragraph format in a much smaller font size and a plain white background, and are accessible only if viewers “scroll” down the banner. Therefore, this does not mitigate the misleading impression.\u003C\u002Fp>\n\n\u003Cp>Finally, the banner and display fail to present information relating to the Boxed Warning, Contraindications, Warnings and Precautions, and Adverse Reactions for Dsuvia with a prominence and readability reasonably comparable with the presentation of information relating to the benefits of Dsuvia. Factors impacting prominence and readability include typography, layout, contrast, headlines, paragraphing, white space, and other techniques apt to achieve emphasis. Specifically, benefit claims for Dsuvia are presented in conjunction with colorful graphics and large bolded headlines, with significant white space. However, the risk information is relegated farther down in paragraph format with less prominence.\u003C\u002Fp>\n\n\u003Cp>By failing to adequately present the risks and benefits associated with Dsuvia, the banner and display create a misleading impression about the safe and effective use of the drug.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For the reasons discussed above, the banner and display misbrand Dsuvia within the meaning of the FD&amp;C Act and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii); (e)(5); (e)(7)(viii).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that AcelRx cease any violations of the FD&amp;C Act. Please submit a written response to this letter within 15 days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Dsuvia that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Dsuvia.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration, within 15 days from the date of receipt of this letter.\u003C\u002Fp>\n\n\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Dsuvia; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\n\n\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\n\n\u003Cp>Please direct your response to the undersigned at the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to \u003Cspan>(301) 847-8444\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>. To ensure timely delivery of your submissions, please use the full address above and include a prominent directional notation (e.g. a sticker) to indicate that the submission is intended for OPDP. Please refer to MA 18 and 23 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nAndrew S.T. Haffer, Pharm.D.\u003Cbr>\nDirector\u003Cbr>\nDivision of Advertising &amp; Promotion Review 1\u003Cbr>\nOffice of Prescription Drug Promotion\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nANDREW S HAFFER\u003Cbr>\n02\u002F11\u002F2021 02:58:02 PM\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional piece(s) cited in this letter.\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Ch3>\u003Cu>Promotional Material\u003C\u002Fu>\u003C\u002Fh3>\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145906\u002Fdownload?attachment\">Flyer\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145907\u002Fdownload?attachment\">Banner\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nVincent J. Angotti\n\nRecipient Title\n\nChief Executive Officer\n\nAcelRx Pharmaceuticals, Inc.\n\n351 Galveston Drive\n\nRedwood City, CA 94063\n\nUnited States\n\nIssuing Office:\n\nThe Office of Prescription Drug Promotion (OPDP)\n\nUnited States\n\nRE: NDA 209128\n\nDSUVIA (sufentanil) sublingual tablet, CII MA 18, 23\n\nWARNING LETTER\n\nDear Mr. Angotti:\n\nThe Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed an “SDS Banner Ad” (banner) (PM-US-DSV-0018) and a tabletop display (PM-US-DSV-0049) (display) for DSUVIA (sufentanil) sublingual tablet, CII (Dsuvia) submitted by AcelRx Pharmaceuticals, Inc. (AcelRx) under cover of Form FDA 2253. The promotional communications, the banner and display, make false or misleading claims and representations about the risks and efficacy of DSUVIA. Thus, the banner and display misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii); (e)(5); (e)(7)(viii). Oral opioids, such as Dsuvia, include risks for accidental ingestion, which may lead to fatal respiratory depression. To address such concerns associated with DSUVIA, the drug is subject to a Risk Evaluation and Mitigation Strategy (REMS) that restricts its use to certain healthcare settings, and the drug’s labeling includes strong limitations on its use and detailed administration instructions. These violations are especially concerning from a public health perspective given the importance of the administration instructions intended to protect from the serious and potentially life-threatening risks that may result from the accidental exposure to misplaced tablets of Dsuvia or overdosage with Dsuvia.\n\nBackground\n\nBelow are the indication and summary of the most serious and most common risks associated with the use of Dsuvia.1 According to the FDA-approved product labeling (PI):\n\nDSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.\n\nLimitations of Use:\n\nNot for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting.\n\nNot for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied.\n\nOnly to be administered by a healthcare provider.\n\nBecause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve DSUVIA for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:\n\n- Have not been tolerated, or are not expected to be tolerated,\n\n- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.\n\nThe PI for Dsuvia contains boxed warnings regarding: accidental exposure and the Dsuvia Risk Evaluation and Mitigation Strategy (REMS) Program; life-threatening respiratory depression; addiction, abuse and misuse; Cytochrome P450 3A4 interactions; and risks from concomitant use with benzodiazepines or other CNS Depressants. Dsuvia is contraindicated in patients with significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and known hypersensitivity to sufentanil or components of Dsuvia. In addition, the PI for Dsuvia includes warnings and precautions regarding life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients; serotonin syndrome with concomitant use of serotonergic drugs; adrenal insufficiency; severe hypotension; risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness; risks of use in patients with gastrointestinal conditions; increased risk of seizures in patients with seizure disorders; bradycardia and neonatal opioid withdrawal syndrome. The most common adverse reactions reported with Dsuvia were nausea, headache, vomiting, dizziness, and hypotension.\n\nFalse or Misleading Risk and Benefit Presentations\n\nPromotional materials misbrand a drug if they are false or misleading with respect to risk or benefits. The determination of whether promotional materials are misleading includes, among other things, not only representations made or suggested in promotional materials, but also failure to reveal facts that are material in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\n\nThe banner includes the claim, “DSUVIA® comes in one strength for acute pain. . . TONGUE AND DONE.” (bolded emphasis original; reference omitted) in conjunction with an image of the single-dose applicator device. Similarly, the display prominently includes the claim “TONGUE AND DONE” (bolded emphasis original). These presentations are misleading because they imply that the administration of Dsuvia consists of a simple, one-step process, when this is not the case. In fact, there are numerous administration steps outlined in the PI, including a separate, distinct step to visually confirm tablet placement in the patient’s sublingual space of the mouth. For example, according to the DOSAGE AND ADMINISTRATION section of the PI, step 7 of the Administration Instructions specifically states (underlined emphasis added):\n\nVISUALLY CONFIRM tablet placement in the sublingual space. See Figure 4. NOTE: If the tablet is NOT in the patient’s mouth, it is important to retrieve and dispose of the tablet according to institutional CII waste procedures.\n\nThe multiple steps involved in the administration of Dsuvia reflect the complexity of use of Dsuvia. Given the potency and the small size of the tablet, the risk of misplaced tablets is a serious safety concern to the patient and others. Risks include overdose and death due to accidental ingestion or exposure, improper dosing (i.e., over- or under-dosing and their associated risks), and the risk of diversion and its associated public health consequences. This is critical information for healthcare providers to know. Therefore, by oversimplifying the administration process, these presentations create a misleading impression about the safe administration of Dsuvia. These presentations are particularly concerning considering a REMS program was required for Dsuvia to ensure that the benefits of the drug outweigh the risk of respiratory depression that can result from accidental exposure.\n\nIn addition, the banner includes the following claims (emphasis original, references omitted):\n\n• “Minimum redosing interval 1 hour”\n\n• “Average redosing interval 3 hours*…\n\n*Shown over a 12-hour period in the pivotal trial.”\n\nThese claims create a misleading impression about the use of Dsuvia because the banner omits the following material information from the DOSING AND ADMINISTRATION section of the PI: “Do not exceed 12 tablets in 24 hours.” By omitting this material information about the maximum daily dosage, the banner creates a misleading impression about the safe use of Dsuvia. These omissions are concerning from a public health perspective due to the serious risks associated with overdose with Dsuvia, including respiratory depression and death, that should be considered when prescribing the product.\n\nFurthermore, the banner includes the claim, “DSUVIA® comes in one strength for acute pain. . .” (reference omitted). Thus, the banner makes representations about the indication and use of the drug but fails to adequately convey material information regarding Dsuvia’s limitations of use, thereby creating a misleading impression about the drug.\n\nOPDP acknowledges that the banner states “DSUVIA is for use only in a certified medically supervised healthcare setting” and that the full indication including limitations of use are included farther down on the banner under the header “IMPORTANT SAFETY INFORMATION” (ISI), (bolded emphasis added). However, unlike the benefit claims in the banner, which utilized a color background and large font, the full indication with the limitations of use are intermingled with risk information in a paragraph format in a much smaller font size and a plain white background, and are accessible only if viewers “scroll” down the banner. Therefore, this does not mitigate the misleading impression.\n\nFinally, the banner and display fail to present information relating to the Boxed Warning, Contraindications, Warnings and Precautions, and Adverse Reactions for Dsuvia with a prominence and readability reasonably comparable with the presentation of information relating to the benefits of Dsuvia. Factors impacting prominence and readability include typography, layout, contrast, headlines, paragraphing, white space, and other techniques apt to achieve emphasis. Specifically, benefit claims for Dsuvia are presented in conjunction with colorful graphics and large bolded headlines, with significant white space. However, the risk information is relegated farther down in paragraph format with less prominence.\n\nBy failing to adequately present the risks and benefits associated with Dsuvia, the banner and display create a misleading impression about the safe and effective use of the drug.\n\nConclusion and Requested Action\n\nFor the reasons discussed above, the banner and display misbrand Dsuvia within the meaning of the FD&C Act and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii); (e)(5); (e)(7)(viii).\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that AcelRx cease any violations of the FD&C Act. Please submit a written response to this letter within 15 days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Dsuvia that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Dsuvia.\n\nFailure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration, within 15 days from the date of receipt of this letter.\n\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Dsuvia; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\n\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\n\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. To ensure timely delivery of your submissions, please use the full address above and include a prominent directional notation (e.g. a sticker) to indicate that the submission is intended for OPDP. Please refer to MA 18 and 23 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter.\n\nSincerely,\n\n{See appended electronic signature page}\n\nAndrew S.T. Haffer, Pharm.D.\n\nDirector\n\nDivision of Advertising & Promotion Review 1\n\nOffice of Prescription Drug Promotion\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nANDREW S HAFFER\n\n02\u002F11\u002F2021 02:58:02 PM\n\n_____________________\n\n1 This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional piece(s) cited in this letter.\n\nPromotional Material\n\nFlyer\n\nBanner","AcelRx Pharmaceuticals, Inc.","acelrx-pharmaceuticals-inc-613257-02112021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Facelrx-pharmaceuticals-inc-613257-02112021","2026-10-26T08:07:49.617912+00:00","Closed Out","2021-02-16","613257","2022-06-22","Vincent J. Angotti","2026-08-20T03:22:43.796+00:00","2021-02-11",{"id":94,"raw":95,"subject":12,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":83,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":86,"posted_date":108,"marcs_cms_no":109,"product_type":26,"closeout_date":110,"issuing_office":99,"recipient_name":111,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},3548,[96,97,98,99,100,13,101,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-27T05:00:00Z\">01\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fallay-pharmaceuticals-llc-609023-01272021\">Allay Pharmaceuticals, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations II","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fallay-pharmaceuticals-llc-609023-07182022\">\u003Ctime datetime=\"2022-07-25T04:00:00Z\">07\u002F25\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rosy Sultana\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Allay Pharmaceuticals, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16600 NW 54th Ave, Unit 23\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hialeah\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33014-6109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 27, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case # 609023\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMs. Sultana:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Allay Pharmaceuticals, LLC, FEI 3007007565, at 16600 NW 54th Avenue, Unit 23, Hialeah, Florida, from May 5 to 15, 2020.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Additionally, your \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;tablets are adulterated under section 501(b) of the FD&amp;C Act, 21 U.S.C. 351(b) for failure to conform to compendial standards for strength, quality, or purity.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered during the course of the inspection reflect that your products are intended to treat a disease or condition. Therefore, your products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)]. Your products, which contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> are also biological products as defined in section 351(i)(1) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)(1)] because they are a “protein” as defined in 21 C.F.R. 600.3(h)(6), or are “analogous” to a protein because the identified biological product (i.e., protein) component in these naturally derived mixtures is necessary for the activity of the product and contributes to achieving the intended therapeutic effect.\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 6, 2020, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately validate the manufacturing processes for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. You lacked adequate data to show homogeneity of your drug product during manufacturing . During your process performance qualification (PPQ), blend samples were \u003Cstrong>(b)(4)\u003C\u002Fstrong> before analysis. When samples are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, it potentially masks the variability of your blend. In addition, you obtained an out-of-specification (OOS) assay result for one of the active ingredients, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in your post-compression testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> strength PPQ lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>FDA also collected three samples of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets during the inspection, two of which were from your process validation lots. All three samples were sub-potent for the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. One of the three also failed content uniformity for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Appropriate controls and understanding of your manufacturing process is essential to ensuring a safe and effective drug product. We acknowledge that your firm has agreed to voluntarily recall lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and to voluntarily destroy lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> which you indicated was not distributed to the market.\u003C\u002Fp>\n\n\u003Cp>The blend process is a critical step in the manufacture of oral solid dosage forms, particularly for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Inadequate handling of blends can promote segregation, increase moisture levels, cause aggregation of particles, and lead to inconsistent flow characteristics. Additionally, because of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;range of this product, content uniformity is critical; it is especially important to prevent patients with \u003Cstrong>(b)(4)\u003C\u002Fstrong> from receiving insufficient or excessive doses.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you will perform concurrent validation to collect sufficient data to evaluate product behavior. Your deviation investigation into the OOS result was in progress and you have developed a revised validation protocol.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you have not provided sufficient data to show where variability is occurring in your process and how you will control it before re-performing validation. In addition, you did not provide a copy of your revised validation protocol. Your use of a concurrent validation approach is inappropriate as you do not appear to have a high degree of understanding of the sources of variation in your manufacturing processes. Furthermore, concurrent validation should be rarely used.\u003C\u002Fp>\n\n\u003Cp>Your manufacturing failures indicate that you do not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers to be appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm070336.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm070336.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A data-driven and scientifically sound analysis that identifies all sources of variability including, but not limited to, raw materials and manual steps (e.g., hand scooping). Determine the capability of each manufacturing process step and provide your corrective action and preventive action (CAPA) plan to reduce process variation.\u003C\u002Fp>\n\n\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• A timeline for performing appropriate process performance qualification (PPQ) for each of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablet drug products.\u003C\u002Fp>\n\n\u003Cp>• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform a thorough investigation after being informed that FDA testing found OOS assay results for one lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets.\u003C\u002Fp>\n\n\u003Cp>You manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets under contract for the product owner, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In the quality agreement with the product owner, you have the primary responsibility for investigating OOS results.\u003C\u002Fp>\n\n\u003Cp>The active ingredient assay specifications you developed with the product owner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products were not appropriate. On April 14, 2020, you were informed of the sub-potent test results and inadequate specification. The active ingredient assay specifications you established with your product owner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. However, the United States Pharmacopeia (USP) monograph for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP has \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> outside of the USP acceptance criteria are adulterated within the meaning of section 501(b) of the FD&amp;C Act, 21 U.S.C. 351(b), in that their strength, quality, or purity falls below the standards set forth in an official compendium recognized in the FD&amp;C Act. FDA notified your customer of this violation in Warning Letter \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Articles represented as a drug recognized in an official compendia must conform to the compendial standards for strength, quality, or purity. We acknowledge that you updated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets active ingredient assay specification.\u003C\u002Fp>\n\n\u003Cp>Your investigation into the OOS sample result was inadequate and did not identify CAPA. Furthermore, an investigation was not performed to ensure that previously released lots met your revised assay specifications. FDA investigators found 13 lots within expiry that exceeded your new assay specification during release or stability testing. These lots should have been identified in your investigation.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you reviewed the batch records and analytical records.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate as you are responsible for conducting a thorough investigation when you become aware that your product may not in compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A review of all other products you manufacture to determine whether or not their specifications are appropriate and justifiable. Conduct a risk assessment for any products and corresponding lots lacking appropriate and justifiable specifications. If any products are found to be outside of compendial standards or other appropriate specifications, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>• Updated procedures to ensure that product specifications undergo a routine review to ensure they remain appropriate.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>• An action plan with timelines and a summary of results from retain sample testing of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablet lots within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients of each lot. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your stability program is inadequate. You failed to have adequate long-term stability data to support the commercial size validation batches manufactured using API from a new supplier. Also, you failed to follow your stability test protocol by not consistently performing disintegration testing. The validation batches using the new API supplier were manufactured from May 16 to June 25, 2019, but not placed into a long-term stability study until May 1, 2020, almost a year later.\u003C\u002Fp>\n\n\u003Cp>Stability data is critical for ensuring that products maintain their identity, strength, quality, purity, and safety throughout their labeled shelf-lives.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you initiated a deviation investigation for the lack of stability testing and that these deficiencies will not reoccur. A stability coordinator will also be hired to oversee the stability program.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not provide interim measures to address the products in the market that are lacking long term stability data.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>\no Stability indicating methods\u003Cbr>\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\no Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>• All procedures that describe these and other elements of your remediated stability program.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to adequately oversee the quality of components received from your supplier and your drug manufacturing operations. For example:\u003C\u002Fp>\n\n\u003Cp>• The variability in API assay results reported by your supplier compared to your testing was not adequately evaluated. The variability observed may compromise the assay and content uniformity of your finished product. For example, your firm’s test results for API lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, had a difference of 7.8% from the API manufacturer’s certificate of analysis (COA). Your firm used your assay result to formulate the finished product. Additionally, the FDA sampled lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the sample results failed to meet the USP assay specification for active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and for content uniformity. In your communication dated September 15, 2020, your firm indicated that this lot was not distributed and will be destroyed.\u003C\u002Fp>\n\n\u003Cp>Per the quality agreement with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm is responsible for the qualification of approved manufacturers. However, during the inspection you had not qualified the new API supplier and you relied on \u003Cstrong>(b)(4)\u003C\u002Fstrong> to perform qualification of the supplier, which is contrary to the agreement.\u003C\u002Fp>\n\n\u003Cp>• Computerized systems in the laboratory had inadequate controls.\u003C\u002Fp>\n\n\u003Cp>• Complaints were not adequately reviewed and investigated.\u003C\u002Fp>\n\n\u003Cp>In your response you stated that your firm recognizes the need to have more interactions with the API manufacturer. You committed to investigating and communicating to the API manufacturer when API release testing results differ more than 3%. Additionally, you have contacted the manufacturer of your HPLC systems to purchase and validate the necessary equipment. You also indicated that your new complaint procedure includes tracking, trending, and evaluating complaints.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not describe when and how you will requalify your API supplier or provide justification for how you determined when differences in API assay need to be investigated. In addition, you did not perform a retrospective review of the test results for your previous API supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Also, you did not perform an assessment to determine the risk from failing to have audit trail enabled controls and unique user passwords.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002FUCM070337.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002FUCM070337.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified, and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing. Include chemical and microbial test methods used to analyze each of your API, along with the corresponding validation or verification if USP methods are used.\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\no A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\no A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>\n\u003Cbr>\n• A detailed description of how your firm will implement an effective system to ensure retention and review of written and electronic laboratory data. Include the following:\u003Cbr>\no Summarize your interim controls to prevent deletion and modification of data.\u003Cbr>\no Define the roles and responsibilities of personnel who have access to analytical instruments and data.\u003Cbr>\no Establish a procedure to ensure that all analytical data including but not limited to sample and standard preparation are documented in accordance with CGMP requirements.\u003Cbr>\no Detail the user privileges for all staff for each of your analytical systems.\u003Cbr>\no Provide a detailed summary of your procedural updates and associated training for user role assignments and controls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the information your firm submitted to FDA's electronic Drug Registration and Listing System and the information collected during the May 2020 inspection, FDA has determined that your firm is distributing \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets, a biological product, without FDA approval or a valid biologics license.\u003C\u002Fp>\n\n\u003Cp>We encourage you to contact FDA's unapproved drugs coordinator, Dr. Sally Loewke, at \u003Cspan>301-796-0710\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> for assistance in communicating with the FDA on the application process for your unapproved biological product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You and your customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>. have a quality agreement regarding the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003Cbr>\n\u003Cbr>\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct the violations cited in this letter promptly. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>FDA may also withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer until the above violations are corrected. We may re-inspect to verify that you have completed your corrective actions.\u003C\u002Fp>\n\n\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act (or you have complied with FDA regulations), include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3007007565. Send your electronic reply to Dr. Shawn Larson – Compliance Officer at Shawn.Larson@fda.hhs.gov and ORAPHARM2_Responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Dr. Larson at \u003Cspan>214-253-5216\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>CC: (Redacted Copy)\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRosy Sultana\n\nRecipient Title\n\nCEO & President\n\nAllay Pharmaceuticals, LLC\n\n16600 NW 54th Ave, Unit 23\n\nHialeah, FL 33014-6109\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nJanuary 27, 2021\n\nCase # 609023\n\nWarning Letter\n\nMs. Sultana:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Allay Pharmaceuticals, LLC, FEI 3007007565, at 16600 NW 54th Avenue, Unit 23, Hialeah, Florida, from May 5 to 15, 2020.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nAdditionally, your (b)(4) tablets are adulterated under section 501(b) of the FD&C Act, 21 U.S.C. 351(b) for failure to conform to compendial standards for strength, quality, or purity.\n\nInformation and records gathered during the course of the inspection reflect that your products are intended to treat a disease or condition. Therefore, your products, (b)(4), are drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)]. Your products, which contain (b)(4) are also biological products as defined in section 351(i)(1) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)(1)] because they are a “protein” as defined in 21 C.F.R. 600.3(h)(6), or are “analogous” to a protein because the identified biological product (i.e., protein) component in these naturally derived mixtures is necessary for the activity of the product and contributes to achieving the intended therapeutic effect.\n\nWe reviewed your June 6, 2020, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to adequately validate the manufacturing processes for your (b)(4) tablets. You lacked adequate data to show homogeneity of your drug product during manufacturing . During your process performance qualification (PPQ), blend samples were (b)(4) before analysis. When samples are (b)(4), it potentially masks the variability of your blend. In addition, you obtained an out-of-specification (OOS) assay result for one of the active ingredients, (b)(4), in your post-compression testing of (b)(4) strength PPQ lot (b)(4).\n\nFDA also collected three samples of (b)(4) tablets during the inspection, two of which were from your process validation lots. All three samples were sub-potent for the active ingredient, (b)(4). One of the three also failed content uniformity for (b)(4).\n\nAppropriate controls and understanding of your manufacturing process is essential to ensuring a safe and effective drug product. We acknowledge that your firm has agreed to voluntarily recall lots (b)(4) and (b)(4), and to voluntarily destroy lot (b)(4) which you indicated was not distributed to the market.\n\nThe blend process is a critical step in the manufacture of oral solid dosage forms, particularly for (b)(4). Inadequate handling of blends can promote segregation, increase moisture levels, cause aggregation of particles, and lead to inconsistent flow characteristics. Additionally, because of the (b)(4) range of this product, content uniformity is critical; it is especially important to prevent patients with (b)(4) from receiving insufficient or excessive doses.\n\nIn your response, you indicated that you will perform concurrent validation to collect sufficient data to evaluate product behavior. Your deviation investigation into the OOS result was in progress and you have developed a revised validation protocol.\n\nYour response is inadequate because you have not provided sufficient data to show where variability is occurring in your process and how you will control it before re-performing validation. In addition, you did not provide a copy of your revised validation protocol. Your use of a concurrent validation approach is inappropriate as you do not appear to have a high degree of understanding of the sources of variation in your manufacturing processes. Furthermore, concurrent validation should be rarely used.\n\nYour manufacturing failures indicate that you do not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers to be appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm070336.pdf.\n\nIn response to this letter, provide the following:\n\n• A data-driven and scientifically sound analysis that identifies all sources of variability including, but not limited to, raw materials and manual steps (e.g., hand scooping). Determine the capability of each manufacturing process step and provide your corrective action and preventive action (CAPA) plan to reduce process variation.\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing appropriate process performance qualification (PPQ) for each of your (b)(4) tablet drug products.\n\n• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm failed to perform a thorough investigation after being informed that FDA testing found OOS assay results for one lot of (b)(4) tablets.\n\nYou manufacture (b)(4) tablets under contract for the product owner, (b)(4). In the quality agreement with the product owner, you have the primary responsibility for investigating OOS results.\n\nThe active ingredient assay specifications you developed with the product owner for (b)(4) and (b)(4) in your (b)(4) products were not appropriate. On April 14, 2020, you were informed of the sub-potent test results and inadequate specification. The active ingredient assay specifications you established with your product owner for (b)(4) and (b)(4) were (b)(4)%. However, the United States Pharmacopeia (USP) monograph for (b)(4), USP has (b)(4) and (b)(4) assay acceptance criteria of (b)(4)%.\n\n(b)(4) outside of the USP acceptance criteria are adulterated within the meaning of section 501(b) of the FD&C Act, 21 U.S.C. 351(b), in that their strength, quality, or purity falls below the standards set forth in an official compendium recognized in the FD&C Act. FDA notified your customer of this violation in Warning Letter (b)(4).\n\nArticles represented as a drug recognized in an official compendia must conform to the compendial standards for strength, quality, or purity. We acknowledge that you updated the (b)(4) tablets active ingredient assay specification.\n\nYour investigation into the OOS sample result was inadequate and did not identify CAPA. Furthermore, an investigation was not performed to ensure that previously released lots met your revised assay specifications. FDA investigators found 13 lots within expiry that exceeded your new assay specification during release or stability testing. These lots should have been identified in your investigation.\n\nIn your response, you stated that you reviewed the batch records and analytical records.\n\nYour response is inadequate as you are responsible for conducting a thorough investigation when you become aware that your product may not in compliance with CGMP.\n\nIn response to this letter, provide the following:\n\n• A review of all other products you manufacture to determine whether or not their specifications are appropriate and justifiable. Conduct a risk assessment for any products and corresponding lots lacking appropriate and justifiable specifications. If any products are found to be outside of compendial standards or other appropriate specifications, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\n• Updated procedures to ensure that product specifications undergo a routine review to ensure they remain appropriate.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• An action plan with timelines and a summary of results from retain sample testing of all (b)(4) tablet lots within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients of each lot. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYour stability program is inadequate. You failed to have adequate long-term stability data to support the commercial size validation batches manufactured using API from a new supplier. Also, you failed to follow your stability test protocol by not consistently performing disintegration testing. The validation batches using the new API supplier were manufactured from May 16 to June 25, 2019, but not placed into a long-term stability study until May 1, 2020, almost a year later.\n\nStability data is critical for ensuring that products maintain their identity, strength, quality, purity, and safety throughout their labeled shelf-lives.\n\nIn your response, you indicated that you initiated a deviation investigation for the lack of stability testing and that these deficiencies will not reoccur. A stability coordinator will also be hired to oversee the stability program.\n\nYour response is inadequate because you did not provide interim measures to address the products in the market that are lacking long term stability data.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\n• All procedures that describe these and other elements of your remediated stability program.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) failed to adequately oversee the quality of components received from your supplier and your drug manufacturing operations. For example:\n\n• The variability in API assay results reported by your supplier compared to your testing was not adequately evaluated. The variability observed may compromise the assay and content uniformity of your finished product. For example, your firm’s test results for API lot (b)(4), used in the manufacture of (b)(4) tablets (b)(4) lot (b)(4), had a difference of 7.8% from the API manufacturer’s certificate of analysis (COA). Your firm used your assay result to formulate the finished product. Additionally, the FDA sampled lot (b)(4) and the sample results failed to meet the USP assay specification for active ingredient, (b)(4), and for content uniformity. In your communication dated September 15, 2020, your firm indicated that this lot was not distributed and will be destroyed.\n\nPer the quality agreement with (b)(4), your firm is responsible for the qualification of approved manufacturers. However, during the inspection you had not qualified the new API supplier and you relied on (b)(4) to perform qualification of the supplier, which is contrary to the agreement.\n\n• Computerized systems in the laboratory had inadequate controls.\n\n• Complaints were not adequately reviewed and investigated.\n\nIn your response you stated that your firm recognizes the need to have more interactions with the API manufacturer. You committed to investigating and communicating to the API manufacturer when API release testing results differ more than 3%. Additionally, you have contacted the manufacturer of your HPLC systems to purchase and validate the necessary equipment. You also indicated that your new complaint procedure includes tracking, trending, and evaluating complaints.\n\nYour response is inadequate. You did not describe when and how you will requalify your API supplier or provide justification for how you determined when differences in API assay need to be investigated. In addition, you did not perform a retrospective review of the test results for your previous API supplier, (b)(4). Also, you did not perform an assessment to determine the risk from failing to have audit trail enabled controls and unique user passwords.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002FUCM070337.pdf.\n\nIn response to this letter, provide the following:\n\n• A comprehensive independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified, and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing. Include chemical and microbial test methods used to analyze each of your API, along with the corresponding validation or verification if USP methods are used.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• A summary of results obtained from testing all components to evaluate the reliability of COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A detailed description of how your firm will implement an effective system to ensure retention and review of written and electronic laboratory data. Include the following:\n\no Summarize your interim controls to prevent deletion and modification of data.\n\no Define the roles and responsibilities of personnel who have access to analytical instruments and data.\n\no Establish a procedure to ensure that all analytical data including but not limited to sample and standard preparation are documented in accordance with CGMP requirements.\n\no Detail the user privileges for all staff for each of your analytical systems.\n\no Provide a detailed summary of your procedural updates and associated training for user role assignments and controls.\n\nUnapproved New Drugs\n\nBased on the information your firm submitted to FDA's electronic Drug Registration and Listing System and the information collected during the May 2020 inspection, FDA has determined that your firm is distributing (b)(4) tablets, a biological product, without FDA approval or a valid biologics license.\n\nWe encourage you to contact FDA's unapproved drugs coordinator, Dr. Sally Loewke, at 301-796-0710 for assistance in communicating with the FDA on the application process for your unapproved biological product.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou and your customer (b)(4). have a quality agreement regarding the manufacture of (b)(4). You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity.\n\nSee FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect the violations cited in this letter promptly. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\n\nFDA may also withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer until the above violations are corrected. We may re-inspect to verify that you have completed your corrective actions.\n\nAfter you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act (or you have complied with FDA regulations), include your reasoning and any supporting information for our consideration.\n\nPlease identify your response with FEI 3007007565. Send your electronic reply to Dr. Shawn Larson – Compliance Officer at Shawn.Larson@fda.hhs.gov and ORAPHARM2_Responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, please contact Dr. Larson at 214-253-5216.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\nCC: (Redacted Copy)\n\n(b)(4)","Allay Pharmaceuticals, LLC","allay-pharmaceuticals-llc-609023-01272021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fallay-pharmaceuticals-llc-609023-01272021","2026-10-26T08:07:52.632004+00:00","2021-02-09","609023","2022-07-25","Rosy Sultana","2026-08-20T03:24:10.327+00:00","VIA Electronic Mail","2021-01-27",{"id":116,"raw":117,"subject":12,"body_html":121,"body_text":122,"firm_name":123,"letter_id":124,"created_at":125,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":130,"body_fetched_at":131,"delivery_method":132,"recipient_title":19,"reference_number":19,"action_taken_date":133,"medical_device_id":19,"response_letter_date":19},21680,[118,119,120,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-14T04:00:00Z\">09\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsca-pharmaceuticals-llc-724202-09142026\">SCA Pharmaceuticals, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kenneth P. Bonnell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Quality Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SCA Pharmaceuticals, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8821 Knoedl Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Little Rock\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72205-4600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 724202\u003C\u002Fp>\u003Cp>September 14, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Bonnell:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on December 13, 2013, and most recently on December 5, 2025. From October 20, 2025, to October 30, 2025, an FDA investigator inspected your facility, SCA Pharmaceuticals, LLC located at 8821 Knoedl Court, Little Rock, Arkansas 72205. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on October 30, 2025. We reviewed your November 21, 2025, and December 31, 2025, responses to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator collected evidence indicating that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator collected evidence indicating that:\u003C\u002Fp>\u003Cp>1. Your facility lacked routine and rigorous certification of the ISO 5 areas, including airflow visualization studies performed under dynamic conditions.\u003C\u002Fp>\u003Cp>2. Your firm did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\u003C\u002Fp>\u003Cp>3. Your component control is not adequately designed or maintained to prevent contamination of product contact surfaces due to the presence of foreign (unusual) material between the stopper ribs of syringes.\u003C\u002Fp>\u003Cp>4. Your compounding technicians and aseptic assistants employ poor practices which introduce risk of microbial contamination into the ISO 5 classified critical areas during production of drugs intended to be sterile.\u003C\u002Fp>\u003Cp>For example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913 and\u002For Methadone HCl 10 mg\u002FmL lot #1125035922, your compounding technicians:\u003C\u002Fp>\u003Cp>a. Moved quickly in a critical area or in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\u003C\u002Fp>\u003Cp>b. Leaned into the hood, allowing their head and upper body to enter the ISO 5 classified critical area, thereby disrupting unidirectional airflow.\u003C\u002Fp>\u003Cp>c. Blocked first pass air by placing gloved hands directly over the following:\u003C\u002Fp>\u003Cp>i. Hanging IV bag ports when making sterile connections.\u003C\u002Fp>\u003Cp>ii. The IV bag ports when disinfecting prior to filling.\u003C\u002Fp>\u003Cp>iii. The open filled syringes and the syringe cap trays during the process of screwing caps onto the syringes.\u003C\u002Fp>\u003Cp>d. Conducted aseptic operations on or directly above the hood deck surface in vertical flow hoods, which prevents unidirectional first air with minimal turbulence from surrounding aseptic operations during sterile connections and filling of drug products intended or expected to be sterile into open sterile containers.\u003C\u002Fp>\u003Cp>e. Regularly rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO 5 work area.\u003C\u002Fp>\u003Cp>Additionally, your aseptic assistants:\u003C\u002Fp>\u003Cp>a. Moved quickly in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\u003C\u002Fp>\u003Cp>b. Used disinfectant in a manner insufficient to achieve adequate levels of disinfection of materials, such as the IV bag ports, during transfer into the ISO 5 classified critical areas by spraying very quickly or from a significant distance or failing to treat both sides of the IV bags. Prior to disinfection, aseptic assistants regularly touched the IV bag ports in the ISO 7 area with their gloved hands.\u003C\u002Fp>\u003Cp>5. Your environmental monitoring program lacks adequate routine environmental monitoring that captures data representative of aseptic production conditions. For example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913:\u003C\u002Fp>\u003Cp>a. The active air sampler is placed to the far right of the hood instead of adjacent to the areas where aseptic operations occur, including the left and center portions of the ISO 5 classified hood.\u003C\u002Fp>\u003Cp>b. Compounding technicians do not always carefully roll their individual fingers across the media touch plate during personnel monitoring. The compounding technician quickly touched each fingertip to the media plates instead of methodically rolling their fingertips.\u003C\u002Fp>\u003Cp>6. Your firm failed to perform adequate airflow visualization studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Your airflow visualization studies are deficient because:\u003C\u002Fp>\u003Cp>a. The studies do not clearly demonstrate that the airflow pattern sweeps over and away from the critical areas near and on the ISO 5 classified LAF hood work surface where aseptic operations occur. Instead, the smoke appears to arc out of the hood significantly higher than the critical area and then travel up toward the ceiling in the surrounding ISO 7 classified area.\u003C\u002Fp>\u003Cp>b. In your most recent airflow visualization study VAL-25-044-FR, you indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> people are allowed in ISO 7 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> during aseptic operations; however, the smoke study videos provided during the FDA inspection only include a maximum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> people, and fail to demonstrate that airflow patterns inside the ISO 5 classified critical areas are not impacted by a large number of personnel moving inside cleanroom Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The FDA investigator also collected evidence indicating CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>2. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\u003C\u002Fp>\u003Cp>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fp>\u003Cp>5. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)). Specifically, our review of the data collected during the inspection revealed that your firm does not maintain the production video recordings which are used to determine root causes and corrective actions during investigations. For example, after recovering microbial contamination inside the ISO 5 classified critical area during the production of Ketamine HCl 10 mg\u002FmL lot 1125035065, your Quality Unit evaluated the production video recording as part of excursion investigation EXC-2025-0045 to examine aseptic practices for potential root causes. However, instead of retaining the video recording as a quality related document, you only retained still images. Your Chief Quality Officer stated that video recordings are kept for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> before being overwritten.\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is also a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s responses to the Form FDA 483 dated November 21, 2025, and December 31, 2025.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear adequate. However, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>1. Although you stated that you performed airflow visualization studies in all \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoods, you did not clearly demonstrate that these studies were performed in all \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoods during the most recent airflow visualization assessment, performed in 2025. Additionally, while you concluded that the hoods are identical and therefore functionally equivalent, this approach does not account for potential variations in the HEPA filter performance, for example, resulting from particulate accumulation over time, nor the impact of physical placement of hoods within the room—including proximity to doors, return vents, and other environmental factors that may affect airflow where production activities are occurring.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. You did not demonstrate that the probable root cause of inadequate material sanitization had no impact on the released portions of the batch associated with microbial excursions in the ISO 5 classified areas during production. You indicated both in your investigations and in your response that your material sanitization process is robust, but also concluded that the microbial contamination was most likely due to inadequate material sanitization.&nbsp;\u003C\u002Fp>\u003Cp>You failed to demonstrate that microbial contamination was not present in the materials associated with the released portions of the batch. You did not demonstrate that the material sanitization process for the released portions of the batches did not include the same deficiencies as the material sanitization for the rejected portion of the batch. Further, you failed to initiate any corrective and preventative action plans to determine whether you need to improve your material sanitization process to prevent reoccurrence.\u003C\u002Fp>\u003Cp>2. It appears that your visual inspection system is inadequate because you classify particulate defects as major and therefore only characterize and investigate the observed particles when the defect rate is above the major defect threshold of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Extrinsic particulates should be classified as critical, and the intrinsic particulates should be evaluated based on multiple factors, including particle size and route of administration, to determine the appropriate defect classification. Your SOP ILP-001-LR, Product Inspection and Defect Classification, states, “If a DRL (Defect Rate Limit) threshold is exceeded related to ‘Particulate\u002Fmaterial in solution,’ the particulate\u002Fmaterial must be identified during the event.” According to your visual inspection data, you detected between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles in \u003Cstrong>(b)(4)\u003C\u002Fstrong> separate lots between April 2025 and September 2025, only \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of which exceeded the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% threshold for major defects. According to your Deviation log, only \u003Cstrong>(b)(4)\u003C\u002Fstrong> defect incidents were investigated between April 2025 and September 2025, and these were related to any Defect Rate Limit Threshold Exceedance, not just those involving particles. Therefore, you do not have an adequate system in place to ensure that you identify and appropriately investigate contaminating particles.\u003C\u002Fp>\u003Cp>3. You did not commit to revising the minor defect classification for “[f]oreign (unusual) material, e.g., cardboard trapped between stopper ribs” to account for the criticality of the foreign material. While you noted that any units exhibiting this defect are rejected, the defect rate limit applied to minor defects (\u003Cstrong>(b)(4)\u003C\u002Fstrong>%) is not appropriate for adequately investigating, trending, and performing corrective actions, as necessary, to mitigate this contamination risk.\u003C\u002Fp>\u003Cp>You did not provide adequate documentation to demonstrate that foreign materials are contained within the ribs of the syringe stoppers in non-product-contact area and will not pose contamination risks to the drug product. In addition, the syringe filling process demonstrates that the foreign material does come into contact with product-contact area of the syringes. For example, any cardboard particles trapped within the syringe ribs may be pressed against the inner syringe wall during filling, potentially introducing particles onto a surface that subsequently contacts the drug product solution.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (# 724202) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>cc: Scott P. Luce, Chief Executive Officer\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKenneth P. Bonnell\n\nRecipient Title\n\nChief Quality Officer\n\nSCA Pharmaceuticals, LLC\n\n8821 Knoedl Court\n\nLittle Rock, AR 72205-4600\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 724202\nSeptember 14, 2026\nDear Mr. Bonnell:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on December 13, 2013, and most recently on December 5, 2025. From October 20, 2025, to October 30, 2025, an FDA investigator inspected your facility, SCA Pharmaceuticals, LLC located at 8821 Knoedl Court, Little Rock, Arkansas 72205. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your facility on October 30, 2025. We reviewed your November 21, 2025, and December 31, 2025, responses to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nB. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator collected evidence indicating that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator collected evidence indicating that:\n1. Your facility lacked routine and rigorous certification of the ISO 5 areas, including airflow visualization studies performed under dynamic conditions.\n2. Your firm did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\n3. Your component control is not adequately designed or maintained to prevent contamination of product contact surfaces due to the presence of foreign (unusual) material between the stopper ribs of syringes.\n4. Your compounding technicians and aseptic assistants employ poor practices which introduce risk of microbial contamination into the ISO 5 classified critical areas during production of drugs intended to be sterile.\nFor example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913 and\u002For Methadone HCl 10 mg\u002FmL lot #1125035922, your compounding technicians:\na. Moved quickly in a critical area or in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\nb. Leaned into the hood, allowing their head and upper body to enter the ISO 5 classified critical area, thereby disrupting unidirectional airflow.\nc. Blocked first pass air by placing gloved hands directly over the following:\ni. Hanging IV bag ports when making sterile connections.\nii. The IV bag ports when disinfecting prior to filling.\niii. The open filled syringes and the syringe cap trays during the process of screwing caps onto the syringes.\nd. Conducted aseptic operations on or directly above the hood deck surface in vertical flow hoods, which prevents unidirectional first air with minimal turbulence from surrounding aseptic operations during sterile connections and filling of drug products intended or expected to be sterile into open sterile containers.\ne. Regularly rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO 5 work area.\nAdditionally, your aseptic assistants:\na. Moved quickly in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\nb. Used disinfectant in a manner insufficient to achieve adequate levels of disinfection of materials, such as the IV bag ports, during transfer into the ISO 5 classified critical areas by spraying very quickly or from a significant distance or failing to treat both sides of the IV bags. Prior to disinfection, aseptic assistants regularly touched the IV bag ports in the ISO 7 area with their gloved hands.\n5. Your environmental monitoring program lacks adequate routine environmental monitoring that captures data representative of aseptic production conditions. For example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913:\na. The active air sampler is placed to the far right of the hood instead of adjacent to the areas where aseptic operations occur, including the left and center portions of the ISO 5 classified hood.\nb. Compounding technicians do not always carefully roll their individual fingers across the media touch plate during personnel monitoring. The compounding technician quickly touched each fingertip to the media plates instead of methodically rolling their fingertips.\n6. Your firm failed to perform adequate airflow visualization studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Your airflow visualization studies are deficient because:\na. The studies do not clearly demonstrate that the airflow pattern sweeps over and away from the critical areas near and on the ISO 5 classified LAF hood work surface where aseptic operations occur. Instead, the smoke appears to arc out of the hood significantly higher than the critical area and then travel up toward the ceiling in the surrounding ISO 7 classified area.\nb. In your most recent airflow visualization study VAL-25-044-FR, you indicated that (b)(4) people are allowed in ISO 7 (b)(4) Room (b)(4) during aseptic operations; however, the smoke study videos provided during the FDA inspection only include a maximum of (b)(4) people, and fail to demonstrate that airflow patterns inside the ISO 5 classified critical areas are not impacted by a large number of personnel moving inside cleanroom Room (b)(4).\nThe FDA investigator also collected evidence indicating CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n2. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n5. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)). Specifically, our review of the data collected during the inspection revealed that your firm does not maintain the production video recordings which are used to determine root causes and corrective actions during investigations. For example, after recovering microbial contamination inside the ISO 5 classified critical area during the production of Ketamine HCl 10 mg\u002FmL lot 1125035065, your Quality Unit evaluated the production video recording as part of excursion investigation EXC-2025-0045 to examine aseptic practices for potential root causes. However, instead of retaining the video recording as a quality related document, you only retained still images. Your Chief Quality Officer stated that video recordings are kept for approximately (b)(4) before being overwritten.\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is also a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nC. Corrective Actions\nWe have reviewed your facility’s responses to the Form FDA 483 dated November 21, 2025, and December 31, 2025.\nSome of your corrective actions appear adequate. However, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n1. Although you stated that you performed airflow visualization studies in all (b)(4) hoods, you did not clearly demonstrate that these studies were performed in all (b)(4) hoods during the most recent airflow visualization assessment, performed in 2025. Additionally, while you concluded that the hoods are identical and therefore functionally equivalent, this approach does not account for potential variations in the HEPA filter performance, for example, resulting from particulate accumulation over time, nor the impact of physical placement of hoods within the room—including proximity to doors, return vents, and other environmental factors that may affect airflow where production activities are occurring.\nSome of your corrective actions appear deficient:\n1. You did not demonstrate that the probable root cause of inadequate material sanitization had no impact on the released portions of the batch associated with microbial excursions in the ISO 5 classified areas during production. You indicated both in your investigations and in your response that your material sanitization process is robust, but also concluded that the microbial contamination was most likely due to inadequate material sanitization.\nYou failed to demonstrate that microbial contamination was not present in the materials associated with the released portions of the batch. You did not demonstrate that the material sanitization process for the released portions of the batches did not include the same deficiencies as the material sanitization for the rejected portion of the batch. Further, you failed to initiate any corrective and preventative action plans to determine whether you need to improve your material sanitization process to prevent reoccurrence.\n2. It appears that your visual inspection system is inadequate because you classify particulate defects as major and therefore only characterize and investigate the observed particles when the defect rate is above the major defect threshold of (b)(4)%. Extrinsic particulates should be classified as critical, and the intrinsic particulates should be evaluated based on multiple factors, including particle size and route of administration, to determine the appropriate defect classification. Your SOP ILP-001-LR, Product Inspection and Defect Classification, states, “If a DRL (Defect Rate Limit) threshold is exceeded related to ‘Particulate\u002Fmaterial in solution,’ the particulate\u002Fmaterial must be identified during the event.” According to your visual inspection data, you detected between (b)(4) and (b)(4) particles in (b)(4) separate lots between April 2025 and September 2025, only (b)(4) lots of which exceeded the (b)(4)% threshold for major defects. According to your Deviation log, only (b)(4) defect incidents were investigated between April 2025 and September 2025, and these were related to any Defect Rate Limit Threshold Exceedance, not just those involving particles. Therefore, you do not have an adequate system in place to ensure that you identify and appropriately investigate contaminating particles.\n3. You did not commit to revising the minor defect classification for “[f]oreign (unusual) material, e.g., cardboard trapped between stopper ribs” to account for the criticality of the foreign material. While you noted that any units exhibiting this defect are rejected, the defect rate limit applied to minor defects ((b)(4)%) is not appropriate for adequately investigating, trending, and performing corrective actions, as necessary, to mitigate this contamination risk.\nYou did not provide adequate documentation to demonstrate that foreign materials are contained within the ribs of the syringe stoppers in non-product-contact area and will not pose contamination risks to the drug product. In addition, the syringe filling process demonstrates that the foreign material does come into contact with product-contact area of the syringes. For example, any cardboard particles trapped within the syringe ribs may be pressed against the inner syringe wall during filling, potentially introducing particles onto a surface that subsequently contacts the drug product solution.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nD. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (# 724202) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\ncc: Scott P. Luce, Chief Executive Officer\n____________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).","SCA Pharmaceuticals, LLC","sca-pharmaceuticals-llc-724202-09142026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsca-pharmaceuticals-llc-724202-09142026","2026-11-17T01:02:03.701861+00:00","2026-10-13","724202","Kenneth P. Bonnell","2026-10-14T12:32:29.583+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-09-14",{"id":135,"raw":136,"subject":12,"body_html":140,"body_text":141,"firm_name":142,"letter_id":143,"created_at":144,"fei_number":19,"letter_url":145,"updated_at":146,"action_type":22,"case_status":23,"posted_date":147,"marcs_cms_no":148,"product_type":48,"closeout_date":19,"issuing_office":11,"recipient_name":149,"body_fetched_at":150,"delivery_method":151,"recipient_title":19,"reference_number":152,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},3596,[137,138,139,11,12,13,13,13],"\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-12T04:00:00Z\">08\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkc-pharmaceuticals-inc-729870-08122026\">K.C. Pharmaceuticals, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-112\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Ratnawati Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>K.C. Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3420 Pomona Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pomona\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91768\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-112\u003C\u002Fp>\u003Cp>August 12, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Li:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, K.C. Pharmaceuticals, Inc., FEI 2026940, at 3420 Pomona Blvd., Pomona, CA, from January 20 to February 13, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 10, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Media Fills\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm continued to manufacture and release sterile drug products manufactured by aseptic processing following media fill failures on June 21, 2024, September 4, 2024, and November 4, 2024 as well as inconclusive media fill results and other significant quality events. Your firm lacked timely and adequate media fill investigations. For instance, your root causes were unsupported and lacked effective corrective actions.\u003C\u002Fp>\u003Cp>Following the inspection, you committed to recalling \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of drug products made from \u003Cstrong>(b)(4)\u003C\u002Fstrong> which reflects the timeframe between the failing media fills. In addition, you commit to improving your quality unit (QU) escalation procedures to ensure proper awareness and to engaging an outside consultant to provide oversight of your QU for six months.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide a retrospective review of all media fills to ensure additional deviations, atypical events, and unexpected results during commercial manufacturing were adequately represented in your media fill programs.\u003C\u002Fp>\u003Cp>\u003Cem>Poor Practices in the Aseptic Processing Areas\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed poor practices and behaviors in ISO 5 areas during commercial operations and media fills. These poor practices, included but are not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Operators inserting their upper torso into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier system (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS) during interventions, breaching the ISO 5 barrier.\u003C\u002Fli>\u003Cli>An operator performing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> RABS intervention directly with the \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> instead of using forceps.\u003C\u002Fli>\u003Cli>Shorter operators opening the \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> and bypassing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> during difficult-to-reach interventions, while taller operators used the \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to retraining the operators on appropriate aseptic behaviors. Also, you commit to revising procedures and engaging outside consultants to review practices.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not address how you plan to ensure operators follow appropriate procedures in the future, including supervisory and quality assurance oversight. Additionally, these poor aseptic practices were not investigated to determine the impact to sterile drug products manufactured under these conditions and distributed to the U.S. market. Your response also fails to reevaluate your aseptic processing design. Specifically, you do not identify and evaluate hazards posed by various manual activities (e.g., planned interventions, unplanned interventions, \u003Cstrong>(b)(4)\u003C\u002Fstrong>) or address the risks that insufficient design poses.\u003C\u002Fp>\u003Cp>\u003Cem>Airflow Visualization Studies (AVS) and Process Design\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our inspection identified aseptic processing design deficiencies which pose significant hazards to drug product sterility, as well as multiple inadequacies in your airflow visualization studies (i.e., smoke studies). For example, unidirectional airflow could not be evaluated in certain AVS. There were interventions performed in which the camera is placed behind the operator and the impact of the intervention on the airflow cannot be visualized.\u003C\u002Fp>\u003Cp>Our inspection also noted other AVS deficiencies. For example, the smoke source was not always positioned at the HEPA filter face to confirm unidirectional airflow and uniform velocity. We previously discussed inadequate smoke studies in our August 3, 2023, Warning Letter issued to your firm.\u003C\u002Fp>\u003Cp>In addition, the worst-case locations for environmental monitoring of the ISO 5 filling room and \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS have not been defined through adequate risk assessment.\u003C\u002Fp>\u003Cp>In your response, you commit to suspending filling operations until remediation activities, including improvements to AVS, are completed. You also acknowledge appropriate smoke studies are required to demonstrate unidirectional airflow patterns and proper aseptic techniques and behaviors are critical elements of sterility assurance. You commit to improve your smoke study protocol with the assistance of external consultants and to re-execute smoke studies in ISO 5, 7, and 8 areas prior to resuming operations.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not address how drug products made with inadequate aseptic processing design and distributed to the U.S. market will be evaluated to ensure their sterility assurance. Your response also fails to consider line design changes that would minimize the need for frequent operator interaction with the aseptic processing line.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter:\u003C\u002Fp>\u003Cul>\u003Cli>Provide your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fli>\u003Cli>Review prior “passing” aseptic process simulations (media fills) for previously missed deviations, unusual activities, and unexpected results. Explain actions taken to evaluate and address the acceptability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs produced using your aseptic filling process that were distributed to the U.S. market.\u003C\u002Fli>\u003Cli>Perform a critical evaluation of airflow unidirectionality in your aseptic process, with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions, with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and be conducted using proper practices (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) to appropriately visualize airflow.\u003C\u002Fli>\u003Cli>Provide your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying corrective and preventive action (CAPA):\u003Cbr>o Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations.\u003Cbr>o Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\u003Cbr>o Frequency and depth of QU oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations.\u003Cbr>o Adequacy of written procedures.\u003Cbr>o Evaluation of the impact poor aseptic technique and cleanroom behavior may have had on the sterility of your drugs.\u003C\u002Fli>\u003Cli>Provide a comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible).\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space.\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to air volume and flow.\u003Cbr>o Facility layout.\u003Cbr>o Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers).\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\u003Cbr>o A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your post-fill visual inspection of aseptically filled over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products was insufficient to identify particulate matter and defects which may be present in each unit. Your drug product containers are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and only very slightly \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and particulates can be seen through them readily, which does not meet the criteria for “difficult to inspect.” For example, your firm only conducted subvisible particulate testing on a sample of units based on your assertion that the bottles were \u003Cstrong>(b)(4)\u003C\u002Fstrong> and not suitable for visual inspection. Further, your Acceptable Quality Limit (AQL) testing was designed to examine for filling, labeling, and packaging defects only, and did not include defect categories for particulates or foreign matter.\u003C\u002Fp>\u003Cp>Your firm’s inadequate visual inspection program provides insufficient assurance to prevent release of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products with particulate matter or foreign material defects.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that 100% visual inspection is not performed and that you lack the proper procedures and\u002For equipment. You commit to modifying your visual inspection program to include the reliable detection of particulate contamination and other visible defects prior to resuming production operations.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you commit to evaluating the visual inspection program and replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not consider a combination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection methods to ensure detection of the wide array of potential visible product defects. Also, you did not consider the impact of particulates or foreign matter in \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products that were distributed to the U.S. market.\u003C\u002Fp>\u003Cp>We encourage the use of suitable \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection for particulates to augment the 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection program. \u003Cstrong>(b)(4)\u003C\u002Fstrong> methods should be rigorously studied, and qualified, to assess their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, product characteristic, and other variables. In addition, any use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate inspection as an adjunct method does not supplant the need for 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection, for various other attributes (e.g., cracks, deformities, closure issues, volume, insufficient crimping, leaks, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, discoloration, turbidity, other appearance defects).\u003C\u002Fp>\u003Cp>In addition, your firm failed to provide adequate data to demonstrate manufacturing systems were adequately maintained, operated, and monitored. For example, you lacked a formalized process and procedure for responding to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> alarms. Alarms occurred at multiple timepoints from 2024 to 2026 without documented evidence of a systematic or appropriate response. OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products manufactured at your firm use \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the main component for each formulation.\u003C\u002Fp>\u003Cp>Further, your firm has not completed commitments made during the Regulatory Meeting held January 10, 2025.\u003C\u002Fp>\u003Cp>In your response, you commit to creating new procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> maintenance and operation, including responding to alarms and performing a comprehensive review of alarm histories to determine if notable alarms require further investigation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide documentation or details on the review of alarms for potential impact to drug products made with \u003Cstrong>(b)(4)\u003C\u002Fstrong> from your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We acknowledge that you are using an independent third-party consultant to evaluate your visual inspection program. You should consider performing a comprehensive assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should incorporate U.S. Pharmacopeia (USP) &lt;790&gt; Visible Particulates in Injections and USP &lt;771&gt; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Products-Quality Tests, including container-specific testing protocols (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for each container type. Your strategy should include:\u003C\u002Fp>\u003Cul>\u003Cli>Implementing 100% visible inspection using enhanced lighting with background contrast methods, as appropriate, for difficult-to-inspect products (DIP) (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers) that allow visual inspection.\u003C\u002Fli>\u003Cli>For drug products that preclude visual inspection (e.g., products packaged in \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers), using destructive testing (e.g., subvisible particulate matter) with appropriate, statistically significant sample sizes to test for critical defects.\u003C\u002Fli>\u003Cli>Where traditional visual inspection methods cannot be used, establishing periodic in-process visible particulate matter testing for both bulk solution and fill\u002Ffinish operations to ensure process control, and implementing enhanced manufacturing controls, including strengthened \u003Cstrong>(b)(4)\u003C\u002Fstrong> and environmental controls.\u003C\u002Fli>\u003Cli>Developing a product-specific, risk-based visual inspection approach incorporating product knowledge, process experience, deviation investigation analysis, and recall\u002Fcomplaint data to ensure ongoing compliance with USP &lt;790&gt;, USP &lt;771&gt;, and CGMP requirements.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, in response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An evaluation of customer and clients’ complaints received for potential particulates that were overlooked due to use of inadequate defect criteria during visual inspection.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including:\u003Cbr>o A \u003Cstrong>(b)(4)\u003C\u002Fstrong> system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>Your total microbial count limits to monitor whether this system is producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> suitable for the intended uses for each of your drug products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the drug products produced by your firm. Total microbial count limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> systems are generally tighter than your current\u002Fproposed action and alert limits for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid dosage forms produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not established stability indicating methods for the OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products you distribute to the U.S. market. For example, the validation protocol for the assay of Naphazoline HCl (NPZ) in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> formulation detailed a stress study; however, the report stated that the stress study would be performed later and reported separately. Assay for NPZ is a test conducted for stability studies of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> formulation. Without forced degradations studies to establish specificity, the accuracy of the test assay results cannot be assured throughout the shelf-life of the product during stability.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that initial forced degradation studies for the current OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> formulations could not be located, and you commit to repeating these studies and creating an action plan based on the results. In addition, you commit to conducting a three-year retrospective review for the active pharmaceutical ingredient (API) testing during stability for each product code and to conducting a review of prior annual product reviews to evaluate any stability trends observed for the API and preservative systems for each product code.\u003C\u002Fp>\u003Cp>Proper document control and data management is foundational to CGMP to ensure the availability and integrity of data. Data should be attributable, legible, contemporaneously recorded, original or a true copy, and accurate (ALCOA) to ensure complete and accurate records.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your review of retrospective data using methods that have not been validated as stability indicating provides insufficient confidence in your marketed drug products. Upon development of your stability indicating methods, you should add additional batches to your stability program, including retains of older batches (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>). You did not assess the impact of inadequate stability testing and the potential for degradation products in OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products within expiry distributed to the U.S. market.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint), as part of a program that encompasses each quality attribute that may change over the product shelf-life.\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>A commitment to notify FDA within 3 days of any stability failures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR (211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not adequately perform system suitability testing for laboratory equipment before testing your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and other critical samples. For example, your firm routinely performed total organic carbon (TOC) and conductivity measurements without prior system suitability of the analyzer.\u003C\u002Fp>\u003Cp>In your response, you acknowledge inadequate procedural requirements and insufficient analyst and supervisor training for performing day-of-use system suitability. You commit to revising procedures and to holistically investigate other test methods.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide details of your review of historical system suitability results that concluded there were no adverse trends for drug products on the market within expiry. Additionally, you did not address the lack of system suitability performance for the other examples cited on the Form FDA 483 and did not expand the review to other laboratory systems beyond the TOC and conductivity systems or retrospectively review results generated with the other systems for accuracy.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Your retrospective review of system suitability results from laboratory equipment used to generate data in support of drug product manufacturing and release for distribution, including risk assessments and remediation plans.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Complaint Handling\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your QU did not adequately ensure procedures were established and followed. For example, your procedure for customer complaints and inquiries is inadequate. Your approach to determining severity and adverse events resulted in delayed and incomplete investigations. Additionally, investigations were based on the client and not the severity of the complaint. Also, adequate complaint investigations were not completed in a timely manner.\u003C\u002Fp>\u003Cp>In your response, you commit to revising your procedure and reviewing past complaints to ensure serious events are properly investigated.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide the status of open complaint investigations or whether additional complaints have been received since the close of the inspection.\u003C\u002Fp>\u003Cp>\u003Cem>Stability Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your QU failed to ensure stability testing was conducted according to your program procedures. Your firm missed stability time points, missed stability tests, or performed incorrect tests on batches placed into your stability program.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the lack of proper QU oversight of the stability program. You commit to performing an impact assessment with the assistance of external consultants and revising your stability program procedure.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide details on how the impact of incomplete stability testing will be assessed for product batches that have been distributed to the US. market.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your overall complaint system, including a retrospective review of all complaints for the last three years from the initial date of the inspection, with an assessment that includes but is not limited to:\u003Cbr>o Nature of complaint, and potential associated risk.\u003Cbr>o Date of first notification and subsequent contacts with complainant.\u003Cbr>o Timing and sufficiency of followups with complainant to obtain photographs and the complaint sample, as well as to obtain any additional contextual information. Determine relevant complaint samples were available and extent of efforts to obtain the complaint sample. If insufficient attempts were made, identify the root cause(s) for not adequately pursuing their return.\u003Cbr>o Review of long-term history for similar or same defects.\u003Cbr>o Identification of potential causes of the defect that led to the complaint, including evaluation whether the scientific justification and evidence relating to the identified root cause(s) were adequately documented. In the event a complaint was attributed to factors outside of the firm’s control (e.g., user error), assess the strength of this determination and whether it was based on conclusive or inconclusive information.\u003Cbr>o CAPA steps taken, including but not limited to manufacturing\u002Fquality improvements (e.g., manufacturing operation, raw materials, supplier, quality control), as well as recalls or heightened quality surveillance (additional testing\u002Fexaminations, adding batch to stability program).\u003Cbr>o For all complaint investigations found by the retrospective review to be deficient due to insufficient root cause or CAPA, perform a thorough analysis of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, out-of-specification history, batch failure history).\u003Cbr>o Based upon this independent review, provide a comprehensive assessment of the complaint system that identifies all deficiencies and needed improvements.\u003Cbr>o The status of your review of open complaint investigations and whether additional complaints have been received since the procedure has been revised.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint), as part of a program that encompasses each quality attribute that may change over the product shelf-life.\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document, \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your inspectional history indicates that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products at this facility.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On February 18, 2026, you initiated a voluntary recall of all commercial drug products manufactured between March 27, 2024, and November 7, 2024 due to failing media fills and a lack of sterility assurance. The company announcement was posted to the FDA website at:\u003C\u002Fp>\u003Cul>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=218993\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219008\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219030\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219049\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219055\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219061\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219063\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219064\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous warning letter (issued August 3, 2023), FDA cited similar severe CGMP violations. The recurrence of these violations demonstrates that your firm’s corrective actions were neither effective nor durable. Notably, your failure to correct these issues led to unacceptable drug product being distributed to the U.S. market.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Request for a Meeting with FDA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>After you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your CAPA in detail. Please direct your request to Christina Reyes at christina.reyes@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2026940 and ATTN: Carrie A. Hughes.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>________________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-112\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMs. Ratnawati Li\n\nRecipient Title\n\nChief Executive Officer\n\nK.C. Pharmaceuticals, Inc.\n\n3420 Pomona Blvd.\n\nPomona, CA 91768\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-112\nAugust 12, 2026\nDear Ms. Li:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, K.C. Pharmaceuticals, Inc., FEI 2026940, at 3420 Pomona Blvd., Pomona, CA, from January 20 to February 13, 2026.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 10, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nMedia Fills\nYour firm continued to manufacture and release sterile drug products manufactured by aseptic processing following media fill failures on June 21, 2024, September 4, 2024, and November 4, 2024 as well as inconclusive media fill results and other significant quality events. Your firm lacked timely and adequate media fill investigations. For instance, your root causes were unsupported and lacked effective corrective actions.\nFollowing the inspection, you committed to recalling (b)(4) batches of drug products made from (b)(4) which reflects the timeframe between the failing media fills. In addition, you commit to improving your quality unit (QU) escalation procedures to ensure proper awareness and to engaging an outside consultant to provide oversight of your QU for six months.\nYour response is inadequate. You did not provide a retrospective review of all media fills to ensure additional deviations, atypical events, and unexpected results during commercial manufacturing were adequately represented in your media fill programs.\nPoor Practices in the Aseptic Processing Areas\nWe observed poor practices and behaviors in ISO 5 areas during commercial operations and media fills. These poor practices, included but are not limited to:\nOperators inserting their upper torso into the (b)(4) restricted access barrier system ((b)(4)RABS) during interventions, breaching the ISO 5 barrier.\nAn operator performing a (b)(4) RABS intervention directly with the (b)(4)RABS (b)(4) instead of using forceps.\nShorter operators opening the (b)(4)RABS (b)(4) and bypassing the (b)(4) during difficult-to-reach interventions, while taller operators used the (b)(4)RABS (b)(4).\nIn your response, you commit to retraining the operators on appropriate aseptic behaviors. Also, you commit to revising procedures and engaging outside consultants to review practices.\nYour response is inadequate. You do not address how you plan to ensure operators follow appropriate procedures in the future, including supervisory and quality assurance oversight. Additionally, these poor aseptic practices were not investigated to determine the impact to sterile drug products manufactured under these conditions and distributed to the U.S. market. Your response also fails to reevaluate your aseptic processing design. Specifically, you do not identify and evaluate hazards posed by various manual activities (e.g., planned interventions, unplanned interventions, (b)(4)) or address the risks that insufficient design poses.\nAirflow Visualization Studies (AVS) and Process Design\nOur inspection identified aseptic processing design deficiencies which pose significant hazards to drug product sterility, as well as multiple inadequacies in your airflow visualization studies (i.e., smoke studies). For example, unidirectional airflow could not be evaluated in certain AVS. There were interventions performed in which the camera is placed behind the operator and the impact of the intervention on the airflow cannot be visualized.\nOur inspection also noted other AVS deficiencies. For example, the smoke source was not always positioned at the HEPA filter face to confirm unidirectional airflow and uniform velocity. We previously discussed inadequate smoke studies in our August 3, 2023, Warning Letter issued to your firm.\nIn addition, the worst-case locations for environmental monitoring of the ISO 5 filling room and (b)(4)RABS have not been defined through adequate risk assessment.\nIn your response, you commit to suspending filling operations until remediation activities, including improvements to AVS, are completed. You also acknowledge appropriate smoke studies are required to demonstrate unidirectional airflow patterns and proper aseptic techniques and behaviors are critical elements of sterility assurance. You commit to improve your smoke study protocol with the assistance of external consultants and to re-execute smoke studies in ISO 5, 7, and 8 areas prior to resuming operations.\nYour response is inadequate. You did not address how drug products made with inadequate aseptic processing design and distributed to the U.S. market will be evaluated to ensure their sterility assurance. Your response also fails to consider line design changes that would minimize the need for frequent operator interaction with the aseptic processing line.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter:\nProvide your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\nReview prior “passing” aseptic process simulations (media fills) for previously missed deviations, unusual activities, and unexpected results. Explain actions taken to evaluate and address the acceptability of (b)(4) drugs produced using your aseptic filling process that were distributed to the U.S. market.\nPerform a critical evaluation of airflow unidirectionality in your aseptic process, with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions, with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and be conducted using proper practices (e.g., (b)(4)) to appropriately visualize airflow.\nProvide your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying corrective and preventive action (CAPA):\no Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations.\no Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\no Frequency and depth of QU oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations.\no Adequacy of written procedures.\no Evaluation of the impact poor aseptic technique and cleanroom behavior may have had on the sterility of your drugs.\nProvide a comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible).\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space.\no Air quality in the ISO 5 area and surrounding room including, but not limited to air volume and flow.\no Facility layout.\no Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers).\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\no A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour post-fill visual inspection of aseptically filled over-the-counter (OTC) (b)(4) drug products was insufficient to identify particulate matter and defects which may be present in each unit. Your drug product containers are (b)(4), and only very slightly (b)(4), and particulates can be seen through them readily, which does not meet the criteria for “difficult to inspect.” For example, your firm only conducted subvisible particulate testing on a sample of units based on your assertion that the bottles were (b)(4) and not suitable for visual inspection. Further, your Acceptable Quality Limit (AQL) testing was designed to examine for filling, labeling, and packaging defects only, and did not include defect categories for particulates or foreign matter.\nYour firm’s inadequate visual inspection program provides insufficient assurance to prevent release of (b)(4) drug products with particulate matter or foreign material defects.\nIn your response, you acknowledge that 100% visual inspection is not performed and that you lack the proper procedures and\u002For equipment. You commit to modifying your visual inspection program to include the reliable detection of particulate contamination and other visible defects prior to resuming production operations.\nYour response is inadequate. Although you commit to evaluating the visual inspection program and replacing the (b)(4), you did not consider a combination of (b)(4) inspection methods to ensure detection of the wide array of potential visible product defects. Also, you did not consider the impact of particulates or foreign matter in (b)(4) drug products that were distributed to the U.S. market.\nWe encourage the use of suitable (b)(4) visual inspection for particulates to augment the 100% (b)(4) visual inspection program. (b)(4) methods should be rigorously studied, and qualified, to assess their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, product characteristic, and other variables. In addition, any use of (b)(4) particulate inspection as an adjunct method does not supplant the need for 100% (b)(4) visual inspection, for various other attributes (e.g., cracks, deformities, closure issues, volume, insufficient crimping, leaks, (b)(4), discoloration, turbidity, other appearance defects).\nIn addition, your firm failed to provide adequate data to demonstrate manufacturing systems were adequately maintained, operated, and monitored. For example, you lacked a formalized process and procedure for responding to your (b)(4) alarms. Alarms occurred at multiple timepoints from 2024 to 2026 without documented evidence of a systematic or appropriate response. OTC (b)(4) drug products manufactured at your firm use (b)(4) as the main component for each formulation.\nFurther, your firm has not completed commitments made during the Regulatory Meeting held January 10, 2025.\nIn your response, you commit to creating new procedures for the (b)(4) maintenance and operation, including responding to alarms and performing a comprehensive review of alarm histories to determine if notable alarms require further investigation.\nYour response is inadequate. You did not provide documentation or details on the review of alarms for potential impact to drug products made with (b)(4) from your (b)(4).\nWe acknowledge that you are using an independent third-party consultant to evaluate your visual inspection program. You should consider performing a comprehensive assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should incorporate U.S. Pharmacopeia (USP) \u003C790> Visible Particulates in Injections and USP \u003C771> (b)(4) Products-Quality Tests, including container-specific testing protocols (e.g., (b)(4)) for each container type. Your strategy should include:\nImplementing 100% visible inspection using enhanced lighting with background contrast methods, as appropriate, for difficult-to-inspect products (DIP) (e.g., (b)(4) containers) that allow visual inspection.\nFor drug products that preclude visual inspection (e.g., products packaged in (b)(4) containers), using destructive testing (e.g., subvisible particulate matter) with appropriate, statistically significant sample sizes to test for critical defects.\nWhere traditional visual inspection methods cannot be used, establishing periodic in-process visible particulate matter testing for both bulk solution and fill\u002Ffinish operations to ensure process control, and implementing enhanced manufacturing controls, including strengthened (b)(4) and environmental controls.\nDeveloping a product-specific, risk-based visual inspection approach incorporating product knowledge, process experience, deviation investigation analysis, and recall\u002Fcomplaint data to ensure ongoing compliance with USP \u003C790>, USP \u003C771>, and CGMP requirements.\nAdditionally, in response to this letter, provide:\nAn evaluation of customer and clients’ complaints received for potential particulates that were overlooked due to use of inadequate defect criteria during visual inspection.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4), including:\no A (b)(4) system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nYour total microbial count limits to monitor whether this system is producing (b)(4) suitable for the intended uses for each of your drug products.\nA detailed risk assessment addressing the potential effects of the observed (b)(4) failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your (b)(4) monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4). Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the drug products produced by your firm. Total microbial count limits for (b)(4) systems are generally tighter than your current\u002Fproposed action and alert limits for the (b)(4) liquid dosage forms produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets the USP (b)(4) monograph specifications and appropriate microbial limits.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nYour firm has not established stability indicating methods for the OTC (b)(4) drug products you distribute to the U.S. market. For example, the validation protocol for the assay of Naphazoline HCl (NPZ) in the (b)(4) formulation detailed a stress study; however, the report stated that the stress study would be performed later and reported separately. Assay for NPZ is a test conducted for stability studies of the (b)(4) formulation. Without forced degradations studies to establish specificity, the accuracy of the test assay results cannot be assured throughout the shelf-life of the product during stability.\nIn your response, you acknowledge that initial forced degradation studies for the current OTC (b)(4) formulations could not be located, and you commit to repeating these studies and creating an action plan based on the results. In addition, you commit to conducting a three-year retrospective review for the active pharmaceutical ingredient (API) testing during stability for each product code and to conducting a review of prior annual product reviews to evaluate any stability trends observed for the API and preservative systems for each product code.\nProper document control and data management is foundational to CGMP to ensure the availability and integrity of data. Data should be attributable, legible, contemporaneously recorded, original or a true copy, and accurate (ALCOA) to ensure complete and accurate records.\nYour response is inadequate. Your review of retrospective data using methods that have not been validated as stability indicating provides insufficient confidence in your marketed drug products. Upon development of your stability indicating methods, you should add additional batches to your stability program, including retains of older batches (e.g., (b)(4)). You did not assess the impact of inadequate stability testing and the potential for degradation products in OTC (b)(4) drug products within expiry distributed to the U.S. market.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint), as part of a program that encompasses each quality attribute that may change over the product shelf-life.\no All procedures that describe these and other elements of your remediated stability program.\nA commitment to notify FDA within 3 days of any stability failures.\n4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR (211.160(b)).\nYour firm did not adequately perform system suitability testing for laboratory equipment before testing your (b)(4) and other critical samples. For example, your firm routinely performed total organic carbon (TOC) and conductivity measurements without prior system suitability of the analyzer.\nIn your response, you acknowledge inadequate procedural requirements and insufficient analyst and supervisor training for performing day-of-use system suitability. You commit to revising procedures and to holistically investigate other test methods.\nYour response is inadequate. You did not provide details of your review of historical system suitability results that concluded there were no adverse trends for drug products on the market within expiry. Additionally, you did not address the lack of system suitability performance for the other examples cited on the Form FDA 483 and did not expand the review to other laboratory systems beyond the TOC and conductivity systems or retrospectively review results generated with the other systems for accuracy.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nYour retrospective review of system suitability results from laboratory equipment used to generate data in support of drug product manufacturing and release for distribution, including risk assessments and remediation plans.\n5. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)).\nComplaint Handling\nYour QU did not adequately ensure procedures were established and followed. For example, your procedure for customer complaints and inquiries is inadequate. Your approach to determining severity and adverse events resulted in delayed and incomplete investigations. Additionally, investigations were based on the client and not the severity of the complaint. Also, adequate complaint investigations were not completed in a timely manner.\nIn your response, you commit to revising your procedure and reviewing past complaints to ensure serious events are properly investigated.\nYour response is inadequate. You did not provide the status of open complaint investigations or whether additional complaints have been received since the close of the inspection.\nStability Program\nYour QU failed to ensure stability testing was conducted according to your program procedures. Your firm missed stability time points, missed stability tests, or performed incorrect tests on batches placed into your stability program.\nIn your response, you acknowledge the lack of proper QU oversight of the stability program. You commit to performing an impact assessment with the assistance of external consultants and revising your stability program procedure.\nYour response is inadequate. You did not provide details on how the impact of incomplete stability testing will be assessed for product batches that have been distributed to the US. market.\nIn response to this letter, provide:\nA comprehensive, independent review of your overall complaint system, including a retrospective review of all complaints for the last three years from the initial date of the inspection, with an assessment that includes but is not limited to:\no Nature of complaint, and potential associated risk.\no Date of first notification and subsequent contacts with complainant.\no Timing and sufficiency of followups with complainant to obtain photographs and the complaint sample, as well as to obtain any additional contextual information. Determine relevant complaint samples were available and extent of efforts to obtain the complaint sample. If insufficient attempts were made, identify the root cause(s) for not adequately pursuing their return.\no Review of long-term history for similar or same defects.\no Identification of potential causes of the defect that led to the complaint, including evaluation whether the scientific justification and evidence relating to the identified root cause(s) were adequately documented. In the event a complaint was attributed to factors outside of the firm’s control (e.g., user error), assess the strength of this determination and whether it was based on conclusive or inconclusive information.\no CAPA steps taken, including but not limited to manufacturing\u002Fquality improvements (e.g., manufacturing operation, raw materials, supplier, quality control), as well as recalls or heightened quality surveillance (additional testing\u002Fexaminations, adding batch to stability program).\no For all complaint investigations found by the retrospective review to be deficient due to insufficient root cause or CAPA, perform a thorough analysis of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, out-of-specification history, batch failure history).\no Based upon this independent review, provide a comprehensive assessment of the complaint system that identifies all deficiencies and needed improvements.\no The status of your review of open complaint investigations and whether additional complaints have been received since the procedure has been revised.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint), as part of a program that encompasses each quality attribute that may change over the product shelf-life.\no All procedures that describe these and other elements of your remediated stability program.\nYour firm’s quality systems are inadequate. See FDA’s guidance document, Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nQuality Unit Authority\nYour inspectional history indicates that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all OTC (b)(4) drug products at this facility.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nDrug Recall\nOn February 18, 2026, you initiated a voluntary recall of all commercial drug products manufactured between March 27, 2024, and November 7, 2024 due to failing media fills and a lack of sterility assurance. The company announcement was posted to the FDA website at:\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=218993\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219008\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219030\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219049\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219055\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219061\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219063\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219064\nRepeat Violations at Facility\nIn a previous warning letter (issued August 3, 2023), FDA cited similar severe CGMP violations. The recurrence of these violations demonstrates that your firm’s corrective actions were neither effective nor durable. Notably, your failure to correct these issues led to unacceptable drug product being distributed to the U.S. market.\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nRequest for a Meeting with FDA\nAfter you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your CAPA in detail. Please direct your request to Christina Reyes at christina.reyes@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days2. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2026940 and ATTN: Carrie A. Hughes.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n________________________________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","K.C. Pharmaceuticals, Inc.","kc-pharmaceuticals-inc-729870-08122026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkc-pharmaceuticals-inc-729870-08122026","2026-10-26T08:09:08.10392+00:00","2026-08-18","729870","Ms. Ratnawati Li","2026-08-19T04:26:34.662+00:00","VIA EMAIL WITH READ RECEIPT","320-26-112","2026-08-12",{"id":155,"raw":156,"subject":161,"body_html":162,"body_text":163,"firm_name":164,"letter_id":165,"created_at":125,"fei_number":19,"letter_url":166,"updated_at":127,"action_type":22,"case_status":23,"posted_date":167,"marcs_cms_no":168,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":169,"body_fetched_at":170,"delivery_method":132,"recipient_title":19,"reference_number":19,"action_taken_date":171,"medical_device_id":19,"response_letter_date":19},21691,[157,158,159,11,160,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-07T04:00:00Z\">08\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpine-pharmaceuticals-llc-728537-08072026\">Pine Pharmaceuticals, LLC\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products ","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alfonse J. Muto PharmD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pine Pharmaceuticals, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>355 Riverwalk Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tonawanda\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>14150-5837\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cbr>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 728537\u003C\u002Fp>\u003Cp>August 7, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Muto:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on March 9, 2018, and most recently on November 19, 2025. From November 4, 2025, to November 14, 2025, FDA investigators inspected your facility, Pine Pharmaceuticals, LLC located at 355 Riverwalk Parkway, Tonawanda, NY 14150. During the inspection, the investigators collected evidence indicating serious deficiencies in your practices for producing drug products which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on November 14, 2025. We reviewed your December 8, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA investigators collected evidence indicating that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators collected evidence indicating that:\u003C\u002Fp>\u003Cp>1. Your firm did not disinfect materials during transfer from the ISO 7 cleanroom into the ISO 5 hood. Specifically, operators failed to sanitize materials, equipment, and hands prior to introducing them into the ISO 5 critical area during the production of drug products intended to be sterile. Furthermore, an operator rested their sleeved arms on ergonomic support bars attached to the ISO 5 hood (located in the ISO 7 background area) and subsequently extended their sleeved arms into the ISO 5 critical area without first sanitizing their sleeves.\u003C\u002Fp>\u003Cp>2. Your environmental monitoring program lacks adequate routine environmental monitoring that captures data representative of aseptic production conditions. Specifically, your firm does not perform routine environmental monitoring of high-touch staging trays (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) that are manually handled by gloved operators to stage materials, including final container closures for drug products intended to be sterile, prior to placement into the ISO 5 classified area. These trays have a difficult-to-clean \u003Cstrong>(b)(4)\u003C\u002Fstrong> design.\u003C\u002Fp>\u003Cp>FDA investigators also collected evidence indicating CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fp>\u003Cp>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fp>\u003Cp>3. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions [21 CFR 211.25(a)].\u003C\u002Fp>\u003Cp>4. Your firm failed to determine actual yield and percentages of theoretical yield at the conclusion of each appropriate phase of manufacturing, processing, packaging, or holding of the drug product [21 CFR 211.103]. Specifically, in addition to the deficiencies noted in the visual inspection reject rate calculations, our review of the data collected during the inspection revealed that the acceptable yield range established in your batch records permits yields as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, allowing up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a batch to be rejected without triggering an investigation, yet the batch can still be released for distribution. Furthermore, although \u003Cstrong>(b)(4)\u003C\u002Fstrong> meets the definition of particulate matter as “mobile undissolved particles, other than air bubbles, unintentionally present in solutions” in SOP-061 (Visual Inspection Finished Product, Rev. 23), it was classified as a “minor” defect in ISSUE-2025-0011, without scientific justification or a clear procedural basis in SOP-061. By classifying \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a minor defect rather than as particulate matter, \u003Cstrong>(b)(4)\u003C\u002Fstrong> rejects are counted only as part of the minor reject rate limit, bypassing both the major defect category trigger and the separate particulate category trigger entirely. Additionally, certain “cosmetic” defects are allowed to be returned to the batch, despite SOP-061 containing no definition, criteria, or examples of what constitutes a “cosmetic” defect, nor does it specify which cosmetic defect may be returned to the batch and which must be rejected.\u003C\u002Fp>\u003Cp>5. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your firm’s responses to the Form FDA 483. We are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>1. Your response states that you implemented post-production surface sampling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per FID 131 batch (PLANDEV-2025-0021) and plan to transition to \u003Cstrong>(b)(4)\u003C\u002Fstrong> trays by the end of Q2 2026. While these actions are intended to address the observed deficiency, we are unable to determine their adequacy due to insufficient supporting documentation and scientific justification. You did not provide data demonstrating the effectiveness of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for cleaning the current trays (particularly the difficult-to-clean \u003Cstrong>(b)(4)\u003C\u002Fstrong>), a risk-based rationale for sampling only \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> bins are used per lot, justification for the chosen sampling site, confirmation that tray sampling will be permanently incorporated into routine procedure MWA-041, a validation protocol for the planned \u003Cstrong>(b)(4)\u003C\u002Fstrong> trays, or a defined plan to verify the effectiveness of the interim tray sampling program.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Your response fails to address the specific deficiencies in the cited investigations and non-conformances. For the particulate complaint (COMP-2025-0005), your firm did not determine root cause for the confirmed cellulose particles or translucent fibers found in the returned vials or the retain sample, reconcile the particulate finding in the retain sample with the multiple particulates observed in the returned vials, or implement corrective actions for the visual inspection failure that allowed particulates to reach distributed product. You classified cellulose as an “intrinsic” particle without scientific justification, despite potential sources (e.g., cleaning wipes) indicating extrinsic contamination. Your response does not clearly commit to identifying and characterizing all observed particulates (including fibers and residues) in future investigations, nor does it define when such identification is required. Additionally, although you revised POL-030 (Product Complaint Handling) and implemented a training checkpoint, you did not provide evidence that the training was completed and did not establish a defined effectiveness verification plan for these corrective actions.\u003C\u002Fp>\u003Cp>For the batches released despite exceeding critical defect limits, your responses rely on retrospective risk assessments, passing targeted\u002Fsecond 100% reinspection and \u003Cstrong>(b)(4)\u003C\u002Fstrong> AQL without thorough root-cause investigations or \u003Cstrong>(b)(4)\u003C\u002Fstrong> process corrections for recurring defects (e.g., dislodged caps, partially crimped seals, particulates). These risk assessments are outcome-based, focusing primarily on the absence of complaints or adverse events rather than evaluating the adequacy of your production and inspection controls. Furthermore, lot disposition for batches exceeding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical reject rate was contingent on the outcome of a pending risk analysis (ISSUE-2025-0008) rather than on a completed investigation and upstream correction, indicating that risk assessment is being used as a substitute for corrective action rather than a complement to it. You also provided no scientific justification for limiting reinspections to preselected defect types rather than conducting a comprehensive 100% visual inspection across all potential defects, and you provided no evidence that CAPA-2025-0017 has been completed. This pattern of relying on reinspection and risk review to achieve passing results, without addressing underlying process failures, fails to demonstrate that the root causes of these defects have been identified, addressed, or controlled.\u003C\u002Fp>\u003Cp>2. Your response concludes that the observed aseptic technique failures were isolated to one operator and posed no product impact, with the risk declared low based primarily on passing environmental monitoring and sterility test results. However, your own batch review data (Tables 1 and 2 in ISSUE-2025-0006) demonstrates a widespread pattern of non-adherence by that operator across \u003Cstrong>(b)(4)\u003C\u002Fstrong> reviewed batches, with \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection adherence to SOP-299 at only 11% and \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection adherence at 0%.\u003C\u002Fp>\u003Cp>Reliance on passing environmental monitoring and sterility test results does not adequately address the significant risk created by these repeated failures to follow basic aseptic techniques, including inadequate sanitization of materials and equipment transferred from the ISO 7 area into the ISO 5 hood during production of drug products intended to be sterile. This approach is scientifically insufficient because microbial contamination does not spread uniformly, and limited environmental monitoring and finished product sterility testing cannot reliably detect low-probability contamination events from consistent \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> lapses. Furthermore, your claim that the process is “closed” is not supported, as aseptic operations occur in ISO 5 hoods with routine interventions, making operator technique a primary sterility assurance control.\u003C\u002Fp>\u003Cp>Although you stated that similar deficiencies do not exist with other operators, you provided no supporting documentation (e.g., audit reports, video reviews, or Manufacturing Quality Assurance (MQA) records) to support this claim. You also did not provide the operator removal record (AI-2025-0524), the revised SOPs under CAPA-2025-0015, or a defined effectiveness verification plan. The repeated nature of these deviations by the same operator, going undetected and uncorrected over an extended period, raises serious concerns about the effectiveness of your routine oversight, training reinforcement, and overall quality system controls.\u003C\u002Fp>\u003Cp>The failures to sanitize or change gloves and sleeves after contact with non-sterile ISO 7 surfaces, and the failure to sanitize materials and equipment transferred from ISO 7 into the ISO 5 area, are not minor risks. They constitute insanitary conditions which can lead to contamination of products intended to be sterile and serious adverse events. Your response also fails to explain why these deviations went undetected for so long and does not address the specific hand sanitization deficiencies noted in the observation, including incomplete coverage of the backs of the hands and interdigital spaces and failure to meet the required \u003Cstrong>(b)(4)\u003C\u002Fstrong> duration as per your SOP-299 (Cleanroom Behavior and Aseptic Technique Procedure, Rev. 04). This is a repeat deficiency from the FDA inspections conducted in May 2021, September 2023, and September 2024.\u003C\u002Fp>\u003Cp>3. Your response states that you conducted a historical review of qualification records and provided additional training for visual inspectors. However, you failed to manage the significant change to SOP-155, Training and Qualification of Qualified Visual Inspectors for Compounded Products, Rev. 09 (which introduced immediate failure of a visual inspector for missing any critical defect) through formal change control or a timely requalification plan for previously qualified inspectors that did not meet the new standard. You did not perform a root-cause analysis for why inspectors continued performing critical visual inspections for approximately three months after the SOP revision without meeting the new standard. Although you dispute the specific example with visual inspector \u003Cstrong>(b)(6), (b)(7)\u003C\u002Fstrong>, you provided no documentation reconciling the answer key discrepancy or addressing the violation of performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> qualification assessments in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also submitted no evidence that all impacted inspectors have been removed from relevant tasks or successfully requalified under the revised criteria. In addition, you have not committed to managing future significant changes to qualification procedures through formal change control. CAPA-2025-0014 remains pending with no supporting documentation.\u003C\u002Fp>\u003Cp>4. Your response states that you reviewed \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches and implemented PLANDEV-2025-0027 to include all rejected units (confirmed and unconfirmed) in reject rate calculations. Although you identified six batches that would have exceeded thresholds when using actual reject rates, you did not demonstrate that formal investigations were opened for these batches. In addition, the permanent updates to SOP-061 (Visual Inspection Finished Product, Rev. 23) and the electronic batch record remain incomplete, with no firm completion dates or effectiveness verification plan. You also did not address the specific Diltiazem HCl lot 83709 example discussed during the inspection close-out. This is a repeat deficiency from the FDA inspection conducted in September 2024.\u003C\u002Fp>\u003Cp>5. Your response acknowledges the lack of validated mixing and \u003Cstrong>(b)(4)\u003C\u002Fstrong> parameters but treats full process validation (CAPA-2025-0013) as conditional, only to be prioritized if future potency variability or out of specification (OOS) events occur. You provided no root-cause analysis explaining why critical process parameters remained undefined and operator-dependent for an extended period despite a prior OOS investigation. You also submitted no supporting documentation for PLANDEV-2025-0028, no revised master production records or executed batch record examples showing the new parameters, and no completion date or detailed validation plan for CAPA-2025-0013.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant.\u003C\u002Fp>\u003Cp>Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (# 728537) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAlfonse J. Muto PharmD\n\nRecipient Title\n\nOwner\n\nPine Pharmaceuticals, LLC\n\n355 Riverwalk Parkway\n\nTonawanda, NY 14150-5837\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 728537\nAugust 7, 2026\nDear Dr. Muto:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on March 9, 2018, and most recently on November 19, 2025. From November 4, 2025, to November 14, 2025, FDA investigators inspected your facility, Pine Pharmaceuticals, LLC located at 355 Riverwalk Parkway, Tonawanda, NY 14150. During the inspection, the investigators collected evidence indicating serious deficiencies in your practices for producing drug products which put patients at risk.\nFDA issued a Form FDA 483 to your facility on November 14, 2025. We reviewed your December 8, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nB. Violations of the FDCA\nAdulterated Drug Products\nFDA investigators collected evidence indicating that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators collected evidence indicating that:\n1. Your firm did not disinfect materials during transfer from the ISO 7 cleanroom into the ISO 5 hood. Specifically, operators failed to sanitize materials, equipment, and hands prior to introducing them into the ISO 5 critical area during the production of drug products intended to be sterile. Furthermore, an operator rested their sleeved arms on ergonomic support bars attached to the ISO 5 hood (located in the ISO 7 background area) and subsequently extended their sleeved arms into the ISO 5 critical area without first sanitizing their sleeves.\n2. Your environmental monitoring program lacks adequate routine environmental monitoring that captures data representative of aseptic production conditions. Specifically, your firm does not perform routine environmental monitoring of high-touch staging trays ((b)(4)) that are manually handled by gloved operators to stage materials, including final container closures for drug products intended to be sterile, prior to placement into the ISO 5 classified area. These trays have a difficult-to-clean (b)(4) design.\nFDA investigators also collected evidence indicating CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\n3. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions [21 CFR 211.25(a)].\n4. Your firm failed to determine actual yield and percentages of theoretical yield at the conclusion of each appropriate phase of manufacturing, processing, packaging, or holding of the drug product [21 CFR 211.103]. Specifically, in addition to the deficiencies noted in the visual inspection reject rate calculations, our review of the data collected during the inspection revealed that the acceptable yield range established in your batch records permits yields as low as (b)(4), allowing up to (b)(4) of a batch to be rejected without triggering an investigation, yet the batch can still be released for distribution. Furthermore, although (b)(4) meets the definition of particulate matter as “mobile undissolved particles, other than air bubbles, unintentionally present in solutions” in SOP-061 (Visual Inspection Finished Product, Rev. 23), it was classified as a “minor” defect in ISSUE-2025-0011, without scientific justification or a clear procedural basis in SOP-061. By classifying (b)(4) as a minor defect rather than as particulate matter, (b)(4) rejects are counted only as part of the minor reject rate limit, bypassing both the major defect category trigger and the separate particulate category trigger entirely. Additionally, certain “cosmetic” defects are allowed to be returned to the batch, despite SOP-061 containing no definition, criteria, or examples of what constitutes a “cosmetic” defect, nor does it specify which cosmetic defect may be returned to the batch and which must be rejected.\n5. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nC. Corrective Actions\nWe have reviewed your firm’s responses to the Form FDA 483. We are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n1. Your response states that you implemented post-production surface sampling of (b)(4) per FID 131 batch (PLANDEV-2025-0021) and plan to transition to (b)(4) trays by the end of Q2 2026. While these actions are intended to address the observed deficiency, we are unable to determine their adequacy due to insufficient supporting documentation and scientific justification. You did not provide data demonstrating the effectiveness of (b)(4) for cleaning the current trays (particularly the difficult-to-clean (b)(4)), a risk-based rationale for sampling only (b)(4) when (b)(4) bins are used per lot, justification for the chosen sampling site, confirmation that tray sampling will be permanently incorporated into routine procedure MWA-041, a validation protocol for the planned (b)(4) trays, or a defined plan to verify the effectiveness of the interim tray sampling program.\nSome of your corrective actions appear deficient:\n1. Your response fails to address the specific deficiencies in the cited investigations and non-conformances. For the particulate complaint (COMP-2025-0005), your firm did not determine root cause for the confirmed cellulose particles or translucent fibers found in the returned vials or the retain sample, reconcile the particulate finding in the retain sample with the multiple particulates observed in the returned vials, or implement corrective actions for the visual inspection failure that allowed particulates to reach distributed product. You classified cellulose as an “intrinsic” particle without scientific justification, despite potential sources (e.g., cleaning wipes) indicating extrinsic contamination. Your response does not clearly commit to identifying and characterizing all observed particulates (including fibers and residues) in future investigations, nor does it define when such identification is required. Additionally, although you revised POL-030 (Product Complaint Handling) and implemented a training checkpoint, you did not provide evidence that the training was completed and did not establish a defined effectiveness verification plan for these corrective actions.\nFor the batches released despite exceeding critical defect limits, your responses rely on retrospective risk assessments, passing targeted\u002Fsecond 100% reinspection and (b)(4) AQL without thorough root-cause investigations or (b)(4) process corrections for recurring defects (e.g., dislodged caps, partially crimped seals, particulates). These risk assessments are outcome-based, focusing primarily on the absence of complaints or adverse events rather than evaluating the adequacy of your production and inspection controls. Furthermore, lot disposition for batches exceeding the (b)(4) critical reject rate was contingent on the outcome of a pending risk analysis (ISSUE-2025-0008) rather than on a completed investigation and upstream correction, indicating that risk assessment is being used as a substitute for corrective action rather than a complement to it. You also provided no scientific justification for limiting reinspections to preselected defect types rather than conducting a comprehensive 100% visual inspection across all potential defects, and you provided no evidence that CAPA-2025-0017 has been completed. This pattern of relying on reinspection and risk review to achieve passing results, without addressing underlying process failures, fails to demonstrate that the root causes of these defects have been identified, addressed, or controlled.\n2. Your response concludes that the observed aseptic technique failures were isolated to one operator and posed no product impact, with the risk declared low based primarily on passing environmental monitoring and sterility test results. However, your own batch review data (Tables 1 and 2 in ISSUE-2025-0006) demonstrates a widespread pattern of non-adherence by that operator across (b)(4) reviewed batches, with (b)(4) disinfection adherence to SOP-299 at only 11% and (b)(4) disinfection adherence at 0%.\nReliance on passing environmental monitoring and sterility test results does not adequately address the significant risk created by these repeated failures to follow basic aseptic techniques, including inadequate sanitization of materials and equipment transferred from the ISO 7 area into the ISO 5 hood during production of drug products intended to be sterile. This approach is scientifically insufficient because microbial contamination does not spread uniformly, and limited environmental monitoring and finished product sterility testing cannot reliably detect low-probability contamination events from consistent (b)(4) and (b)(4) lapses. Furthermore, your claim that the process is “closed” is not supported, as aseptic operations occur in ISO 5 hoods with routine interventions, making operator technique a primary sterility assurance control.\nAlthough you stated that similar deficiencies do not exist with other operators, you provided no supporting documentation (e.g., audit reports, video reviews, or Manufacturing Quality Assurance (MQA) records) to support this claim. You also did not provide the operator removal record (AI-2025-0524), the revised SOPs under CAPA-2025-0015, or a defined effectiveness verification plan. The repeated nature of these deviations by the same operator, going undetected and uncorrected over an extended period, raises serious concerns about the effectiveness of your routine oversight, training reinforcement, and overall quality system controls.\nThe failures to sanitize or change gloves and sleeves after contact with non-sterile ISO 7 surfaces, and the failure to sanitize materials and equipment transferred from ISO 7 into the ISO 5 area, are not minor risks. They constitute insanitary conditions which can lead to contamination of products intended to be sterile and serious adverse events. Your response also fails to explain why these deviations went undetected for so long and does not address the specific hand sanitization deficiencies noted in the observation, including incomplete coverage of the backs of the hands and interdigital spaces and failure to meet the required (b)(4) duration as per your SOP-299 (Cleanroom Behavior and Aseptic Technique Procedure, Rev. 04). This is a repeat deficiency from the FDA inspections conducted in May 2021, September 2023, and September 2024.\n3. Your response states that you conducted a historical review of qualification records and provided additional training for visual inspectors. However, you failed to manage the significant change to SOP-155, Training and Qualification of Qualified Visual Inspectors for Compounded Products, Rev. 09 (which introduced immediate failure of a visual inspector for missing any critical defect) through formal change control or a timely requalification plan for previously qualified inspectors that did not meet the new standard. You did not perform a root-cause analysis for why inspectors continued performing critical visual inspections for approximately three months after the SOP revision without meeting the new standard. Although you dispute the specific example with visual inspector (b)(6), (b)(7), you provided no documentation reconciling the answer key discrepancy or addressing the violation of performing (b)(4) qualification assessments in (b)(4). You also submitted no evidence that all impacted inspectors have been removed from relevant tasks or successfully requalified under the revised criteria. In addition, you have not committed to managing future significant changes to qualification procedures through formal change control. CAPA-2025-0014 remains pending with no supporting documentation.\n4. Your response states that you reviewed (b)(4) batches and implemented PLANDEV-2025-0027 to include all rejected units (confirmed and unconfirmed) in reject rate calculations. Although you identified six batches that would have exceeded thresholds when using actual reject rates, you did not demonstrate that formal investigations were opened for these batches. In addition, the permanent updates to SOP-061 (Visual Inspection Finished Product, Rev. 23) and the electronic batch record remain incomplete, with no firm completion dates or effectiveness verification plan. You also did not address the specific Diltiazem HCl lot 83709 example discussed during the inspection close-out. This is a repeat deficiency from the FDA inspection conducted in September 2024.\n5. Your response acknowledges the lack of validated mixing and (b)(4) parameters but treats full process validation (CAPA-2025-0013) as conditional, only to be prioritized if future potency variability or out of specification (OOS) events occur. You provided no root-cause analysis explaining why critical process parameters remained undefined and operator-dependent for an extended period despite a prior OOS investigation. You also submitted no supporting documentation for PLANDEV-2025-0028, no revised master production records or executed batch record examples showing the new parameters, and no completion date or detailed validation plan for CAPA-2025-0013.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant.\nRegardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nD. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (# 728537) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).","Pine Pharmaceuticals, LLC","pine-pharmaceuticals-llc-728537-08072026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpine-pharmaceuticals-llc-728537-08072026","2026-10-06","728537","Alfonse J. Muto PharmD","2026-10-14T12:33:28.352+00:00","2026-08-07",{"id":173,"raw":174,"subject":12,"body_html":179,"body_text":180,"firm_name":181,"letter_id":182,"created_at":183,"fei_number":19,"letter_url":184,"updated_at":185,"action_type":22,"case_status":23,"posted_date":186,"marcs_cms_no":187,"product_type":26,"closeout_date":19,"issuing_office":188,"recipient_name":189,"body_fetched_at":190,"delivery_method":191,"recipient_title":19,"reference_number":19,"action_taken_date":192,"medical_device_id":19,"response_letter_date":19},1886,[175,176,177,178,12,13,13,13],"\u003Ctime datetime=\"2023-08-29T13:20:00Z\">08\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-03T04:00:00Z\">08\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkc-pharmaceuticals-inc-654986-08032023\">K.C. Pharmaceuticals Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Ratna Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>K.C. Pharmaceuticals Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3215 Producer Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pomona\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91768\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:RLi@kc-ph.com\"> RLi@kc-ph.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Li:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, K.C. Pharmaceuticals Inc., FEI 2026940 at 3215 Producer Way, Pomona, from January 18 to January 27, 2023 and from February 10 to February 13, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 7, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that includes validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Smoke Studies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your smoke studies for your aseptic processing lines were not performed under conditions that adequately simulate actual manufacturing. For example, the smoke study performed in 2018 did not represent routine dynamic manufacturing conditions on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic filling line. During the current inspection, you stated that the 2018 smoke study was the only smoke study performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line. Your firm began commercial manufacturing using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;line in 2020 without adequate smoke studies.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, and in your response, you acknowledge that your smoke study for line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed in September 2022, was inadequate. A repeat smoke study was performed in December 2022, however your quality unit had not completed their review at the time of the inspection and this study was not made available for the investigators to review.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge that this is a repeat observation. You state that a corrective action and preventive action (CAPA) has been raised to address deficiencies in smoke studies from a holistic perspective with assistance of a third-party consultant. You have decided to repeat smoke studies on both aseptic filling lines to ensure aseptic filling interventions are properly evaluated and documented.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it includes plans to perform a product impact assessment without providing detailed information as to how you are determining the impact to products manufactured on lines without adequate smoke studies. Without adequate smoke studies, you cannot substantively assess whether unidirectional ISO 5 airflow is protecting the drug product from contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Media Fill Failure Investigations\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Since 2020, there have been multiple media fill failures representing both filling lines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to complete the investigations of two failures in 2020 on line \u003Cstrong>(b)(4)\u003C\u002Fstrong> and did not adequately address the root cause of a failure that occurred in 2021 on line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, instead invalidating the media fill without adequate scientific justification.\u003C\u002Fp>\n\n\u003Cp>In your May 23, 2023 response to our request for additional information you provided investigation NCR-20-081, opened on May 15, 2023, which describes the incomplete media fill failure investigations that occurred in October and November 2020 relating to line \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that the investigations into these failures had not been closed. The media fill failure in October 2020 occurred after approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of finished drug products were manufactured since May 2020.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\n\t\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fli>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>A complete independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation. This item is especially critical due to the missing documentation described in your May 2023 correspondence.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your aseptic processing operation is inadequately designed to prevent contamination of your ophthalmic drug products.\u003C\u002Fp>\n\n\u003Cp>For example, your firm lacked adequate building management systems (BMS) to monitor and record differential pressures in your aseptic processing facility. You recorded differential pressures by observing photohelic gauges with upper and lower limits that can be \u003Cstrong>(b)(4)\u003C\u002Fstrong> accessed and adjusted. Additionally, your operators recorded differential pressures at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of every fill batch, approximately every \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of filling operations. This frequency is not adequate to detect pressure deviations (e.g., reversals) that could ultimately impact aseptic conditions on the filling line.\u003C\u002Fp>\n\n\u003Cp>In addition, the ISO 5 aseptic processing line, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is described as an \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, we observed several \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the walls of the enclosure. These \u003Cstrong>(b)(4)\u003C\u002Fstrong> were open to the surrounding room during aseptic processing and did not contain any \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Similarly, the smoke study video that you provided in your May 2023 correspondence showed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> line with \u003Cstrong>(b)(4)\u003C\u002Fstrong> opened to the surrounding room while the smoke study was being conducted. During this smoke study video, operators are seen conducting interventions on this aseptic filling line with their \u003Cstrong>(b)(4)\u003C\u002Fstrong> arms and \u003Cstrong>(b)(4)\u003C\u002Fstrong> hands, by reaching through the open ports instead of using installed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While your firm refers to this aseptic processing line as an \u003Cstrong>(b)(4)\u003C\u002Fstrong>, both its design and operation does not meet the minimum standards of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Aseptic processes should be designed to minimize exposure of sterile articles to potential contamination hazards, including, but not limited to, variation in environmental conditions. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness. A suitable facility monitoring system is critical to maintain appropriate environmental conditions throughout all of your cleanrooms. All deviations from established limits should be appropriately investigated to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to installing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> over the photohelic gauges to prevent access. However, in your June 23, 2023 response to our request for additional information, you acknowledge that you have not implemented a continuous monitoring system that ensures differential pressures will be continuously monitored, adequately recorded, and any differential pressure deviations will be detected, documented, and investigated.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Cleaning validation studies for aseptic processing line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used to manufacture multiple formulations of ophthalmic drug products, has not been completed. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> compounding tank and product transfer line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used to formulate bulk ophthalmic drugs for filling on line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, did not have recovery studies or limits of detection. Additionally, when identifying the \u003Cstrong>(b)(4)\u003C\u002Fstrong> conditions under which to conduct the cleaning validation, you relied only on the viscosity of your multiple ophthalmic drug products to make the determination, omitting other factors that can make certain formulations harder to clean. While you chose the product Eye Drops Systane-Ultra Like (EDSU) as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you lacked documented scientific evidence to support use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> viscosity as adequate basis for validating the hardest to clean product surface.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to performing a risk assessment and product impact assessment, but lack details regarding what you will evaluate and how you will do so. You did not commit to performing additional verification of cleaning to ensure cross-contamination is not occurring when using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> compounding tank, product transfer line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or other equipment. Your response also commits to performing a new study to determine \u003Cstrong>(b)(4)\u003C\u002Fstrong> product(s), without providing details as to what properties would be evaluated and how.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality Unit\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to orapharm4_responses@fda.hhs.gov or by mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier CMS 654986.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact Compliance Officer William V. Millar by email at william.millar@fda.hhs.gov or by phone at (503) 671-9711 Ext. 30.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nElectronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Ratna Li\n\nRecipient Title\n\nChief Executive Officer\n\nK.C. Pharmaceuticals Inc.\n\n3215 Producer Way\n\nPomona, CA 91768\n\nUnited States\n\nRLi@kc-ph.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nAugust 3, 2023\n\nDear Ms. Li:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, K.C. Pharmaceuticals Inc., FEI 2026940 at 3215 Producer Way, Pomona, from January 18 to January 27, 2023 and from February 10 to February 13, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 7, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that includes validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nSmoke Studies\n\nYour smoke studies for your aseptic processing lines were not performed under conditions that adequately simulate actual manufacturing. For example, the smoke study performed in 2018 did not represent routine dynamic manufacturing conditions on the (b)(4) aseptic filling line. During the current inspection, you stated that the 2018 smoke study was the only smoke study performed on the (b)(4) filling line. Your firm began commercial manufacturing using the (b)(4) line in 2020 without adequate smoke studies.\n\nAdditionally, during the inspection, and in your response, you acknowledge that your smoke study for line (b)(4), performed in September 2022, was inadequate. A repeat smoke study was performed in December 2022, however your quality unit had not completed their review at the time of the inspection and this study was not made available for the investigators to review.\n\nIn your response, you acknowledge that this is a repeat observation. You state that a corrective action and preventive action (CAPA) has been raised to address deficiencies in smoke studies from a holistic perspective with assistance of a third-party consultant. You have decided to repeat smoke studies on both aseptic filling lines to ensure aseptic filling interventions are properly evaluated and documented.\n\nYour response is inadequate because it includes plans to perform a product impact assessment without providing detailed information as to how you are determining the impact to products manufactured on lines without adequate smoke studies. Without adequate smoke studies, you cannot substantively assess whether unidirectional ISO 5 airflow is protecting the drug product from contamination.\n\nMedia Fill Failure Investigations\n\nSince 2020, there have been multiple media fill failures representing both filling lines, (b)(4) and (b)(4). Your firm failed to complete the investigations of two failures in 2020 on line (b)(4) and did not adequately address the root cause of a failure that occurred in 2021 on line (b)(4), instead invalidating the media fill without adequate scientific justification.\n\nIn your May 23, 2023 response to our request for additional information you provided investigation NCR-20-081, opened on May 15, 2023, which describes the incomplete media fill failure investigations that occurred in October and November 2020 relating to line (b)(4). Your firm stated that the investigations into these failures had not been closed. The media fill failure in October 2020 occurred after approximately (b)(4) batches of finished drug products were manufactured since May 2020.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nA complete independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation. This item is especially critical due to the missing documentation described in your May 2023 correspondence.\n\n2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\n\nYour aseptic processing operation is inadequately designed to prevent contamination of your ophthalmic drug products.\n\nFor example, your firm lacked adequate building management systems (BMS) to monitor and record differential pressures in your aseptic processing facility. You recorded differential pressures by observing photohelic gauges with upper and lower limits that can be (b)(4) accessed and adjusted. Additionally, your operators recorded differential pressures at the (b)(4) of every fill batch, approximately every (b)(4), and at the (b)(4) of filling operations. This frequency is not adequate to detect pressure deviations (e.g., reversals) that could ultimately impact aseptic conditions on the filling line.\n\nIn addition, the ISO 5 aseptic processing line, (b)(4), is described as an (b)(4). During the inspection, we observed several (b)(4) in the walls of the enclosure. These (b)(4) were open to the surrounding room during aseptic processing and did not contain any (b)(4). Similarly, the smoke study video that you provided in your May 2023 correspondence showed the (b)(4) line with (b)(4) opened to the surrounding room while the smoke study was being conducted. During this smoke study video, operators are seen conducting interventions on this aseptic filling line with their (b)(4) arms and (b)(4) hands, by reaching through the open ports instead of using installed (b)(4). While your firm refers to this aseptic processing line as an (b)(4), both its design and operation does not meet the minimum standards of a (b)(4).\n\nAseptic processes should be designed to minimize exposure of sterile articles to potential contamination hazards, including, but not limited to, variation in environmental conditions. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness. A suitable facility monitoring system is critical to maintain appropriate environmental conditions throughout all of your cleanrooms. All deviations from established limits should be appropriately investigated to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\n\nIn your response, you commit to installing a (b)(4) over the photohelic gauges to prevent access. However, in your June 23, 2023 response to our request for additional information, you acknowledge that you have not implemented a continuous monitoring system that ensures differential pressures will be continuously monitored, adequately recorded, and any differential pressure deviations will be detected, documented, and investigated.\n\nIn response to this letter, provide the following:\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\n3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nCleaning validation studies for aseptic processing line (b)(4), used to manufacture multiple formulations of ophthalmic drug products, has not been completed. For example, the (b)(4) compounding tank and product transfer line (b)(4), used to formulate bulk ophthalmic drugs for filling on line (b)(4), did not have recovery studies or limits of detection. Additionally, when identifying the (b)(4) conditions under which to conduct the cleaning validation, you relied only on the viscosity of your multiple ophthalmic drug products to make the determination, omitting other factors that can make certain formulations harder to clean. While you chose the product Eye Drops Systane-Ultra Like (EDSU) as (b)(4), you lacked documented scientific evidence to support use of (b)(4) viscosity as adequate basis for validating the hardest to clean product surface.\n\nIn your response, you commit to performing a risk assessment and product impact assessment, but lack details regarding what you will evaluate and how you will do so. You did not commit to performing additional verification of cleaning to ensure cross-contamination is not occurring when using the (b)(4) compounding tank, product transfer line (b)(4), or other equipment. Your response also commits to performing a new study to determine (b)(4) product(s), without providing details as to what properties would be evaluated and how.\n\nIn response to this letter, provide:\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as (b)(4) in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all (b)(4):\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nIneffective Quality Unit\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to orapharm4_responses@fda.hhs.gov or by mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612-2506\n\nPlease identify your response with unique identifier CMS 654986.\n\nIf you have questions regarding this letter, please contact Compliance Officer William V. Millar by email at william.millar@fda.hhs.gov or by phone at (503) 671-9711 Ext. 30.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations IV","K.C. Pharmaceuticals Inc.","kc-pharmaceuticals-inc-654986-08032023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkc-pharmaceuticals-inc-654986-08032023","2026-10-26T08:09:08.037683+00:00","2023-08-29","654986","Division of Pharmaceutical Quality Operations IV","Ms. Ratna Li","2026-08-20T00:43:58.805+00:00","Electronic Mail","2023-08-03",{"id":194,"raw":195,"subject":200,"body_html":201,"body_text":202,"firm_name":203,"letter_id":204,"created_at":205,"fei_number":19,"letter_url":206,"updated_at":207,"action_type":22,"case_status":23,"posted_date":208,"marcs_cms_no":209,"product_type":26,"closeout_date":19,"issuing_office":199,"recipient_name":210,"body_fetched_at":211,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":212,"medical_device_id":19,"response_letter_date":19},2866,[196,197,198,199,200,13,13,13],"\u003Ctime datetime=\"2022-02-15T14:20:00Z\">02\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-03T05:00:00Z\">02\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022\">ECI Pharmaceuticals, LLC \u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Register and List","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John S. Copanos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>ECI Pharmaceuticals, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 N Fort Lauderdale Beach Blvd, #1802\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Lauderdale\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL#2267\u003C\u002Fp>\n\n\u003Cp>February 3, 2022\u003Cbr>\n\u003Cbr>\nDear John Copanos:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&amp;C Act, and in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 352(o) and 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market-surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCarolyn E. Becker\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn S. Copanos\n\nECI Pharmaceuticals, LLC\n\n1 N Fort Lauderdale Beach Blvd, #1802\n\nFort Lauderdale, FL 33304\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter\n\nWL#2267\n\nFebruary 3, 2022\n\nDear John Copanos:\n\nThe United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\n\nSection 510(j) of the FD&C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market-surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker","ECI Pharmaceuticals, LLC","eci-pharmaceuticals-llc-625254-02032022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022","2026-10-26T08:08:30.597522+00:00","2022-02-15","625254","John S. Copanos","2026-08-20T02:11:05.284+00:00","2022-02-03",{"id":214,"raw":215,"subject":200,"body_html":219,"body_text":220,"firm_name":203,"letter_id":221,"created_at":205,"fei_number":19,"letter_url":222,"updated_at":223,"action_type":22,"case_status":86,"posted_date":224,"marcs_cms_no":19,"product_type":26,"closeout_date":224,"issuing_office":199,"recipient_name":210,"body_fetched_at":225,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":212,"medical_device_id":19,"response_letter_date":19},2803,[216,197,217,199,200,13,218,13],"\u003Ctime datetime=\"2022-03-22T13:20:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022-0\">ECI Pharmaceuticals, LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-03162022\">\u003Ctime datetime=\"2022-03-22T04:00:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John S. Copanos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>ECI Pharmaceuticals, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 N Fort Lauderdale Beach Blvd, #1802\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Lauderdale\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL#2267\u003C\u002Fp>\n\n\u003Cp>February 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear John Copanos:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&amp;C Act, and in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 352(o) and 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market -surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker, J.D.\u003Cbr>\nDirector, Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn S. Copanos\n\nECI Pharmaceuticals, LLC\n\n1 N Fort Lauderdale Beach Blvd, #1802\n\nFort Lauderdale, FL 33304\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter\n\nWL#2267\n\nFebruary 3, 2022\n\nDear John Copanos:\n\nThe United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\n\nSection 510(j) of the FD&C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market -surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker, J.D.\n\nDirector, Office of Unapproved Drugs & Labeling Compliance","eci-pharmaceuticals-llc-625254-02032022-0","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022-0","2026-10-26T08:08:30.626458+00:00","2022-03-22","2026-08-20T02:05:02.272+00:00",{"id":227,"raw":228,"subject":233,"body_html":235,"body_text":236,"firm_name":237,"letter_id":238,"created_at":239,"fei_number":19,"letter_url":240,"updated_at":241,"action_type":22,"case_status":86,"posted_date":242,"marcs_cms_no":243,"product_type":26,"closeout_date":244,"issuing_office":232,"recipient_name":245,"body_fetched_at":246,"delivery_method":247,"recipient_title":19,"reference_number":19,"action_taken_date":248,"medical_device_id":19,"response_letter_date":19},3419,[229,230,231,232,233,13,234,13],"\u003Ctime datetime=\"2021-04-06T13:20:00Z\">04\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-26T04:00:00Z\">03\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frpk-pharmaceuticals-inc-613400-03262021\">RPK Pharmaceuticals Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research","Failure to Comply with Drug Listing Requirements\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frpk-pharmaceuticals-inc-613400-06012021\">\u003Ctime datetime=\"2021-06-07T04:00:00Z\">06\u002F07\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rich Mangini\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>RPK Pharmaceuticals Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3281 Whipple Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Union City\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94587\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 26, 2021\u003C\u002Fp>\n\n\u003Cp>WL # 1663\u003C\u002Fp>\n\n\u003Cp>Dear Rich Mangini:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug product, “clotrimazole and betamethasone dipropionate cream” (NDC 53002-9740). Our review determined that your firm has submitted a label for this drug that does not match the name of the listed drug. As such, your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) as explained below.\u003C\u002Fp>\n\n\u003Cp>We note that FDA previously sent your firm two letters, one on April 13, 2020 notifying you of listing deficiencies and a subsequent removal notification on May 28, 2020. As stated in the removal notification letter, the continued deficiency resulted in your product’s removal from FDA’s Online NDC Directory.\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(B)(ii), 21 U.S.C. 360(j)(1)(B)(ii), a firm must include in the listing, among other requirements, the “label and package insert for such [listed] drug.” However, the label you provided to FDA does not match the drug you listed with FDA. Specifically, the label image you provided to FDA states “triamcinolone 0.1 % ointment,” whereas the product name included in the drug listing submission is “clotrimazole and betamethasone dipropionate cream.” These are different drug products with different active ingredients.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&amp;C Act, and in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 352(o) and 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your product. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov for further assistance. Include the case identification number of 1663, on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker, J.D.\u003Cbr>\nDirector, Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nOffice of Compliance\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRich Mangini\n\nRPK Pharmaceuticals Inc.\n\n3281 Whipple Rd\n\nUnion City, CA 94587\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWARNING LETTER\n\nMarch 26, 2021\n\nWL # 1663\n\nDear Rich Mangini:\n\nThe United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug product, “clotrimazole and betamethasone dipropionate cream” (NDC 53002-9740). Our review determined that your firm has submitted a label for this drug that does not match the name of the listed drug. As such, your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as explained below.\n\nWe note that FDA previously sent your firm two letters, one on April 13, 2020 notifying you of listing deficiencies and a subsequent removal notification on May 28, 2020. As stated in the removal notification letter, the continued deficiency resulted in your product’s removal from FDA’s Online NDC Directory.\n\nSection 510(j) of the FD&C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(B)(ii), 21 U.S.C. 360(j)(1)(B)(ii), a firm must include in the listing, among other requirements, the “label and package insert for such [listed] drug.” However, the label you provided to FDA does not match the drug you listed with FDA. Specifically, the label image you provided to FDA states “triamcinolone 0.1 % ointment,” whereas the product name included in the drug listing submission is “clotrimazole and betamethasone dipropionate cream.” These are different drug products with different active ingredients.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your product. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov for further assistance. Include the case identification number of 1663, on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker, J.D.\n\nDirector, Office of Unapproved Drugs & Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nOffice of Compliance\n\nU.S. Food and Drug Administration","RPK Pharmaceuticals Inc.","rpk-pharmaceuticals-inc-613400-03262021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frpk-pharmaceuticals-inc-613400-03262021","2026-10-26T08:09:51.606294+00:00","2021-04-06","613400","2021-06-07","Rich Mangini","2026-08-20T03:13:43.992+00:00","VIA UNITED PARCEL SERVICE","2021-03-26",{"id":250,"raw":251,"subject":12,"body_html":255,"body_text":256,"firm_name":257,"letter_id":258,"created_at":18,"fei_number":19,"letter_url":259,"updated_at":260,"action_type":22,"case_status":23,"posted_date":261,"marcs_cms_no":262,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":263,"body_fetched_at":264,"delivery_method":113,"recipient_title":19,"reference_number":265,"action_taken_date":266,"medical_device_id":19,"response_letter_date":19},688,[252,253,254,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-27T04:00:00Z\">08\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famneal-pharmaceuticals-llc-709894-08272025\">Amneal Pharmaceuticals, LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-104\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chintu Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amneal Pharmaceuticals, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>50 Horseblock Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brookhaven\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11719-9509\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:chintu@amneal.com\"> chintu@amneal.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-104\u003C\u002Fp>\u003Cp>August 27, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, from March 10 to 19, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 3, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to conduct an adequate investigation into recurring problems with visible particulate matter contamination. In 2024, your firm initiated an investigation when two batches of ropivacaine hydrochloride injection, supplied in polypropylene bags, exceeded your acceptance criteria for visual inspection. You identified the polypropylene bags as the source of the inordinately high levels of particulate contamination (predominately, white fibers). You performed an additional visual inspection and conducted a risk assessment that you believed justified releasing these batches. However, your risk assessment was inadequate as it minimized the severity associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space. Your assessment failed to properly evaluate the potential impact of visible particulates on patient safety, as it did not adequately consider the route of administration and patient population receiving the product.\u003C\u002Fp>\u003Cp>The presence of particulate matter in epidural injectable products can pose significant health risks to patients. These risks are of particular concern for patients receiving long-term epidural therapy. There is a reasonable probability that particulate matter in the epidural space may cause an epidural inflammatory process, epidural abscess, or meningitis. Depending on the location of the epidural injection, the particles could potentially cause damage to the spinal cord including spinal cord infarction or permanent nerve injury.\u003C\u002Fp>\u003Cp>Your firm was aware of the risk of particulate contamination from the polypropylene bags purchased from your vendor for more than a year prior to your 2024 investigation. You had rejected several batches of a sterile drug product after investigating particulate contamination in late 2022 and early 2023. Your investigations found that the polypropylene bags were the source of the visible white fibers and noted difficulties in detecting these fibers when performing visual inspection. Notably, for multiple batches, your firm continued to detect visible fiber particles during acceptable quality limit inspections of limited sample sizes following performance of visual inspections.\u003C\u002Fp>\u003Cp>However, you continued to use these polypropylene bags to produce sterile injectable drug products and did not implement appropriate corrective action and preventive action (CAPA) to prevent recurrence.\u003C\u002Fp>\u003Cp>Based on your investigations into particulate contamination, you relaxed the “major defects” rate from no more than (NMT) \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, and the overall rejection limit from NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. You implemented these significantly relaxed limits due to the high rate of particulate contamination in polypropylene bag lots received from your unreliable vendor. The inappropriately high tolerance for defective polypropylene bags accommodated the use of poor-quality polypropylene bags in the production of parenteral drug product batches.\u003C\u002Fp>\u003Cp>It is unacceptable to increase lot acceptance specifications to excessive levels to enable use of unsuitable polypropylene bags received from your supplier.\u003C\u002Fp>\u003Cp>In your response, you indicate that, on March 26, 2025, you filed a Field Alert Report for two lots of ropivacaine hydrochloride injection, USP, 500 mg\u002F100 mL infusion bags due to particulate contamination. You also initiated a recall of these two lots on April 18, 2025. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Famneal-pharmaceutical-llc-issues-nationwide-recall-ropivacaine-hydrochloride-injection-usp. However, these actions were initiated only after FDA identified these problems during the current inspection.\u003C\u002Fp>\u003Cp>You also indicate that you will be revising your major defect and total defect limits for polypropylene bag visual inspection from NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, and NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, respectively, and will reject batches that fail to meet your acceptable quality limit after visual inspection. These defect levels remain unacceptably high.\u003C\u002Fp>\u003Cp>Furthermore, the health hazard assessment included in your response minimized the severity of risks associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space.\u003C\u002Fp>\u003Cp>We encourage the use of suitable \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection methods for particulates to augment the 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection program. \u003Cstrong>(b)(4)\u003C\u002Fstrong> methods should be rigorously studied and qualified to assess their capability and robustness under various conditions, including machine settings, container-closure sizes, defect types, product characteristics, and other variables. In addition, any use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate inspection as an adjunct method does not supplant the need for 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection. It is essential that a final visual inspection program ensures reliable detection of not only particulates, but various other defects (e.g., container or closure abnormalities, cracks, volume, crimping issues, atypical \u003Cstrong>(b)(4)\u003C\u002Fstrong>, discoloration, bubbles, and any other appearance defects).\u003C\u002Fp>\u003Cp>It is important that significant quality defects, including visible particulate contamination, are appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your process design and production controls.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your materials system, including but not limited to:\u003Cbr>o An evaluation of all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\u003Cbr>o An assessment of all materials to determine whether they are consistently of acceptable quality.\u003Cbr>o A review to ensure assigned expiration or retest dates are appropriate (supported by data).\u003Cbr>o An assessment of the adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A commitment to have a third-party review your firm’s defect categorization pertaining to the visual inspection program, including defining critical, major, and minor defects.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\u003Cul>\u003Cli>Identification of interim steps and controls to ensure lots being produced and distributed into U.S. commerce are essentially free of visible particulate matter.\u003C\u002Fli>\u003Cli>Revision of your risk assessment procedures to ensure thorough evaluation of potential patient impact, and address factors including but not limited to route of administration, patient population, and particle characteristics.\u003C\u002Fli>\u003Cli>Training for all relevant personnel on revised policies, procedures, and other associated items.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, we observed the preparation and reading of bacterial endotoxin tests and identified numerous deficiencies:\u003C\u002Fp>\u003Cul>\u003Cli>Failure to completely discharge the micropipette solution during preparation of water for injection samples, which may compromise the accuracy and reproducibility of the test results.\u003C\u002Fli>\u003Cli>Transfer of gel-clot sample tubes from the incubator to the waste container in a single rapid motion during microbiological analysis, without the crucial pause required to inspect the firmness of the gel for endotoxin detection.\u003C\u002Fli>\u003Cli>The analyst responsible for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification of the gel-clot assessment was unable to adequately observe or verify the process due to the primary microbiologist’s rapid assessment. Despite this basic deficiency, the secondary analyst signed off on the verification.\u003C\u002Fli>\u003Cli>Inadequate documentation practices when recording sample results of bacterial endotoxin tests for water for injection, including non-contemporaneous documenting of negative sample results and assigning a passing result to a positive control sample prior to the actual observation and confirmation of the result.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you revised various procedures, provided associated training, retested reserve samples of potentially impacted drug products, and purchased new equipment to increase laboratory automation.\u003C\u002Fp>\u003Cp>Your response is inadequate due to its limited scope, which primarily addressed the specific deficiencies identified during the FDA inspection. You did not conduct a comprehensive evaluation to determine if similar deficiencies exist in other laboratory operations or address additional opportunities for laboratory equipment automation.\u003C\u002Fp>\u003Cp>It is imperative that your organization conducts a more thorough and systemic review of all laboratory processes, testing methodologies, equipment capabilities, and documentation practices to ensure compliance with CGMP and prevent recurrence of similar issues in the future.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018907202 and ATTN: CDR Frank Verni, Compliance Officer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>cc:&nbsp;\u003C\u002Fp>\u003Cp>Mr. Sandeep Raktate, President (Operations)\u003Cbr>Sandeep.Rakate@amneal.com\u003C\u002Fp>\u003Cp>_______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-104\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chintu Patel\n\nRecipient Title\n\nCo-Chief Executive Officer\n\nAmneal Pharmaceuticals, LLC\n\n50 Horseblock Road\n\nBrookhaven, NY 11719-9509\n\nUnited States\n\nchintu@amneal.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-104\nAugust 27, 2025\nDear Mr. Patel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, from March 10 to 19, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 3, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm failed to conduct an adequate investigation into recurring problems with visible particulate matter contamination. In 2024, your firm initiated an investigation when two batches of ropivacaine hydrochloride injection, supplied in polypropylene bags, exceeded your acceptance criteria for visual inspection. You identified the polypropylene bags as the source of the inordinately high levels of particulate contamination (predominately, white fibers). You performed an additional visual inspection and conducted a risk assessment that you believed justified releasing these batches. However, your risk assessment was inadequate as it minimized the severity associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space. Your assessment failed to properly evaluate the potential impact of visible particulates on patient safety, as it did not adequately consider the route of administration and patient population receiving the product.\nThe presence of particulate matter in epidural injectable products can pose significant health risks to patients. These risks are of particular concern for patients receiving long-term epidural therapy. There is a reasonable probability that particulate matter in the epidural space may cause an epidural inflammatory process, epidural abscess, or meningitis. Depending on the location of the epidural injection, the particles could potentially cause damage to the spinal cord including spinal cord infarction or permanent nerve injury.\nYour firm was aware of the risk of particulate contamination from the polypropylene bags purchased from your vendor for more than a year prior to your 2024 investigation. You had rejected several batches of a sterile drug product after investigating particulate contamination in late 2022 and early 2023. Your investigations found that the polypropylene bags were the source of the visible white fibers and noted difficulties in detecting these fibers when performing visual inspection. Notably, for multiple batches, your firm continued to detect visible fiber particles during acceptable quality limit inspections of limited sample sizes following performance of visual inspections.\nHowever, you continued to use these polypropylene bags to produce sterile injectable drug products and did not implement appropriate corrective action and preventive action (CAPA) to prevent recurrence.\nBased on your investigations into particulate contamination, you relaxed the “major defects” rate from no more than (NMT) (b)(4)% to NMT (b)(4)%, and the overall rejection limit from NMT (b)(4)% to NMT (b)(4)%. You implemented these significantly relaxed limits due to the high rate of particulate contamination in polypropylene bag lots received from your unreliable vendor. The inappropriately high tolerance for defective polypropylene bags accommodated the use of poor-quality polypropylene bags in the production of parenteral drug product batches.\nIt is unacceptable to increase lot acceptance specifications to excessive levels to enable use of unsuitable polypropylene bags received from your supplier.\nIn your response, you indicate that, on March 26, 2025, you filed a Field Alert Report for two lots of ropivacaine hydrochloride injection, USP, 500 mg\u002F100 mL infusion bags due to particulate contamination. You also initiated a recall of these two lots on April 18, 2025. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Famneal-pharmaceutical-llc-issues-nationwide-recall-ropivacaine-hydrochloride-injection-usp. However, these actions were initiated only after FDA identified these problems during the current inspection.\nYou also indicate that you will be revising your major defect and total defect limits for polypropylene bag visual inspection from NMT (b)(4)% to NMT (b)(4)%, and NMT (b)(4)% to NMT (b)(4)%, respectively, and will reject batches that fail to meet your acceptable quality limit after visual inspection. These defect levels remain unacceptably high.\nFurthermore, the health hazard assessment included in your response minimized the severity of risks associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space.\nWe encourage the use of suitable (b)(4) visual inspection methods for particulates to augment the 100% (b)(4) visual inspection program. (b)(4) methods should be rigorously studied and qualified to assess their capability and robustness under various conditions, including machine settings, container-closure sizes, defect types, product characteristics, and other variables. In addition, any use of (b)(4) particulate inspection as an adjunct method does not supplant the need for 100% (b)(4) visual inspection. It is essential that a final visual inspection program ensures reliable detection of not only particulates, but various other defects (e.g., container or closure abnormalities, cracks, volume, crimping issues, atypical (b)(4), discoloration, bubbles, and any other appearance defects).\nIt is important that significant quality defects, including visible particulate contamination, are appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your process design and production controls.\nIn response to this letter, provide:\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive, independent review of your materials system, including but not limited to:\no An evaluation of all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\no An assessment of all materials to determine whether they are consistently of acceptable quality.\no A review to ensure assigned expiration or retest dates are appropriate (supported by data).\no An assessment of the adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA commitment to have a third-party review your firm’s defect categorization pertaining to the visual inspection program, including defining critical, major, and minor defects.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nIdentification of interim steps and controls to ensure lots being produced and distributed into U.S. commerce are essentially free of visible particulate matter.\nRevision of your risk assessment procedures to ensure thorough evaluation of potential patient impact, and address factors including but not limited to route of administration, patient population, and particle characteristics.\nTraining for all relevant personnel on revised policies, procedures, and other associated items.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nDuring our inspection, we observed the preparation and reading of bacterial endotoxin tests and identified numerous deficiencies:\nFailure to completely discharge the micropipette solution during preparation of water for injection samples, which may compromise the accuracy and reproducibility of the test results.\nTransfer of gel-clot sample tubes from the incubator to the waste container in a single rapid motion during microbiological analysis, without the crucial pause required to inspect the firmness of the gel for endotoxin detection.\nThe analyst responsible for the (b)(4) verification of the gel-clot assessment was unable to adequately observe or verify the process due to the primary microbiologist’s rapid assessment. Despite this basic deficiency, the secondary analyst signed off on the verification.\nInadequate documentation practices when recording sample results of bacterial endotoxin tests for water for injection, including non-contemporaneous documenting of negative sample results and assigning a passing result to a positive control sample prior to the actual observation and confirmation of the result.\nIn your response, you state that you revised various procedures, provided associated training, retested reserve samples of potentially impacted drug products, and purchased new equipment to increase laboratory automation.\nYour response is inadequate due to its limited scope, which primarily addressed the specific deficiencies identified during the FDA inspection. You did not conduct a comprehensive evaluation to determine if similar deficiencies exist in other laboratory operations or address additional opportunities for laboratory equipment automation.\nIt is imperative that your organization conducts a more thorough and systemic review of all laboratory processes, testing methodologies, equipment capabilities, and documentation practices to ensure compliance with CGMP and prevent recurrence of similar issues in the future.\nIn response to this letter, provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nQuality Unit Authority\nSignificant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.1 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018907202 and ATTN: CDR Frank Verni, Compliance Officer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\ncc:\nMr. Sandeep Raktate, President (Operations)\nSandeep.Rakate@amneal.com\n_______________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Amneal Pharmaceuticals, LLC","amneal-pharmaceuticals-llc-709894-08272025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famneal-pharmaceuticals-llc-709894-08272025","2026-10-26T08:07:55.421238+00:00","2025-09-02","709894","Mr. Chintu Patel","2026-08-19T16:26:25.704+00:00","320-25-104","2025-08-27",{"id":268,"raw":269,"subject":274,"body_html":275,"body_text":276,"firm_name":277,"letter_id":278,"created_at":279,"fei_number":19,"letter_url":280,"updated_at":281,"action_type":22,"case_status":23,"posted_date":282,"marcs_cms_no":283,"product_type":284,"closeout_date":19,"issuing_office":285,"recipient_name":286,"body_fetched_at":287,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":288,"medical_device_id":19,"response_letter_date":19},2142,[270,271,272,273,274,13,13,13],"\u003Ctime datetime=\"2023-04-04T13:20:00Z\">04\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-22T05:00:00Z\">11\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspire-pharmaceuticals-inc-630328-11222022\">Aspire Pharmaceuticals, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East II ","CGMP\u002FManufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Madhav Pai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aspire Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>41 Veronica Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Somerset\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08873-6800\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #630328\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Pai:\u003Cbr>\n\u003Cbr>\nThis is to advise you that the U.S. Food and Drug Administration (FDA) conducted a joint inspection of your dietary supplement and drug manufacturing facility, located at 37 &amp; 41 Veronica Avenue, Somerset, NJ 08873-6800 on November 29 through 30, 2021; December 1 through 3, 6 through 9, 13 through 14, 17, 2021; and February 1 and 3, 2022. Based on our inspection and our. review of labeling collected during the inspection, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You may find the Act and the FDA's regulations through links on FDA's home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>We received e-mail correspondences from you dated March 14, 2022, April 11, 2022, May 11, 2022, July 11, 2022, and August 11 , 2022, written in response to the Form FDA 483, lnspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement cGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, our investigators found significant violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act (21 U.S.C. § 342(g)(1)] because the dietary supplements have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the cGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to ensure that the tests or examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your finished product testing uses \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to verify if finished product specifications for strength have been met for your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Mini Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Formula Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Finished product testing using \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" is not an appropriate, scientifically valid method to verify finished product specifications.\u003C\u002Fp>\n\n\u003Cp>i. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for ingredients including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nii. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Mini Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for each of the ingredients in the product. In addition, during the inspection, you stated that no testing for the strength of any ingredient has been conducted for this product.\u003Cbr>\niii. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for the ingredients&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> extract and \u003Cstrong>(b)(4)\u003C\u002Fstrong> extract. Your specifications for this product, dated May 20, 2021, removed a test for the strength of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, a maker in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> extract. The previous version of your specifications, dated November 6, 2020, included a test for \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>to determine the amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> using your method, \"MSIH-201 ,\" instead of \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\" During the inspection, you indicated the change to \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" was at the request of the customer, as documented in your change control document dated May 18, 2021. You could not provide a basis for why removing this test and replacing it with \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" would ensure the product met finished product specifications.\u003Cbr>\niv. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for the ingredients&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nv. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Formula Softgel product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for the ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong> (standardized to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Extract, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Paste, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Extract, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Oil, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (from \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract, \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract (standardized to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract (standardized to \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>b. You use FTIR for identity testing for some of the ingredients in your dietary supplement products. Your procedure, RMA-279, \"Testing Procedure for Identification by IR in Raw Material\" requires comparison of the sample spectrum to a \"Reference Standard\u002FReference Sample or Monograph Spectrum.\" During the inspection, you informed our investigators that your firm uses a purchased reference standard if there is one commercially available. For many of the ingredients, you use a reference sample because there is no reference standard available. A reference sample is a previous lot of the material from the vendor or a sample provided from the vendor to be used as reference material. However, your laboratory does not require verification of the previous lot or that the provided material is appropriate for use as a standard. Identity testing using FTIR to compare the sample spectrum to an unverified reference sample is not an appropriate, scientifically valid method to verify that specifications are met. For example:\u003C\u002Fp>\n\n\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>: You used FTIR for identity testing of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;is received as a pre-blend of \u003Cstrong>(b)(4)\u003C\u002Fstrong> different ingredients. During the inspection, you stated that FTIR cannot determine if each of the ingredients is present in the product. Identity testing must be able to confirm the identity of each ingredient in the finished product.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> was ultimately used in the manufacturing of the finished dietary supplement \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgel lot&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nii. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract: You used FTIR for identity testing of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> was ultimately used in the manufacturing of the finished dietary supplement \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgel lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\niii. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract: You used FTIR for identity testing of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> was ultimately used in the manufacturing of the finished dietary supplement \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>c. You use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Test Method to test your dietary supplement products for compliance with microbial specifications. This system includes testing for:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Total aerobic plate count, procedure MICROSTP-001\u003C\u002Fli>\n\t\u003Cli>Yeast and mold, procedure MICROSTP-002\u003C\u002Fli>\n\t\u003Cli>Salmonella, procedure MICROSTP-003\u003C\u002Fli>\n\t\u003Cli>Staphylococcus aureus, procedure MICROSTP-004\u003C\u002Fli>\n\t\u003Cli>Escherichia coli, procedure MICROSTP-005\u003C\u002Fli>\n\t\u003Cli>Enterobacteriaceae, procedure MICROSTP-006\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, you are not conducting suitability testing to demonstrate whether these methods are appropriate for testing all of your products. According to your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Technical Report, dated April 8, 2019, you conducted suitability testing for ten products, but not for all products. The report also determined that two of the ten products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, required modified preparation steps for neutralization, or else the test may not provide a valid result.\u003C\u002Fp>\n\n\u003Cp>The ingredients and amount of ingredients unique to individual dietary supplement products may interfere with the ability of microbial tests to provide a reliable result. Without suitability testing to demonstrate that a product does not interfere with the test, the method may not be determined to be an appropriate, scientifically valid method to verify that specifications are met.\u003C\u002Fp>\n\n\u003Cp>Your response dated April 11, 2022 states you will provide new documents and procedures, including Finished Product Dossiers for all the products identified during the inspection and Finished Product Specification and Report Forms. However, we are unable to evaluate the adequacy of your corrective actions because your submission did not include documentation that shows that you are implementing such corrections. For example, you provided only draft examples of your Finished Product Dossiers and Finished Product Specification and Report Forms for some of your dietary supplement products.\u003C\u002Fp>\n\n\u003Cp>In addition, your response suggested exempting ingredients that do not have verification methods from finished product testing, however, you did not provide the required documentation for such exemptions. Note that, to exempt one or more product specifications from verification requirements under 21 CFR 111.75(d), you must document why any component and in-process testing, examination, or monitoring, and any other information, will ensure that such exempted product specification is met without verification through periodic testing of the finished batch, and your quality control personnel must review and approve the documentation that you provide.\u003C\u002Fp>\n\n\u003Cp>2. Your firm's quality control personnel failed to conduct a material review and make a disposition decision when the established specification was not met, as required by 21 CFR 111.113(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, out of specification results were received for the following components and finished products:\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk softgels, \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Suspension raw material lot&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. For these components and finished products, your quality control unit failed to follow your procedure, \"MICRO009: Laboratory Investigation of \"Out of Specification\" Results for Microbiological Testing,\" which outlines the appropriate steps when a microbial specification is not met during testing. Your procedure states, if laboratory testing results fail to meet the specification, \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" and, \"The&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (Attachment Ill).\" You did not follow your procedure to conduct and document a laboratory investigation using Attachment Ill of your procedure; rather, you retested the samples until a passing result was obtained, and then reported the passing result without conducting an investigation for the initial failing results. No material review or disposition decision was performed by your firm in these examples where the dietary supplements or components failed to meet established specifications.\u003C\u002Fp>\n\n\u003Cp>Your response dated April 11, 2022 states, \"Investigations and Corrective Actions are completed. All microbiological testing is currently being sent out while improvements to the micro lab facility and procedures can be carried out to address the apparent contamination issues in the micro lab. (Status: Completed on time).\" We are unable to evaluate the adequacy of your response because you did not provide documentation to support that you have made the proposed corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, your product \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is a misbranded dietary supplement within the meaning of section 403 of the Act [21 U.S.C. § 343] because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>Your \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" product is misbranded within the meaning of section 403(q)(1)(A) of the Act (21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, the product's label declares serving size as 2. The directions state to take two (2) softgels daily divided between morning and evening, with food, or as recommended by a healthcare practitioner. Serving size should be one based on one softgel per eating occasion.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comments:\u003C\u002Fp>\n\n\u003Cp>1. During the inspection, we observed that your quality control operations did not include reviewing and approving the results of required tests as required by 21 CFR 111.110(c). For example, your laboratory Data Reviewer did not review the electronic audit trail for your analytical testing. According to your response letter, dated April 11, 2022; training was provided to include guidelines for audit trail review and are being followed. You also provided an example of what the training consisted of; however, you did not include the names of the personnel who were retained. FDA will assess this observation during the next inspection in order to determine the effectiveness of the training on personnel.\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels Supplement Facts label declares \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" but only lists one ingredient, that being \u003Cstrong>(b)(4)\u003C\u002Fstrong> fruit. We note a proprietary blend refers to more than one ingredient. (21 CFR 101.36(c)].\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Human Drugs CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This section summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501 (a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response, dated March 11, 2022, and subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fp>\n\n\u003Cp>Your quality control (QC) analysts routinely recorded raw data, such as sample weights, into unofficial notebooks during release testing. Our inspection found an analyst maintained two separate notebooks recording different sample weights for the same assay test. Your analyst admitted to altering the sample weights in the approved notebook so that calculations based on those results would meet your release specifications. At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Aspire Daytime Mucus and Sinus soft gel bulk product failed to meet your firm's internal assay specification for the active ingredients. Your quality unit released these batches based on a review of inaccurate laboratory data.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you conducted an investigation, retested the \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches that were released based on falsified data, and concluded that all \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches met your firm's acceptance criteria after retesting.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your quality unit failed to conduct a comprehensive retrospective investigation to determine the extent of breaches of data integrity found during the inspection. It also lacks a root cause investigation into the original assay results failing to meet your release specification when the actual sample weights documented in the unofficial composition notebook were used for the calculation. You failed to provide scientific justification to invalidate the original unexpected results and only report the favorable results.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fp>\n\n\u003Cp>You failed to establish sufficient specifications and analytical testing procedures for critical quality attributes for the drugs that you manufacture. You lacked specifications and failed to test for the 4-aminophenol impurity in acetaminophen-containing drug products.\u003C\u002Fp>\n\n\u003Cp>For example, at least three acetaminophen-containing solid oral dosage form drug products lacked the specification and testing procedure for 4-aminophenol content.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that your drug products do not have a specific USP monograph, and therefore there was not a method for testing for impurities. You also committed to developing, validating, and implementing an analytical method to detect and quantify impurities by September 2022.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Regardless of whether a drug product has a USP monograph, you are responsible for ensuring you have scientifically sound specifications and test methods used to determine drug quality and purity prior to release. The 4-aminophenol impurity is a known impurity of acetaminophen and should be controlled and established as a condition of release of acetaminophen-containing drug products. FDA is also concerned that you plan to continue manufacturing and releasing the same drug products without testing for the 4-aminophenol impurity prior to implementing an analytical testing method. for this impurity. You have not implemented interim controls to ensure product quality and to mitigate the risk to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each batch of your drug products before a batch disposition decision, and the associated procedures, including but not limited to 4-aminophenol content for all acetaminophen containing drug products.\u003C\u002Fli>\n\t\u003Cli>An assessment to ensure complete and appropriate specifications are established for batch release and stability studies for all drug products manufactured by your firm.\u003C\u002Fli>\n\t\u003Cli>Your detailed plan for retrospective testing of all drug product batches that were insufficiently tested and remain within expiry. Determine whether each batch conforms to all appropriate specifications, including but not limited to 4-aminophenol impurity content.\u003C\u002Fli>\n\t\u003Cli>A risk assessment on marketed finished drug product batches containing acetaminophen that were not tested for the 4-aminophenol impurity.\u003C\u002Fli>\n\t\u003Cli>Interim controls established prior to completing the development, validation, and implementation of the test method to detect the 4-aminophenol impurity.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\n\n\u003Cp>During this ·inspection, FDA investigators observed that your firm performed multiple single \"trial\" injections of test samples on high performance liquid chromatography (HPLC) systems without any scientific justification.\u003C\u002Fp>\n\n\u003Cp>Your response stated that your firm's standard operating procedures (SOPs) for liquid chromatographic analysis and gas chromatographic analysis allow \"trial\" injections of the standard solution only to verify the resolution of HPLC and gas chromatography (GC) systems, and the \"trial\" injections must be a part of the sample set sequence. Your investigation report PE-22-0005 confirmed that \"trial\" injections were performed using test samples instead of standards.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. The inspection documented that your HPLC audit trail records showed that these \"trial\" injections were not part of the sample set sequence, which is contrary to the statement in your firm's response to the Form FDA 483 observations. In addition, these standalone sample \"trial\" injections were made before your official reinjections of the content uniformity samples in a sample set sequence, which is contrary to the statement in your retrospective investigation PE-22-0005.\u003C\u002Fp>\n\n\u003Cp>The injection of trial samples is not acceptable, in part, because all data from analysis of product samples must be retained and reviewed (21 CFR 211 .22, 211.165, 211.192, and 211.194). Therefore, FDA considers it a violative practice to perform a trial injection. FDA also considers it a violative practice to use an actual sample in test, preparation, or equilibration runs as a means of disguising testing into compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Reinjecting to obtain favorable results\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate documentation of all calculations and rationale for additional laboratory testing when unexpected content uniformity results for acetaminophen in batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> were obtained during a process validation study for Aspire Mucus and Pain Relief soft gel drug product. Your analyst noticed differences in the peak shapes, reinjected the samples the next day, and used favorable reinjection results to invalidate the original results. Your response indicated that the laboratory manager was informed of the unexpected test results and authorized the reinjection of the samples. However, neither the inspection nor your firm's response included evidence to support that statement.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that a retrospective investigation PE-22-0005 was initiated for the unexpected content uniformity results for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> in Aspire Mucus and Pain Relief soft gel process validation. Your investigation, initiated four months after the event, concluded that the initial results were invalidated because the analyst forgot to add the check standard.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your above conclusion is not supported by the chromatography data available. For example, there were two sample sets run on October 11, 2021 : the first set (without the check standard) was aborted in the middle of the run; and the second set (with the check standard) was completed and generated higher peak area counts for the two content uniformity samples. Your firm's conclusion contradicts the analyst's notebook (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) comments which attributed the higher results to the different peak shapes compared to the rest of the samples analyzed in the same sample set.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to investigate above limit results for purified water\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Our review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system audit trail report noted multiple results for total microbial testing of your purified water system were above limit. No investigation was performed. You also failed to follow your SOP MICRO009 and SOP QA025 which require an out of specification (OOS) investigation to be initiated when obtaining out of limit microbial test and purified water results, respectively. Purified water is used as one of the components in your OTC drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that your in-house testing was for information only and you sent the purified water samples to an outside testing laboratory for microbial release testing during the period of January 21, 2021, to July 9, 2021. You also stated that you suspended all internal microbiological laboratory operations until personnel and resources are in place to ensure compliance with all regulatory requirements.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Samples to your external laboratory were sent only after you obtained the in-house out of limit results.\u003C\u002Fli>\n\t\u003Cli>You lack evidence to support that a protocol was in place for the testing of your samples later claimed to be for information only.\u003C\u002Fli>\n\t\u003Cli>You failed to address the in-house test failures from September to November 2021.\u003C\u002Fli>\n\t\u003Cli>Your retrospective investigation was performed in March 2022, approximately one year after the first out of limit result was obtained.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm remains responsible for investigating all out of limit test results in a timely manner.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; &nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, - complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequately scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA's guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a consultant highly qualified in data integrity assessment to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>1. comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fp>\n\n\u003Cp>a) A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\nb) Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\nc) An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility's operations in which you discovered data integrity lapses.\u003Cbr>\nd) A comprehensive retrospective evaluation of the nature of the (testing\u002Fmanufacturing\u002Fother] data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>2. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>3. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\u003C\u002Fp>\n\n\u003Cp>a) A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\nb) A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\nc) Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\nd) Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company's data.\u003Cbr>\ne) A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Compliance Officer Melissa B. Libby at U.S. Food &amp; Drug Administration, 10 Waterview Blvd., 3rd Floor, Parsippany, NJ 07054. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Melissa Libby by telephone at (973) 331-4997 or by email at melissa.libby@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Randy F. Pack\u003Cbr>\nDistrict Director\u002FProgram Division Director\u003Cbr>\nBaltimore District Office\u003Cbr>\nHuman &amp; Animal Food East, Division 2\u003Cbr>\nOffice of Regulatory Affairs\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nDr. Madhav Pai\n\nRecipient Title\n\nPresident & CEO\n\nAspire Pharmaceuticals, Inc.\n\n41 Veronica Avenue\n\nSomerset, NJ 08873-6800\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nWARNING LETTER\n\nCMS #630328\n\nNovember 22, 2022\n\nDear Dr. Pai:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) conducted a joint inspection of your dietary supplement and drug manufacturing facility, located at 37 & 41 Veronica Avenue, Somerset, NJ 08873-6800 on November 29 through 30, 2021; December 1 through 3, 6 through 9, 13 through 14, 17, 2021; and February 1 and 3, 2022. Based on our inspection and our. review of labeling collected during the inspection, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You may find the Act and the FDA's regulations through links on FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nWe received e-mail correspondences from you dated March 14, 2022, April 11, 2022, May 11, 2022, July 11, 2022, and August 11 , 2022, written in response to the Form FDA 483, lnspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\n\nDietary Supplement cGMP Violations\n\nDuring the inspection, our investigators found significant violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act (21 U.S.C. § 342(g)(1)] because the dietary supplements have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\n\nYour significant violations of the cGMP requirements are as follows:\n\n1. You failed to ensure that the tests or examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1). Specifically:\n\na. Your finished product testing uses \"(b)(4)\" as a method to verify if finished product specifications for strength have been met for your (b)(4) Softgels - lot (b)(4), (b)(4) Mini Softgels - lot (b)(4), (b)(4) Softgels - lot (b)(4), (b)(4) Softgels - lot (b)(4), and (b)(4) Formula Softgels - lot (b)(4). Finished product testing using \"(b)(4)\" is not an appropriate, scientifically valid method to verify finished product specifications.\n\ni. For your (b)(4) Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for ingredients including, but not limited to, (b)(4).\n\nii. For your (b)(4) Mini Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for each of the ingredients in the product. In addition, during the inspection, you stated that no testing for the strength of any ingredient has been conducted for this product.\n\niii. For your (b)(4) Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for the ingredients (b)(4) extract and (b)(4) extract. Your specifications for this product, dated May 20, 2021, removed a test for the strength of (b)(4), a maker in the (b)(4) extract. The previous version of your specifications, dated November 6, 2020, included a test for (b)(4) to determine the amount of (b)(4) using your method, \"MSIH-201 ,\" instead of \"(b)(4).\" During the inspection, you indicated the change to \"(b)(4)\" was at the request of the customer, as documented in your change control document dated May 18, 2021. You could not provide a basis for why removing this test and replacing it with \"(b)(4)\" would ensure the product met finished product specifications.\n\niv. For your (b)(4) Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for the ingredients (b)(4).\n\nv. For your (b)(4) Formula Softgel product: You use \"(b)(4)\" as a method to determine whether specifications are met for the ingredients (b)(4) (standardized to (b)(4)), (b)(4) Extract, (b)(4) Paste, (b)(4) Extract, (b)(4) Oil, (b)(4) (from (b)(4)), (b)(4) Extract, (b)(4), (b)(4) Extract (standardized to (b)(4)), and (b)(4) Extract (standardized to (b)(4)).\n\nb. You use FTIR for identity testing for some of the ingredients in your dietary supplement products. Your procedure, RMA-279, \"Testing Procedure for Identification by IR in Raw Material\" requires comparison of the sample spectrum to a \"Reference Standard\u002FReference Sample or Monograph Spectrum.\" During the inspection, you informed our investigators that your firm uses a purchased reference standard if there is one commercially available. For many of the ingredients, you use a reference sample because there is no reference standard available. A reference sample is a previous lot of the material from the vendor or a sample provided from the vendor to be used as reference material. However, your laboratory does not require verification of the previous lot or that the provided material is appropriate for use as a standard. Identity testing using FTIR to compare the sample spectrum to an unverified reference sample is not an appropriate, scientifically valid method to verify that specifications are met. For example:\n\ni. (b)(4): You used FTIR for identity testing of (b)(4) lot (b)(4). During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. In addition, (b)(4) is received as a pre-blend of (b)(4) different ingredients. During the inspection, you stated that FTIR cannot determine if each of the ingredients is present in the product. Identity testing must be able to confirm the identity of each ingredient in the finished product. (b)(4) lot (b)(4) was ultimately used in the manufacturing of the finished dietary supplement (b)(4) Softgel lot (b)(4).\n\nii. (b)(4) Extract: You used FTIR for identity testing of (b)(4) Extract lot (b)(4). During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. (b)(4) lot (b)(4) was ultimately used in the manufacturing of the finished dietary supplement (b)(4) Softgel lot (b)(4).\n\niii. (b)(4) Extract: You used FTIR for identity testing of (b)(4) Extract lot (b)(4). During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. (b)(4) Extract lot (b)(4) was ultimately used in the manufacturing of the finished dietary supplement (b)(4) lot (b)(4).\n\nc. You use the (b)(4) Test Method to test your dietary supplement products for compliance with microbial specifications. This system includes testing for:\n\nTotal aerobic plate count, procedure MICROSTP-001\n\nYeast and mold, procedure MICROSTP-002\n\nSalmonella, procedure MICROSTP-003\n\nStaphylococcus aureus, procedure MICROSTP-004\n\nEscherichia coli, procedure MICROSTP-005\n\nEnterobacteriaceae, procedure MICROSTP-006\n\nHowever, you are not conducting suitability testing to demonstrate whether these methods are appropriate for testing all of your products. According to your (b)(4) Technical Report, dated April 8, 2019, you conducted suitability testing for ten products, but not for all products. The report also determined that two of the ten products, (b)(4), required modified preparation steps for neutralization, or else the test may not provide a valid result.\n\nThe ingredients and amount of ingredients unique to individual dietary supplement products may interfere with the ability of microbial tests to provide a reliable result. Without suitability testing to demonstrate that a product does not interfere with the test, the method may not be determined to be an appropriate, scientifically valid method to verify that specifications are met.\n\nYour response dated April 11, 2022 states you will provide new documents and procedures, including Finished Product Dossiers for all the products identified during the inspection and Finished Product Specification and Report Forms. However, we are unable to evaluate the adequacy of your corrective actions because your submission did not include documentation that shows that you are implementing such corrections. For example, you provided only draft examples of your Finished Product Dossiers and Finished Product Specification and Report Forms for some of your dietary supplement products.\n\nIn addition, your response suggested exempting ingredients that do not have verification methods from finished product testing, however, you did not provide the required documentation for such exemptions. Note that, to exempt one or more product specifications from verification requirements under 21 CFR 111.75(d), you must document why any component and in-process testing, examination, or monitoring, and any other information, will ensure that such exempted product specification is met without verification through periodic testing of the finished batch, and your quality control personnel must review and approve the documentation that you provide.\n\n2. Your firm's quality control personnel failed to conduct a material review and make a disposition decision when the established specification was not met, as required by 21 CFR 111.113(a)(1).\n\nSpecifically, out of specification results were received for the following components and finished products:(b)(4) lot (b)(4), (b)(4) lot (b)(4), (b)(4) lot (b)(4) bulk softgels, (b)(4) raw material lot (b)(4), (b)(4) raw material lot (b)(4), and (b)(4) Suspension raw material lot (b)(4). For these components and finished products, your quality control unit failed to follow your procedure, \"MICRO009: Laboratory Investigation of \"Out of Specification\" Results for Microbiological Testing,\" which outlines the appropriate steps when a microbial specification is not met during testing. Your procedure states, if laboratory testing results fail to meet the specification, \"(b)(4)\" and, \"The (b)(4) (Attachment Ill).\" You did not follow your procedure to conduct and document a laboratory investigation using Attachment Ill of your procedure; rather, you retested the samples until a passing result was obtained, and then reported the passing result without conducting an investigation for the initial failing results. No material review or disposition decision was performed by your firm in these examples where the dietary supplements or components failed to meet established specifications.\n\nYour response dated April 11, 2022 states, \"Investigations and Corrective Actions are completed. All microbiological testing is currently being sent out while improvements to the micro lab facility and procedures can be carried out to address the apparent contamination issues in the micro lab. (Status: Completed on time).\" We are unable to evaluate the adequacy of your response because you did not provide documentation to support that you have made the proposed corrective actions.\n\nMisbranded Dietary Supplements\n\nIn addition, your product (b)(4), is a misbranded dietary supplement within the meaning of section 403 of the Act [21 U.S.C. § 343] because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\nYour \"(b)(4)\" product is misbranded within the meaning of section 403(q)(1)(A) of the Act (21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, the product's label declares serving size as 2. The directions state to take two (2) softgels daily divided between morning and evening, with food, or as recommended by a healthcare practitioner. Serving size should be one based on one softgel per eating occasion.\n\nWe also offer the following comments:\n\n1. During the inspection, we observed that your quality control operations did not include reviewing and approving the results of required tests as required by 21 CFR 111.110(c). For example, your laboratory Data Reviewer did not review the electronic audit trail for your analytical testing. According to your response letter, dated April 11, 2022; training was provided to include guidelines for audit trail review and are being followed. You also provided an example of what the training consisted of; however, you did not include the names of the personnel who were retained. FDA will assess this observation during the next inspection in order to determine the effectiveness of the training on personnel.\n\n2. Your (b)(4) Softgels Supplement Facts label declares \"(b)(4)\" but only lists one ingredient, that being (b)(4) fruit. We note a proprietary blend refers to more than one ingredient. (21 CFR 101.36(c)].\n\nHuman Drugs CGMP Violations\n\nThis section summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501 (a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe acknowledge receipt of your response, dated March 11, 2022, and subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nYour quality control (QC) analysts routinely recorded raw data, such as sample weights, into unofficial notebooks during release testing. Our inspection found an analyst maintained two separate notebooks recording different sample weights for the same assay test. Your analyst admitted to altering the sample weights in the approved notebook so that calculations based on those results would meet your release specifications. At least (b)(4) batches of Aspire Daytime Mucus and Sinus soft gel bulk product failed to meet your firm's internal assay specification for the active ingredients. Your quality unit released these batches based on a review of inaccurate laboratory data.\n\nIn your response, you stated that you conducted an investigation, retested the (b)(4) batches that were released based on falsified data, and concluded that all (b)(4) batches met your firm's acceptance criteria after retesting.\n\nYour response is inadequate because your quality unit failed to conduct a comprehensive retrospective investigation to determine the extent of breaches of data integrity found during the inspection. It also lacks a root cause investigation into the original assay results failing to meet your release specification when the actual sample weights documented in the unofficial composition notebook were used for the calculation. You failed to provide scientific justification to invalidate the original unexpected results and only report the favorable results.\n\nIn response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYou failed to establish sufficient specifications and analytical testing procedures for critical quality attributes for the drugs that you manufacture. You lacked specifications and failed to test for the 4-aminophenol impurity in acetaminophen-containing drug products.\n\nFor example, at least three acetaminophen-containing solid oral dosage form drug products lacked the specification and testing procedure for 4-aminophenol content.\n\nIn your response, you stated that your drug products do not have a specific USP monograph, and therefore there was not a method for testing for impurities. You also committed to developing, validating, and implementing an analytical method to detect and quantify impurities by September 2022.\n\nYour response is inadequate. Regardless of whether a drug product has a USP monograph, you are responsible for ensuring you have scientifically sound specifications and test methods used to determine drug quality and purity prior to release. The 4-aminophenol impurity is a known impurity of acetaminophen and should be controlled and established as a condition of release of acetaminophen-containing drug products. FDA is also concerned that you plan to continue manufacturing and releasing the same drug products without testing for the 4-aminophenol impurity prior to implementing an analytical testing method. for this impurity. You have not implemented interim controls to ensure product quality and to mitigate the risk to patients.\n\nIn response to this letter, provide:\n\nA list of chemical and microbial test methods and specifications used to analyze each batch of your drug products before a batch disposition decision, and the associated procedures, including but not limited to 4-aminophenol content for all acetaminophen containing drug products.\n\nAn assessment to ensure complete and appropriate specifications are established for batch release and stability studies for all drug products manufactured by your firm.\n\nYour detailed plan for retrospective testing of all drug product batches that were insufficiently tested and remain within expiry. Determine whether each batch conforms to all appropriate specifications, including but not limited to 4-aminophenol impurity content.\n\nA risk assessment on marketed finished drug product batches containing acetaminophen that were not tested for the 4-aminophenol impurity.\n\nInterim controls established prior to completing the development, validation, and implementation of the test method to detect the 4-aminophenol impurity.\n\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nDuring this ·inspection, FDA investigators observed that your firm performed multiple single \"trial\" injections of test samples on high performance liquid chromatography (HPLC) systems without any scientific justification.\n\nYour response stated that your firm's standard operating procedures (SOPs) for liquid chromatographic analysis and gas chromatographic analysis allow \"trial\" injections of the standard solution only to verify the resolution of HPLC and gas chromatography (GC) systems, and the \"trial\" injections must be a part of the sample set sequence. Your investigation report PE-22-0005 confirmed that \"trial\" injections were performed using test samples instead of standards.\n\nYour response is inadequate. The inspection documented that your HPLC audit trail records showed that these \"trial\" injections were not part of the sample set sequence, which is contrary to the statement in your firm's response to the Form FDA 483 observations. In addition, these standalone sample \"trial\" injections were made before your official reinjections of the content uniformity samples in a sample set sequence, which is contrary to the statement in your retrospective investigation PE-22-0005.\n\nThe injection of trial samples is not acceptable, in part, because all data from analysis of product samples must be retained and reviewed (21 CFR 211 .22, 211.165, 211.192, and 211.194). Therefore, FDA considers it a violative practice to perform a trial injection. FDA also considers it a violative practice to use an actual sample in test, preparation, or equilibration runs as a means of disguising testing into compliance.\n\nReinjecting to obtain favorable results\n\nYour firm lacked adequate documentation of all calculations and rationale for additional laboratory testing when unexpected content uniformity results for acetaminophen in batches (b)(4) were obtained during a process validation study for Aspire Mucus and Pain Relief soft gel drug product. Your analyst noticed differences in the peak shapes, reinjected the samples the next day, and used favorable reinjection results to invalidate the original results. Your response indicated that the laboratory manager was informed of the unexpected test results and authorized the reinjection of the samples. However, neither the inspection nor your firm's response included evidence to support that statement.\n\nIn your response, you indicated that a retrospective investigation PE-22-0005 was initiated for the unexpected content uniformity results for batch (b)(4) and (b)(4) in Aspire Mucus and Pain Relief soft gel process validation. Your investigation, initiated four months after the event, concluded that the initial results were invalidated because the analyst forgot to add the check standard.\n\nYour response is inadequate. Your above conclusion is not supported by the chromatography data available. For example, there were two sample sets run on October 11, 2021 : the first set (without the check standard) was aborted in the middle of the run; and the second set (with the check standard) was completed and generated higher peak area counts for the two content uniformity samples. Your firm's conclusion contradicts the analyst's notebook ((b)(4)) comments which attributed the higher results to the different peak shapes compared to the rest of the samples analyzed in the same sample set.\n\nFailure to investigate above limit results for purified water\n\nOur review of your (b)(4) system audit trail report noted multiple results for total microbial testing of your purified water system were above limit. No investigation was performed. You also failed to follow your SOP MICRO009 and SOP QA025 which require an out of specification (OOS) investigation to be initiated when obtaining out of limit microbial test and purified water results, respectively. Purified water is used as one of the components in your OTC drug products.\n\nIn your response, you stated that your in-house testing was for information only and you sent the purified water samples to an outside testing laboratory for microbial release testing during the period of January 21, 2021, to July 9, 2021. You also stated that you suspended all internal microbiological laboratory operations until personnel and resources are in place to ensure compliance with all regulatory requirements.\n\nYour response is inadequate:\n\nSamples to your external laboratory were sent only after you obtained the in-house out of limit results.\n\nYou lack evidence to support that a protocol was in place for the testing of your samples later claimed to be for information only.\n\nYou failed to address the in-house test failures from September to November 2021.\n\nYour retrospective investigation was performed in March 2022, approximately one year after the first out of limit result was obtained.\n\nYour firm remains responsible for investigating all out of limit test results in a timely manner.\n\nIn response to this letter, provide:\n\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, - complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA's guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain a consultant highly qualified in data integrity assessment to assist in your remediation. In response to this letter, provide the following:\n\n1. comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\na) A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\nb) Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\nc) An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility's operations in which you discovered data integrity lapses.\n\nd) A comprehensive retrospective evaluation of the nature of the (testing\u002Fmanufacturing\u002Fother] data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n2. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n3. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\n\na) A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\nb) A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\nc) Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\nd) Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company's data.\n\ne) A status report for any of the above activities already underway or completed.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Compliance Officer Melissa B. Libby at U.S. Food & Drug Administration, 10 Waterview Blvd., 3rd Floor, Parsippany, NJ 07054. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Melissa Libby by telephone at (973) 331-4997 or by email at melissa.libby@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRandy F. Pack\n\nDistrict Director\u002FProgram Division Director\n\nBaltimore District Office\n\nHuman & Animal Food East, Division 2\n\nOffice of Regulatory Affairs\n\nU.S. Food and Drug Administration","Aspire Pharmaceuticals, Inc.","aspire-pharmaceuticals-inc-630328-11222022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspire-pharmaceuticals-inc-630328-11222022","2026-10-26T08:07:58.561486+00:00","2023-04-04","630328","Dietary Supplements","Division of Human and Animal Food Operations East II","Dr. Madhav Pai","2026-08-20T01:10:12.698+00:00","2022-11-22",{"id":290,"raw":291,"subject":296,"body_html":297,"body_text":298,"firm_name":299,"letter_id":300,"created_at":279,"fei_number":19,"letter_url":301,"updated_at":302,"action_type":22,"case_status":23,"posted_date":303,"marcs_cms_no":304,"product_type":26,"closeout_date":19,"issuing_office":295,"recipient_name":305,"body_fetched_at":306,"delivery_method":307,"recipient_title":19,"reference_number":19,"action_taken_date":308,"medical_device_id":19,"response_letter_date":19},2287,[292,293,294,295,296,13,13,13],"\u003Ctime datetime=\"2022-12-20T14:20:00Z\">12\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-27T04:00:00Z\">07\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsagent-pharmaceuticals-inc-636636-07272022\">Sagent Pharmaceuticals, Inc.\u003C\u002Fa>","Division Pharmaceutical Quality Operations I","CGMP\u002FDrugs\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Delivery Confirmation\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Peter A. Kaemmerer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sagent Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n                      \u003Cdd>SterRx, LLC\u003C\u002Fdd>\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1901 N. Roselle Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Suite 450\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Schaumburg\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60195\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Dr. Kaemmerer:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Ca id=\"footnoteref1_7e09l7s\" href=\"#footnote1_7e09l7s\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa> on May 29, 2015, and reregistered most recently on November 29, 2021. &nbsp;From September 21, 2021 to November 4, 2021, FDA investigators inspected your facility that was acquired by Sagent Pharmaceuticals, Inc., SterRx, LLC, located at 141 Idaho Avenue, Plattsburgh, NY 12903. During the inspection, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk. &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on November 4, 2021, and an amended Form FDA 483 on December 1, 2021. FDA acknowledges receipt of your facility’s responses, including correspondence dated November 23, 2021, January 31, 2022, March 31, 2022, and June 30, 2022. FDA also acknowledges that your firm voluntarily ceased “production and distribution of all aseptically processed products” as of October 5, 2021. In addition, we acknowledge that on November 12, 2021, your firm initiated a voluntary recall of approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of certain drug products intended to be sterile that were within expiry due to a lack of sterility assurance. Furthermore, FDA acknowledges your firm’s February 4, 2022 \"45-day Notification of Intent to Resume Distribution\" of sterile products on or after \u003Cstrong>(b)(4)\u003C\u002Fstrong> and your firm’s commitment to destroy \u003Cstrong>(b)(4)\u003C\u002Fstrong> in-process lots pursuant to a teleconference held on March 21, 2022. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Ca id=\"footnoteref2_e7a6d2f\" href=\"#footnote2_e7a6d2f\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. &nbsp;Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:&nbsp;\u003C\u002Fp>\n\n\u003Cp>1. Your facility is designed and operated in a way that first air is either not provided or blocked within ISO 5 areas where critical in-process operations are performed. &nbsp;For example:\u003Cbr>\na. Lack of first pass air over unwrapped, open IV bags prior to filling.\u003Cbr>\nb. Blocked first pass air for exposed sterile closures (ports and syringe plungers) during introduction and conveyance on IV bag filling lines.\u003C\u002Fp>\n\n\u003Cp>2. Your smoke studies demonstrated that the air in an ISO 5 classified zone was turbulent and non-laminar near areas where IV bag filling and sealing are performed.&nbsp;\u003C\u002Fp>\n\n\u003Cp>3. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>4. Your firm does not maintain the sterility of inter seals and outer closures for IV bags during production. \u003Cstrong>(b)(4)\u003C\u002Fstrong> IV bags and caps with ports are exposed to worse than ISO 5 quality air prior to and during assembly\u002Fcapping.&nbsp;\u003C\u002Fp>\n\n\u003Cp>5. The ISO-classified areas had visibly dirty equipment and difficult to clean surfaces. Specifically, chipped and missing paint, apparent rust, adhesive tape, and a build-up of residues were observed on and around \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment in an area where parisons are cut and conveyed to the point of aseptic filling.\u003C\u002Fp>\n\n\u003Cp>6. Sterilized equipment and utensils wrapped \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were stored in your “transition area,” an unclassified area, without an established hold time to ensure that these items remain sterile.\u003C\u002Fp>\n\n\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish an adequate air supply \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to ensure container closure systems provide protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product (21 CFR 211.94(b)).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to ensure that substances required for equipment operations, such as lubricants and coolants, do not come in contact with components, drug product containers, closures, in-process materials, or drug products so as to alter the safety, identity, strength, quality or purity of the drug product beyond the official or other established requirements (211.65(b)).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\n\n\u003Cp>7. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. FDA acknowledges that your firm voluntarily ceased “production and distribution of all aseptically processed products” as of October 5, 2021, and that your firm intended to resume distribution of sterile products on or after \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We also acknowledge that on November 12, 2021, your firm initiated a voluntary recall of certain lots of drug products intended to be sterile that were within expiry due to a lack of sterility assurance. In addition, we acknowledge that your firm voluntarily destroyed \u003Cstrong>(b)(4)\u003C\u002Fstrong> in-process lots in March 2022 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in-process lot on May 2, 2022. Furthermore, FDA acknowledges your “intent to continue [the voluntary destruction] process with the remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots within inventory…”\u003C\u002Fp>\n\n\u003Cp>We are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation. &nbsp;For example:\u003C\u002Fp>\n\n\u003Cp>1. In response to Observation 1 of the Form FDA 483, you stated in part: new smoke studies will be performed; environmental monitoring for particles will be revised; \u003Cstrong>(b)(4)\u003C\u002Fstrong> machinery and surrounding barriers will be assessed; integrity testing (leak check test) will be performed, equipment that remains in use will be relocated to ensure first pass air is not blocked; and employee training will be provided to include operator prevention of obstructing first pass air. However, you did not provide:\u003C\u002Fp>\n\n\u003Cp>a. CMTs 2021-424, 2021-426, 2021-427, 2021-428, 2021-429, 2021-430, and 2021-431 referenced in your response pertaining to \u003Cstrong>(b)(4)\u003C\u002Fstrong> smoke studies, changes to particle monitoring, equipment and barrier assessment, leak check testing, and operator training.\u003Cbr>\nb. Change controls 2021-109 and 2021-110 referenced in your response pertaining to decommissioning of filling lines, installation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle monitoring equipment, and environmental monitoring revisions.\u003C\u002Fp>\n\n\u003Cp>2. In response to Observation 2 of the Form FDA 483, you provided a written risk assessment for capping of \u003Cstrong>(b)(4)\u003C\u002Fstrong> IV bags and a study evaluating the sterility of caps. However, you did not provide any supporting documentation, such as air certification reports, to demonstrate that the caps and bags are not exposed to worse than ISO 5 quality air during loading, conveying, and capping.&nbsp;\u003C\u002Fp>\n\n\u003Cp>3. In response to Observation 3 of the Form FDA 483, you stated in part: limits for the ISO 5 zones will be changed to \u003Cstrong>(b)(4)\u003C\u002Fstrong>; environmental monitoring limits will be standardized \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and the entire environmental monitoring program will be evaluated. &nbsp;Additionally, your response stated \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide:\u003C\u002Fp>\n\n\u003Cp>a. CMTs 2021-435 and 2021-436 referenced in your response pertaining to your environmental monitoring evaluation, revised procedures for ISO 5 zones, and changes to particle monitoring.\u003Cbr>\nb. Completed document change controls DCC-002749 and DCC-003733 referenced in your response pertaining to revised viable action limits.\u003C\u002Fp>\n\n\u003Cp>4. In response to Observation 4 of the Form FDA 483, you stated in part: the bag filling line would be decommissioned and a new corporate policy, PQL-QA-0025 will be implemented to ensure equipment is adequate for GMP processes. However, you did not provide a copy of PQL-QA-0025 or CMT 2021-444 referenced in your response for policy implementation and employee training.\u003C\u002Fp>\n\n\u003Cp>5. In response to Observation 5 of the Form FDA 483, you stated in part: the bag filling line would be decommissioned; an assessment would be performed for all product contact lubricants; and SOP-VAL-0103, Equipment\u002FUtility and Software Validation\u002FQualification, would be revised to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide a copy of the revised SOP-VAL-0103 or CMTs 2021-438 and 2021-439 referenced in your response for SOP revisions and employee training.\u003C\u002Fp>\n\n\u003Cp>6. In response to Observation 6 of the Form FDA 483, you stated in part: the site will transition to compliance software for non-conformances and CAPAs; enhanced training for aseptic techniques and investigations will be developed; and SOP-QA-0157, Manufacturing Investigation Procedure, will be revised. However, you did not provide:\u003C\u002Fp>\n\n\u003Cp>a. CMT 2021-414 referenced in your response pertaining to your changes to investigations, CAPAs, and related training.\u003Cbr>\nb. A copy of SOP-QA-0157.\u003C\u002Fp>\n\n\u003Cp>7. In response to Observation 7 of the Form FDA 483, you stated in part: SOP-VAL-0103, Equipment\u002FUtility and Software Validation\u002FQualification, will be revised and employee training will be conducted. However, you did not provide a copy of SOP-VAL-0103 or CMT 2021-439 referenced in your response for SOP revisions and employee training.\u003C\u002Fp>\n\n\u003Cp>8. In response to Observation 8 of the Form FDA 483, you stated in part: revisions will be made to SOP-P-0435, Operation and Maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide a copy of SOP-P-0435 or CMT 2021-411 referenced in your response. Additionally, you did not provide supporting documentation referenced in the attachment identified as \u003Cstrong>(b)(4)\u003C\u002Fstrong> including but not limited to third-party studies for the lethality of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. \u003Cem>See\u003C\u002Fem> section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. &nbsp;Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [\u003Cem>See\u003C\u002Fem> 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. We also recommend a third-party consultant with relevant sterile drug manufacturing expertise to assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations, or you may inform us that you do not intend to resume production of drugs intended or expected to be sterile. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #636636 and include FEI: 3010840309. &nbsp;\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Nancy Espinal, Compliance Officer, at Nancy.Espinal@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F&nbsp;&nbsp; &nbsp;\u003Cbr>\nNerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I\u002FNew Jersey District\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc: SterRx, LLC&nbsp;\u003Cbr>\nAttention: Sarah J. McCoy,&nbsp;\u003Cbr>\nDirector, Plant Operations\u003Cbr>\n141 Idaho Avenue&nbsp;\u003Cbr>\nPlattsburgh, NY 12903\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_7e09l7s\">\u003Ca href=\"#footnoteref1_7e09l7s\">1\u003C\u002Fa>See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_e7a6d2f\">\u003Ca href=\"#footnoteref2_e7a6d2f\">2\u003C\u002Fa>We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Delivery Confirmation\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Peter A. Kaemmerer\n\nRecipient Title\n\nChief Executive Officer\n\nSagent Pharmaceuticals, Inc.\n\nSterRx, LLC\n\n1901 N. Roselle Road\n\nSuite 450\n\nSchaumburg, IL 60195\n\nUnited States\n\nIssuing Office:\n\nDivision Pharmaceutical Quality Operations I\n\nUnited States\n\nDear Dr. Kaemmerer:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on May 29, 2015, and reregistered most recently on November 29, 2021. From September 21, 2021 to November 4, 2021, FDA investigators inspected your facility that was acquired by Sagent Pharmaceuticals, Inc., SterRx, LLC, located at 141 Idaho Avenue, Plattsburgh, NY 12903. During the inspection, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your facility on November 4, 2021, and an amended Form FDA 483 on December 1, 2021. FDA acknowledges receipt of your facility’s responses, including correspondence dated November 23, 2021, January 31, 2022, March 31, 2022, and June 30, 2022. FDA also acknowledges that your firm voluntarily ceased “production and distribution of all aseptically processed products” as of October 5, 2021. In addition, we acknowledge that on November 12, 2021, your firm initiated a voluntary recall of approximately (b)(4) lots of certain drug products intended to be sterile that were within expiry due to a lack of sterility assurance. Furthermore, FDA acknowledges your firm’s February 4, 2022 \"45-day Notification of Intent to Resume Distribution\" of sterile products on or after (b)(4) and your firm’s commitment to destroy (b)(4) in-process lots pursuant to a teleconference held on March 21, 2022. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. Your facility is designed and operated in a way that first air is either not provided or blocked within ISO 5 areas where critical in-process operations are performed. For example:\n\na. Lack of first pass air over unwrapped, open IV bags prior to filling.\n\nb. Blocked first pass air for exposed sterile closures (ports and syringe plungers) during introduction and conveyance on IV bag filling lines.\n\n2. Your smoke studies demonstrated that the air in an ISO 5 classified zone was turbulent and non-laminar near areas where IV bag filling and sealing are performed.\n\n3. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\n\n4. Your firm does not maintain the sterility of inter seals and outer closures for IV bags during production. (b)(4) IV bags and caps with ports are exposed to worse than ISO 5 quality air prior to and during assembly\u002Fcapping.\n\n5. The ISO-classified areas had visibly dirty equipment and difficult to clean surfaces. Specifically, chipped and missing paint, apparent rust, adhesive tape, and a build-up of residues were observed on and around (b)(4) equipment in an area where parisons are cut and conveyed to the point of aseptic filling.\n\n6. Sterilized equipment and utensils wrapped (b)(4) and (b)(4) were stored in your “transition area,” an unclassified area, without an established hold time to ensure that these items remain sterile.\n\nFDA investigators also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n\n1. Your firm failed to establish an adequate air supply (b)(4) particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\n\n2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n3. Your firm failed to ensure container closure systems provide protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product (21 CFR 211.94(b)).\n\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\n\n5. Your firm failed to ensure that substances required for equipment operations, such as lubricants and coolants, do not come in contact with components, drug product containers, closures, in-process materials, or drug products so as to alter the safety, identity, strength, quality or purity of the drug product beyond the official or other established requirements (211.65(b)).\n\n6. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\n7. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\n8. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nD. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483. FDA acknowledges that your firm voluntarily ceased “production and distribution of all aseptically processed products” as of October 5, 2021, and that your firm intended to resume distribution of sterile products on or after (b)(4). We also acknowledge that on November 12, 2021, your firm initiated a voluntary recall of certain lots of drug products intended to be sterile that were within expiry due to a lack of sterility assurance. In addition, we acknowledge that your firm voluntarily destroyed (b)(4) in-process lots in March 2022 and (b)(4) in-process lot on May 2, 2022. Furthermore, FDA acknowledges your “intent to continue [the voluntary destruction] process with the remaining (b)(4) lots within inventory…”\n\nWe are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation. For example:\n\n1. In response to Observation 1 of the Form FDA 483, you stated in part: new smoke studies will be performed; environmental monitoring for particles will be revised; (b)(4) machinery and surrounding barriers will be assessed; integrity testing (leak check test) will be performed, equipment that remains in use will be relocated to ensure first pass air is not blocked; and employee training will be provided to include operator prevention of obstructing first pass air. However, you did not provide:\n\na. CMTs 2021-424, 2021-426, 2021-427, 2021-428, 2021-429, 2021-430, and 2021-431 referenced in your response pertaining to (b)(4) smoke studies, changes to particle monitoring, equipment and barrier assessment, leak check testing, and operator training.\n\nb. Change controls 2021-109 and 2021-110 referenced in your response pertaining to decommissioning of filling lines, installation of (b)(4) particle monitoring equipment, and environmental monitoring revisions.\n\n2. In response to Observation 2 of the Form FDA 483, you provided a written risk assessment for capping of (b)(4) IV bags and a study evaluating the sterility of caps. However, you did not provide any supporting documentation, such as air certification reports, to demonstrate that the caps and bags are not exposed to worse than ISO 5 quality air during loading, conveying, and capping.\n\n3. In response to Observation 3 of the Form FDA 483, you stated in part: limits for the ISO 5 zones will be changed to (b)(4); environmental monitoring limits will be standardized (b)(4); and the entire environmental monitoring program will be evaluated. Additionally, your response stated (b)(4) and (b)(4). However, you did not provide:\n\na. CMTs 2021-435 and 2021-436 referenced in your response pertaining to your environmental monitoring evaluation, revised procedures for ISO 5 zones, and changes to particle monitoring.\n\nb. Completed document change controls DCC-002749 and DCC-003733 referenced in your response pertaining to revised viable action limits.\n\n4. In response to Observation 4 of the Form FDA 483, you stated in part: the bag filling line would be decommissioned and a new corporate policy, PQL-QA-0025 will be implemented to ensure equipment is adequate for GMP processes. However, you did not provide a copy of PQL-QA-0025 or CMT 2021-444 referenced in your response for policy implementation and employee training.\n\n5. In response to Observation 5 of the Form FDA 483, you stated in part: the bag filling line would be decommissioned; an assessment would be performed for all product contact lubricants; and SOP-VAL-0103, Equipment\u002FUtility and Software Validation\u002FQualification, would be revised to include (b)(4). However, you did not provide a copy of the revised SOP-VAL-0103 or CMTs 2021-438 and 2021-439 referenced in your response for SOP revisions and employee training.\n\n6. In response to Observation 6 of the Form FDA 483, you stated in part: the site will transition to compliance software for non-conformances and CAPAs; enhanced training for aseptic techniques and investigations will be developed; and SOP-QA-0157, Manufacturing Investigation Procedure, will be revised. However, you did not provide:\n\na. CMT 2021-414 referenced in your response pertaining to your changes to investigations, CAPAs, and related training.\n\nb. A copy of SOP-QA-0157.\n\n7. In response to Observation 7 of the Form FDA 483, you stated in part: SOP-VAL-0103, Equipment\u002FUtility and Software Validation\u002FQualification, will be revised and employee training will be conducted. However, you did not provide a copy of SOP-VAL-0103 or CMT 2021-439 referenced in your response for SOP revisions and employee training.\n\n8. In response to Observation 8 of the Form FDA 483, you stated in part: revisions will be made to SOP-P-0435, Operation and Maintenance of the (b)(4). However, you did not provide a copy of SOP-P-0435 or CMT 2021-411 referenced in your response. Additionally, you did not provide supporting documentation referenced in the attachment identified as (b)(4) including but not limited to third-party studies for the lethality of the (b)(4).\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. We also recommend a third-party consultant with relevant sterile drug manufacturing expertise to assist you in conducting this comprehensive evaluation.\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations, or you may inform us that you do not intend to resume production of drugs intended or expected to be sterile. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #636636 and include FEI: 3010840309.\n\nIf you have questions regarding the contents of this letter, please contact Nancy Espinal, Compliance Officer, at Nancy.Espinal@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations Division I\u002FNew Jersey District\n\nCc: SterRx, LLC\n\nAttention: Sarah J. McCoy,\n\nDirector, Plant Operations\n\n141 Idaho Avenue\n\nPlattsburgh, NY 12903\n\n1See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.","Sagent Pharmaceuticals, Inc.","sagent-pharmaceuticals-inc-636636-07272022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsagent-pharmaceuticals-inc-636636-07272022","2026-10-26T08:09:52.81159+00:00","2022-12-20","636636","Dr. Peter A. Kaemmerer","2026-08-20T01:22:07.468+00:00","Via Email Delivery Confirmation","2022-07-27",{"id":310,"raw":311,"subject":315,"body_html":317,"body_text":318,"firm_name":319,"letter_id":320,"created_at":43,"fei_number":19,"letter_url":321,"updated_at":322,"action_type":22,"case_status":86,"posted_date":323,"marcs_cms_no":324,"product_type":26,"closeout_date":325,"issuing_office":11,"recipient_name":326,"body_fetched_at":327,"delivery_method":328,"recipient_title":19,"reference_number":19,"action_taken_date":329,"medical_device_id":19,"response_letter_date":19},1247,[312,313,314,11,315,13,316,13],"\u003Ctime datetime=\"2024-09-24T13:20:00Z\">09\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-20T04:00:00Z\">09\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fazurity-pharmaceuticals-inc-656489-09202024\">Azurity Pharmaceuticals, Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fazurity-pharmaceuticals-inc-656489-02242026\">\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Blackburn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Azurity Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8 Cabot Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Woburn\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:richard.blackburn@azurity.com\"> richard.blackburn@azurity.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 20, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 656489\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Blackburn:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Azurity Pharmaceuticals, Inc. FEI 3003395329, at 841 Woburn Street, Wilmington, MA, from February 2, 2023, to March 2, 2023. Based on our inspection and subsequent review of your firm’s website, we found violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act).\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures various prescription drug products referred to as FIRST Unit-of-Use Kits, including FIRST® Lansoprazole, FIRST® Pantoprazole, FIRST® Metronidazole, and FIRST® Mouthwash BLM. As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>This warning letter also summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP regulations, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FIRST® Lansoprazole, FIRST® Pantoprazole, FIRST® Metronidazole, and FIRST® Mouthwash BLM are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>The labeling published on your website http:\u002F\u002Fwww.azurity.com for the above-listed FIRST Unit-of-Use Kits provides evidence of the intended uses\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of these products as drugs. Examples of these claims include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>FIRST® Lansoprazole and FIRST® Pantoprazole Kits\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The package inserts for FIRST® Lansoprazole and FIRST® Pantoprazole refer to these products as proton pump inhibitors. According to medical references, the mechanism of action for proton pump inhibitors is to decrease acid secretion in gastric parietal cells through inhibition of the (H+, K+)-ATPase enzyme system, blocking the final step in gastric acid production, thus reducing gastric acidity.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>FIRST® Metronidazole Kit\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The package insert for FIRST® Metronidazole states that this product is a prescription drug for oral use that meets USP &lt;51&gt; Antimicrobial Effectiveness Testing, and it directs healthcare professionals to “See PRECAUTIONS and usage described in the [FDA] approved labeling for metronidazole containing products for additional information.” The labeling for FDA-approved metronidazole products includes, but are not limited to, indications for use such as the treatment of symptomatic and asymptomatic trichomoniasis amebiasis, anaerobic bacterial infections and amebiasis.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>FIRST® Mouthwash BLM\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The package insert for FIRST® Mouthwash BLM states that this product is an oral prescription product comprised of diphenhydramine powder USP and lidocaine powder USP and provides a suspension “comparable to the active ingredients contained in 1:1:1 Magic Mouthwash.” According to medical references, Magic Mouthwash is used for palliation of generalized oral mucositis.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>FIRST® Lansoprazole, FIRST® Pantoprazole, FIRST® Metronidazole, and FIRST® Mouthwash BLM are new drugs as defined by section 201(p)(1) of the FD&amp;C Act, 21 U.S.C. 321(p)(1), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003Cbr>\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s investigations into unexplained discrepancies were inadequate. Your quality unit (QU) failed to thoroughly investigate all finished product batches and components associated with unexplained discrepancies. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your QU did not investigate numerous complaints involving crystallization of two \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL batches. Your firm received approximately 86 complaints of crystallization within the first two months of distribution from early December 2022 to February 2023. Your QU did not evaluate this adverse trend until our inspection was initiated. A Field Alert Report was submitted during the inspection and the two batches were recalled before the conclusion of our inspection.\u003C\u002Fli>\n\t\u003Cli>Upon receiving a consumer complaint regarding the potential presence of lead in two batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL, \u003Cstrong>(b)(4)\u003C\u002Fstrong>-ounce \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your subsequent investigation focused solely on one of the two batches. Notably, a third batch, utilizing the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> component as one of the complaint batches, was not included as part of your investigation. Additionally, your firm stated during our inspection that no testing was conducted to investigate whether lead was present.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPAs), and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the investigations were not adequate. You commit to implement a more robust process for evaluating complaints and expediting actions.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate as you fail to provide supporting documentation of your commitments. Additionally, you fail to provide a retrospective review of complaints and manufacturing investigations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>An independent assessment of your CAPA program. Based on this assessment, provide a plan that evaluates and remediates the program, including but not limited to ensuring robust:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Triggers for fulfilling both corrective and preventive objectives\u003Cbr>\n&nbsp; &nbsp; o Root cause analysis\u003Cbr>\n&nbsp; &nbsp; o CAPA effectiveness\u003Cbr>\n&nbsp; &nbsp; o Analysis of investigations trends on a routine basis\u003Cbr>\n&nbsp; &nbsp; o CAPA program improvements, whenever needed\u003Cbr>\n&nbsp; &nbsp; o Implementation of final QU decisions\u003Cbr>\n&nbsp; &nbsp; o Support of the program by executive management\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent, retrospective review of all complaints and associated investigations for your drug products. Provide the consultant’s recommendations based on a review that includes but is not limited to an evaluation of:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All investigations related to complaints of drug products currently within expiry, the level of criticality for each defect, all potentially impacted batches (i.e., distributed, undistributed and rejected batches; approved and pending application drug products), and any associated issues identified during both product\u002Fprocess development and via commercial batch experience.\u003Cbr>\n&nbsp; &nbsp; o The sufficiency (i.e., scope, trend analysis, root cause, CAPA) of the investigations, whether the complaint sample was obtained, all results of analysis of complaint and reserve samples.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent, comprehensive review of your company’s complaint handling program that identifies deficiencies and a corresponding CAPA.\u003C\u002Fli>\n\t\u003Cli>A management strategy including the interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, supplier changes, adding batches to your stability program to assure stability, drug application actions, and steps to enhance vigilance in response to serious quality complaints.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately assess stability test results for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL, \u003Cstrong>(b)(4)\u003C\u002Fstrong>-ounce \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine appropriate storage conditions and expiration dates. For example, stability testing of process performance qualification batches and annual stability batches of this drug product resulted in numerous OOS individual unknown impurity results during related substances testing. Your firm’s investigations documented that this unknown impurity had been seen in stability studies since 2019 and had increased over time for all batches. At the time of our inspection, you had not identified a root cause nor steps taken to mitigate the unknown impurity.\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm decided to cease production of this product until a thorough investigation into the impurity could be conducted.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge your inadequate evaluation of impurities during process validation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL, \u003Cstrong>(b)(4)\u003C\u002Fstrong>-ounce \u003Cstrong>(b)(4)\u003C\u002Fstrong> and commit to reassess the stability method.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate as you fail to provide documentation supporting your commitments. Additionally, you fail to provide a retrospective review of stability results of your other drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective risk assessment of the stability of all batches of your drug product on the U.S. market within expiry which should include retain sample testing using validated stability indicating test methods. The assessment and testing should include assay, impurity, and degradants. If the test results or risk assessments indicate substandard quality of your drug products, take rapid corrective actions, such as customer notifications and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Test Results Out-of-Specification\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of violations identified above and for preventing their recurrence and the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003Cbr>\n\u003Cbr>\nYou should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal actions without further notice, including, without limitation, seizure and injunction. Other federal agencies may take this warning letter into account when considering the award of contracts. You should discontinue marketing all of the unapproved prescription drugs manufactured at your facility immediately. Additionally, FDA may withhold approval of requests for export certificates or approval of pending new drug applications listing your facility as a manufacturer until the above violations are corrected. A reinspection may be necessary to verify corrective actions have been completed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that you contact CDER’s Drug Shortages Staff immediately at\u003Cbr>\ndrugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under section 506c(a) of the FD&amp;C Act, 21 U.S.C. 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) working days of receiving this letter of the steps you have taken to bring your firm into compliance with the law. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If the corrective action cannot be completed within fifteen (15) working days of receiving this letter, state the reason for the delay and the timeframe within which the corrections will be completed. Please include copies of any documentation demonstrating that corrections have been made. If you no longer manufacture or market the above-mentioned products, or any other unapproved new drug products that you have listed in the FDA electronic Drug Registration and Listing System (eDRLS), your response should indicate this, including the reasons that, and the date on which, you ceased production. Also, please indicate your progress in updating the drug listing eDRLS files in accordance with 21 CFR 207.30(a)(2). If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “CMS 656489” in the subject line of the email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 201.128.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Proton Pump Inhibitors. Drug Facts and Comparisons [online]. Available from Wolters Kluwer Health, Inc. Accessed April 25, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See FDA-approved labeling for Metronidazole: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F018845s014,018930s013lbl.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Magic Mouthwash Oral. Drug Facts and Comparisons [online]. Available from Wolters Kluwer Health, Inc. Accessed April 25, 2024.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRichard Blackburn\n\nRecipient Title\n\nChief Executive Officer\n\nAzurity Pharmaceuticals, Inc.\n\n8 Cabot Road\n\nWoburn, MA 01801\n\nUnited States\n\nrichard.blackburn@azurity.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nSeptember 20, 2024\n\nRE: 656489\n\nDear Mr. Blackburn:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Azurity Pharmaceuticals, Inc. FEI 3003395329, at 841 Woburn Street, Wilmington, MA, from February 2, 2023, to March 2, 2023. Based on our inspection and subsequent review of your firm’s website, we found violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act).\n\nYour firm manufactures various prescription drug products referred to as FIRST Unit-of-Use Kits, including FIRST® Lansoprazole, FIRST® Pantoprazole, FIRST® Metronidazole, and FIRST® Mouthwash BLM. As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nThis warning letter also summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP regulations, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nUnapproved New Drug Violations\n\nFIRST® Lansoprazole, FIRST® Pantoprazole, FIRST® Metronidazole, and FIRST® Mouthwash BLM are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nThe labeling published on your website http:\u002F\u002Fwww.azurity.com for the above-listed FIRST Unit-of-Use Kits provides evidence of the intended uses1 of these products as drugs. Examples of these claims include, but may not be limited to, the following:\n\nFIRST® Lansoprazole and FIRST® Pantoprazole Kits\n\nThe package inserts for FIRST® Lansoprazole and FIRST® Pantoprazole refer to these products as proton pump inhibitors. According to medical references, the mechanism of action for proton pump inhibitors is to decrease acid secretion in gastric parietal cells through inhibition of the (H+, K+)-ATPase enzyme system, blocking the final step in gastric acid production, thus reducing gastric acidity.2\n\nFIRST® Metronidazole Kit\n\nThe package insert for FIRST® Metronidazole states that this product is a prescription drug for oral use that meets USP \u003C51> Antimicrobial Effectiveness Testing, and it directs healthcare professionals to “See PRECAUTIONS and usage described in the [FDA] approved labeling for metronidazole containing products for additional information.” The labeling for FDA-approved metronidazole products includes, but are not limited to, indications for use such as the treatment of symptomatic and asymptomatic trichomoniasis amebiasis, anaerobic bacterial infections and amebiasis.3\n\nFIRST® Mouthwash BLM\n\nThe package insert for FIRST® Mouthwash BLM states that this product is an oral prescription product comprised of diphenhydramine powder USP and lidocaine powder USP and provides a suspension “comparable to the active ingredients contained in 1:1:1 Magic Mouthwash.” According to medical references, Magic Mouthwash is used for palliation of generalized oral mucositis.4\n\nFIRST® Lansoprazole, FIRST® Pantoprazole, FIRST® Metronidazole, and FIRST® Mouthwash BLM are new drugs as defined by section 201(p)(1) of the FD&C Act, 21 U.S.C. 321(p)(1), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved applications pursuant to section 505 of the FD&C Act are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nCGMP Violations\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm’s investigations into unexplained discrepancies were inadequate. Your quality unit (QU) failed to thoroughly investigate all finished product batches and components associated with unexplained discrepancies. For example:\n\nYour QU did not investigate numerous complaints involving crystallization of two (b)(4) Injection (b)(4) mg\u002FmL batches. Your firm received approximately 86 complaints of crystallization within the first two months of distribution from early December 2022 to February 2023. Your QU did not evaluate this adverse trend until our inspection was initiated. A Field Alert Report was submitted during the inspection and the two batches were recalled before the conclusion of our inspection.\n\nUpon receiving a consumer complaint regarding the potential presence of lead in two batches of (b)(4) mg\u002FmL, (b)(4)-ounce (b)(4), your subsequent investigation focused solely on one of the two batches. Notably, a third batch, utilizing the same (b)(4) component as one of the complaint batches, was not included as part of your investigation. Additionally, your firm stated during our inspection that no testing was conducted to investigate whether lead was present.\n\nInadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPAs), and recurring problems that compromise the ability to manufacture safe and effective drug products.\n\nIn your response, you acknowledge the investigations were not adequate. You commit to implement a more robust process for evaluating complaints and expediting actions.\n\nYour response is inadequate as you fail to provide supporting documentation of your commitments. Additionally, you fail to provide a retrospective review of complaints and manufacturing investigations.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nAn independent assessment of your CAPA program. Based on this assessment, provide a plan that evaluates and remediates the program, including but not limited to ensuring robust:\n\no Triggers for fulfilling both corrective and preventive objectives\n\no Root cause analysis\n\no CAPA effectiveness\n\no Analysis of investigations trends on a routine basis\n\no CAPA program improvements, whenever needed\n\no Implementation of final QU decisions\n\no Support of the program by executive management\n\nAn independent, retrospective review of all complaints and associated investigations for your drug products. Provide the consultant’s recommendations based on a review that includes but is not limited to an evaluation of:\n\no All investigations related to complaints of drug products currently within expiry, the level of criticality for each defect, all potentially impacted batches (i.e., distributed, undistributed and rejected batches; approved and pending application drug products), and any associated issues identified during both product\u002Fprocess development and via commercial batch experience.\n\no The sufficiency (i.e., scope, trend analysis, root cause, CAPA) of the investigations, whether the complaint sample was obtained, all results of analysis of complaint and reserve samples.\n\nAn independent, comprehensive review of your company’s complaint handling program that identifies deficiencies and a corresponding CAPA.\n\nA management strategy including the interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, supplier changes, adding batches to your stability program to assure stability, drug application actions, and steps to enhance vigilance in response to serious quality complaints.\n\n2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYou did not adequately assess stability test results for your (b)(4) mg\u002FmL, (b)(4)-ounce (b)(4) to determine appropriate storage conditions and expiration dates. For example, stability testing of process performance qualification batches and annual stability batches of this drug product resulted in numerous OOS individual unknown impurity results during related substances testing. Your firm’s investigations documented that this unknown impurity had been seen in stability studies since 2019 and had increased over time for all batches. At the time of our inspection, you had not identified a root cause nor steps taken to mitigate the unknown impurity.\n\nDuring the inspection, your firm decided to cease production of this product until a thorough investigation into the impurity could be conducted.\n\nIn your response, you acknowledge your inadequate evaluation of impurities during process validation of (b)(4) mg\u002FmL, (b)(4)-ounce (b)(4) and commit to reassess the stability method.\n\nYour response is inadequate as you fail to provide documentation supporting your commitments. Additionally, you fail to provide a retrospective review of stability results of your other drug products.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nA retrospective risk assessment of the stability of all batches of your drug product on the U.S. market within expiry which should include retain sample testing using validated stability indicating test methods. The assessment and testing should include assay, impurity, and degradants. If the test results or risk assessments indicate substandard quality of your drug products, take rapid corrective actions, such as customer notifications and product recalls.\n\nTest Results Out-of-Specification\n\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of violations identified above and for preventing their recurrence and the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal actions without further notice, including, without limitation, seizure and injunction. Other federal agencies may take this warning letter into account when considering the award of contracts. You should discontinue marketing all of the unapproved prescription drugs manufactured at your facility immediately. Additionally, FDA may withhold approval of requests for export certificates or approval of pending new drug applications listing your facility as a manufacturer until the above violations are corrected. A reinspection may be necessary to verify corrective actions have been completed.\n\nFDA requests that you contact CDER’s Drug Shortages Staff immediately at\n\ndrugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under section 506c(a) of the FD&C Act, 21 U.S.C. 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\n\nPlease notify this office in writing within fifteen (15) working days of receiving this letter of the steps you have taken to bring your firm into compliance with the law. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If the corrective action cannot be completed within fifteen (15) working days of receiving this letter, state the reason for the delay and the timeframe within which the corrections will be completed. Please include copies of any documentation demonstrating that corrections have been made. If you no longer manufacture or market the above-mentioned products, or any other unapproved new drug products that you have listed in the FDA electronic Drug Registration and Listing System (eDRLS), your response should indicate this, including the reasons that, and the date on which, you ceased production. Also, please indicate your progress in updating the drug listing eDRLS files in accordance with 21 CFR 207.30(a)(2). If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “CMS 656489” in the subject line of the email.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n____________________\n\n1 See 21 CFR 201.128.\n\n2 Proton Pump Inhibitors. Drug Facts and Comparisons [online]. Available from Wolters Kluwer Health, Inc. Accessed April 25, 2024\n\n3 See FDA-approved labeling for Metronidazole: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F018845s014,018930s013lbl.pdf.\n\n4 Magic Mouthwash Oral. Drug Facts and Comparisons [online]. Available from Wolters Kluwer Health, Inc. Accessed April 25, 2024.","Azurity Pharmaceuticals, Inc.","azurity-pharmaceuticals-inc-656489-09202024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fazurity-pharmaceuticals-inc-656489-09202024","2026-10-26T08:07:59.979908+00:00","2024-09-24","656489","2026-03-03","Richard Blackburn","2026-08-19T23:32:46.773+00:00","Via Email","2024-09-20",{"id":331,"raw":332,"subject":337,"body_html":338,"body_text":339,"firm_name":340,"letter_id":341,"created_at":239,"fei_number":19,"letter_url":342,"updated_at":343,"action_type":22,"case_status":23,"posted_date":344,"marcs_cms_no":345,"product_type":346,"closeout_date":19,"issuing_office":336,"recipient_name":347,"body_fetched_at":348,"delivery_method":349,"recipient_title":19,"reference_number":19,"action_taken_date":350,"medical_device_id":19,"response_letter_date":19},3291,[333,334,335,336,337,13,13,13],"\u003Ctime datetime=\"2021-06-29T13:20:00Z\">06\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-17T04:00:00Z\">06\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faquavit-pharmaceuticals-inc-607150-06172021\">Aquavit Pharmaceuticals, Inc\u003C\u002Fa>","Office of Medical Device and Radiological Health Division 1 – East","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sobin Chang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aquavit Pharmaceuticals, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>145 W 57th Street, 15th Floor\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10019\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sobin.chang@aquavitpharma.com\"> sobin.chang@aquavitpharma.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Division 1 – East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 607150\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n06\u002F17\u002F2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Chang:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> and the Advanced Skin Application Platform (A.S.A.P!) Micro Infusion System in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>According to your firm’s websites, https:\u002F\u002Faquagoldfinetouch.com and https:\u002F\u002Fskinworkout.com, the AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> is a microchannel microinjector available for physician and clinical practitioner use that delivers “specially selected therapeutics” into the dermis to address a wide range of skin concerns, and the A.S.A.P! Micro Infusion System is a microchannel applicator designed for at-home use to deliver microdroplets of treatment solutions directly into the skin. Based on our review of your firm’s websites, FDA has determined that the AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> and A.S.A.P! Micro Infusion System are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify FDA of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>A review of your firm’s websites, https:\u002F\u002Faquagoldfinetouch.com and https:\u002F\u002Fskinworkout.com (last accessed March 22, 2021), revealed the following claims:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AQUAGOLD® fine touch:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• “When you want to look your best, the professionals turn to AQUAGOLD® fine touch™, the world’s foremost revolutionary microinjector device. Our patented applicator uses microchannel technology to precisely administer your personalized treatments. AQUAGOLD® fine touch™ delivers low dose microinjections with 24K pure gold-plated surgical-grade (SUS 316L) stainless steel microchannels, each thinner than a human hair. AQUAGOLD® fine touch™ is the perfect solution for painless treatment of sensitive areas including peri-oral (around the mouth), peri-orbital (around the eyes), forehead, neck, back of hands, and décolletage. AQUAGOLD® fine touch™ is available only for physicians and clinical practitioners.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• \u003Cstrong>“What are the advantages of AQUAGOLD® fine touch™?\u003C\u002Fstrong>The AQUAGOLD® fine touch™ has the proven ability to deliver micro-doses of a drug or biologic just under the dermis at a consistent depth and pain-free. This is a major advantage over the conventional syringe approach.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• \u003Cstrong>“How is AQUAGOLD® fine touch™ different from microneedle devices?\u003C\u002Fstrong> The intended use of AQUAGOLD® fine touch™ is to microdose and microinject, whereas the intended use of other common microneedle devices is to puncture or wound the skin.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• \u003Cstrong>“MORE THAN JUST NEEDLING[:]\u003C\u002Fstrong> The microchannel screw-like design safely and consistently delivers therapeutics at a consistent depth with minimal damage to the dermis, targeting all layers of the skin while stimulating collagen and elastin production.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• \u003Cstrong>“UNIQUE 2-IN-1 TREATMENt[:]\u003C\u002Fstrong> Targeted treatments that include a wound-healing response, and simultaneously stimulate collagen and elastin production.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• \u003Cstrong>“PERSONALIZED MEDICINE[:]\u003C\u002Fstrong> Specially selected therapeutics for a treatment customized just for you. Address a wide range of skin concerns from acne scars and fine lines to hyperhydrosis and alopecia.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on these claims, the AQUAGOLD® fine touch is a device because it is intended to deliver microdoses and microinjections of products into the skin for various medical purposes (e.g., stimulating collagen and elastin production, promoting wound healing, treating acne scars, hyperhidrosis, and alopecia).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The risks of AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> use may include, but are not limited to: severe skin reactions and inflammation; allergic reactions; bleeding; infection from zoonotic or other human materials; adverse reactions relating to contamination with bacteria or viruses, exposure to heavy metals and toxins or cross-contamination; scarring; keloid formation; undesired skin pigment changes; granuloma formation; nerve and blood vessel damage; and overdosage. Many of these risks may be severe and permanent.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A.S.A.P! Micro Infusion System:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• “A.S.A.P! is designed to work with our SKINWORKOUT program of specially formulated pharmaceutical grade pure sterilized hyaluronic acids and proprietary compounds to support your skin health . . . The program features two specially formulated skin health serums, U.R. (Ultimate Radiance and T.T. (Targeted Toning). U.R. is a high-performance sterilized serum with the purest hyaluronic acid, PDRN, and growth factors. It’s a rejuvenating blend that treats signs of aging and helps to regenerate damaged skin. T.T. is an intensely hydrating sterilized serum with the purest hyaluronic acid, Glutathione, Niacinamide, and Tranexamic Acid. This gentle yet effective serum helps even out skin tones, brightens skin, and reduces inflammation. Glutathione prevents dark spots and brightens the skin. Niacinamide helps with skin brightening and the enhancement of skin tone to even out your complexion. Tranexamic Acid is a nice treatment for freckling.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• “For consumers, we introduced the SKINWORKOUT®. This system includes the first in the US, sterilized pharmaceutical grade HA serums (U.R. and T.T.) for after-care and maintenance for any in-office treatments. The A.S.A.P.!™ Microinfusion system allows the optimal infusion of any valuable serums we use at home. A perfect match with U.R. and T.T.!”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>• “SKINWORKOUT® features our revolutionary micro infusion applicator, A.S.A.P.!™ (Advanced Skin Application Platform), designed to infuse specialized, pharmaceutical grade serums into the skin using our patented repeated motion called Microchannel Technology®. Unlike traditional skin care applications, microinfusion allows skin health serums to be infused directly into your skin rather than sitting on the surface.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on these claims, the A.S.A.P! Micro Infusion System is a device because it is intended to deliver micro-droplets of serums into the skin for various medical purposes (e.g., helping to regenerate damaged skin, reducing inflammation). The risks of A.S.A.P! Micro Infusion System use include, but are not limited to, all of the risks associated with AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> use (see above).\u003C\u002Fp>\n\n\u003Cp>In addition, the AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> and the A.S.A.P! Micro Infusion System are devices because they are intended to affect the structure or any function of the body. The AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> and A.S.A.P! Micro Infusion System include microchannels (needles) that are 0.6mm and 0.2mm in length, respectively. Thus, these penetrate well beyond the stratum corneum (which is typically 0.02-0.04mm thick\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>). Based on the design and technology of these products, the entire microchannel is inserted into the skin and there is no mechanism that would prevent the user from inserting the entire microchannel into the skin. Therefore, your devices result in needle penetration beyond the stratum corneum and into the living layers of the skin (epidermis and dermis), showing that they are “intended to affect the structure or any function of the body” under section 201(h) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Microneedling devices for aesthetic use are Class II devices regulated under 21 CFR 878.4430 and require premarket notification [510(k)]. At this time, no microneedling device has been cleared for over-the-counter (OTC) or home use. Additionally, devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biological products are not included in this classification and may need to be evaluated by the Center for Biologics Evaluation and Research (CBER) and\u002For the Center for Drug Evaluation and Research (CDER).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at: \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>We note that your firm is also marketing other products that are drugs, biological products and\u002For combination products, which are subject to additional\u002Fdifferent requirements than those discussed above. For example, you are marketing the SKINWORKOUT® U.R. (Ultimate Radiance) and the SKINWORKOUT® T.T. (Targeted Toning) as serums that are intended to be injected into the human body for various medical purposes. On your firm’s website (https:\u002F\u002Fskinworkout.com), you state that the SKINWORKOUT® U.R. (Ultimate Radiance) is a serum containing hyaluronic acid, “growth factors,” polydeoxyribonucleotide, and tri-peptides, among other things, and that it promotes the formation of collagen and elastin, stimulates cellular renewal, and helps regenerate damaged skin. You also state that the SKINWORKOUT® T.T. (Targeted Toning) is a serum containing hyaluronic acid, glutathione, and niacinamide, among other things, and that it activates a metabolic process to brighten the skin and reduces inflammation. You also are marketing the A.S.A.P! + Two Serums Skin Care Gift Set, which is a set that includes the Ultimate Radiance Serum, Targeted Toning Serum, A.S.A.P! Microinfusion System, and a cap.\u003Cbr>\n\u003Cbr>\nWe note that for combination products (see 21 CFR 3.2(e)), the regulations at 21 CFR Part 4 also apply. The appropriate marketing application for a combination product generally depends on which agency component (i.e., CBER, CDER or the Center for Devices and Radiological Health) has the lead responsibility for the premarket review and regulation of the combination product. Your firm may obtain formal or informal determinations regarding the assignment (the agency component with the lead regulatory responsibility), as well as the classification, of products by submitting RFDs or pre-RFDs, respectively, with the FDA’s Office of Combination Products (OCP). For further information about the RFD and pre-RFD processes, you may visit OCP’s website at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FCombinationProducts\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FCombinationProducts\u002Fdefault.htm\u003C\u002Fa> or contact OCP at 301-796-8930 or combination@fda.gov. You should also review the following guidances for additional information: How to Write a Request for Designation (RFD): Guidance for Industry (fda.gov) and How to Prepare a Pre-Request for Designation (Pre-RFD) (fda.gov).\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address the violations described in this letter. Failure to adequately address any violations may lead to regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Also, other federal agencies may take your compliance history into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that you have complied with the Act and FDA regulations, please provide your reasoning and any supporting information for our consideration as part of your response to FDA within fifteen business days.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact Compliance Officer, Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1 – East\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, M.D., M.B.A., F.A.C.S.\u003Cbr>\nDirector\u003Cbr>\nOHT4: Office of Surgical\u003Cbr>\nand Infection Control Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc: Aquavit Life Sciences, Inc.\u003Cbr>\n145 W 57th Street, Floor 15\u003Cbr>\nNew York, NY 10019\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA has had previous interactions with your firm regarding these products, including in correspondence related to: (1) It Has Come To Our Attention (IHCTOA) letters sent to your firm on May 10, 2016 and July 18, 2016, (2) a Request For Designation (RFD) your firm submitted to FDA on April 10, 2017, and (3) FDA’s inspection of your firm from October 23, 2019 to December 19, 2019.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As discussed further below, your firm is also marketing other products that are drugs, biological products, and\u002For combination products, which are subject to additional\u002Fdifferent requirements from those discussed in this letter. Please refer to page 4 of this letter for additional information on these issues.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The AQUAGOLD® \u003Cem>fine touch\u003C\u002Fem> has been listed with product code GAA (Needle, Aspiration And Injection, Disposable) under 21 CFR 878.4800. Based on the claims discussed further below, the device does not fall under that product code or regulation. We note that the A.S.A.P! Micro Infusion System has not been listed. Under section 502(o) of the Act, 21 U.S.C. § 352(o), a device that is not listed as required by section 510(j) is deemed to be misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> We note that FDA issued the \u003Cstrong>Regulatory Considerations for Microneedling Products - Guidance for Industry and Food and Drug Administration Staff (fda.gov)\u003C\u002Fstrong> (November 2020) to assist industry in understanding when a microneedling product is a device as defined in section 201(h) of the Act. The guidance discusses a firm’s claims and statements associated with a microneedling product that FDA believes would generally cause the product to meet the device definition (e.g., it treats scars, treats wrinkles and deep facial lines, treats acne, treats alopecia, stimulates collagen production, and promotes wound healing). The guidance also states that FDA may consider the design and technological characteristics\u002Ffeatures of a microneedling product in determining whether it is a device under the Act. As noted in the guidance, microneedling products that are combination products are outside the scope of the guidance.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Haftek M. (2017) Stratum Corneum Histopathology. In: Humbert P., Fanian F., Maibach H., Agache P. (eds) Agache's Measuring the Skin. Springer, Cham. https:\u002F\u002Fdoi.org\u002F10.1007\u002F978-3-319-32383-1_23.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSobin Chang\n\nRecipient Title\n\nChief Executive Officer\n\nAquavit Pharmaceuticals, Inc\n\n145 W 57th Street, 15th Floor\n\nNew York, NY 10019\n\nUnited States\n\nsobin.chang@aquavitpharma.com\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Division 1 – East\n\nUnited States\n\nWARNING LETTER\n\nCMS # 607150\n\n06\u002F17\u002F2021\n\nDear Ms. Chang:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the AQUAGOLD® fine touch and the Advanced Skin Application Platform (A.S.A.P!) Micro Infusion System in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).1 Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.2\n\nAccording to your firm’s websites, https:\u002F\u002Faquagoldfinetouch.com and https:\u002F\u002Fskinworkout.com, the AQUAGOLD® fine touch is a microchannel microinjector available for physician and clinical practitioner use that delivers “specially selected therapeutics” into the dermis to address a wide range of skin concerns, and the A.S.A.P! Micro Infusion System is a microchannel applicator designed for at-home use to deliver microdroplets of treatment solutions directly into the skin. Based on our review of your firm’s websites, FDA has determined that the AQUAGOLD® fine touch and A.S.A.P! Micro Infusion System are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify FDA of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).3\n\nA review of your firm’s websites, https:\u002F\u002Faquagoldfinetouch.com and https:\u002F\u002Fskinworkout.com (last accessed March 22, 2021), revealed the following claims:\n\nAQUAGOLD® fine touch:\n\n• “When you want to look your best, the professionals turn to AQUAGOLD® fine touch™, the world’s foremost revolutionary microinjector device. Our patented applicator uses microchannel technology to precisely administer your personalized treatments. AQUAGOLD® fine touch™ delivers low dose microinjections with 24K pure gold-plated surgical-grade (SUS 316L) stainless steel microchannels, each thinner than a human hair. AQUAGOLD® fine touch™ is the perfect solution for painless treatment of sensitive areas including peri-oral (around the mouth), peri-orbital (around the eyes), forehead, neck, back of hands, and décolletage. AQUAGOLD® fine touch™ is available only for physicians and clinical practitioners.”\n\n• “What are the advantages of AQUAGOLD® fine touch™?The AQUAGOLD® fine touch™ has the proven ability to deliver micro-doses of a drug or biologic just under the dermis at a consistent depth and pain-free. This is a major advantage over the conventional syringe approach.”\n\n• “How is AQUAGOLD® fine touch™ different from microneedle devices? The intended use of AQUAGOLD® fine touch™ is to microdose and microinject, whereas the intended use of other common microneedle devices is to puncture or wound the skin.”\n\n• “MORE THAN JUST NEEDLING[:] The microchannel screw-like design safely and consistently delivers therapeutics at a consistent depth with minimal damage to the dermis, targeting all layers of the skin while stimulating collagen and elastin production.”\n\n• “UNIQUE 2-IN-1 TREATMENt[:] Targeted treatments that include a wound-healing response, and simultaneously stimulate collagen and elastin production.”\n\n• “PERSONALIZED MEDICINE[:] Specially selected therapeutics for a treatment customized just for you. Address a wide range of skin concerns from acne scars and fine lines to hyperhydrosis and alopecia.”\n\nBased on these claims, the AQUAGOLD® fine touch is a device because it is intended to deliver microdoses and microinjections of products into the skin for various medical purposes (e.g., stimulating collagen and elastin production, promoting wound healing, treating acne scars, hyperhidrosis, and alopecia).4 The risks of AQUAGOLD® fine touch use may include, but are not limited to: severe skin reactions and inflammation; allergic reactions; bleeding; infection from zoonotic or other human materials; adverse reactions relating to contamination with bacteria or viruses, exposure to heavy metals and toxins or cross-contamination; scarring; keloid formation; undesired skin pigment changes; granuloma formation; nerve and blood vessel damage; and overdosage. Many of these risks may be severe and permanent.\n\nA.S.A.P! Micro Infusion System:\n\n• “A.S.A.P! is designed to work with our SKINWORKOUT program of specially formulated pharmaceutical grade pure sterilized hyaluronic acids and proprietary compounds to support your skin health . . . The program features two specially formulated skin health serums, U.R. (Ultimate Radiance and T.T. (Targeted Toning). U.R. is a high-performance sterilized serum with the purest hyaluronic acid, PDRN, and growth factors. It’s a rejuvenating blend that treats signs of aging and helps to regenerate damaged skin. T.T. is an intensely hydrating sterilized serum with the purest hyaluronic acid, Glutathione, Niacinamide, and Tranexamic Acid. This gentle yet effective serum helps even out skin tones, brightens skin, and reduces inflammation. Glutathione prevents dark spots and brightens the skin. Niacinamide helps with skin brightening and the enhancement of skin tone to even out your complexion. Tranexamic Acid is a nice treatment for freckling.”\n\n• “For consumers, we introduced the SKINWORKOUT®. This system includes the first in the US, sterilized pharmaceutical grade HA serums (U.R. and T.T.) for after-care and maintenance for any in-office treatments. The A.S.A.P.!™ Microinfusion system allows the optimal infusion of any valuable serums we use at home. A perfect match with U.R. and T.T.!”\n\n• “SKINWORKOUT® features our revolutionary micro infusion applicator, A.S.A.P.!™ (Advanced Skin Application Platform), designed to infuse specialized, pharmaceutical grade serums into the skin using our patented repeated motion called Microchannel Technology®. Unlike traditional skin care applications, microinfusion allows skin health serums to be infused directly into your skin rather than sitting on the surface.”\n\nBased on these claims, the A.S.A.P! Micro Infusion System is a device because it is intended to deliver micro-droplets of serums into the skin for various medical purposes (e.g., helping to regenerate damaged skin, reducing inflammation). The risks of A.S.A.P! Micro Infusion System use include, but are not limited to, all of the risks associated with AQUAGOLD® fine touch use (see above).\n\nIn addition, the AQUAGOLD® fine touch and the A.S.A.P! Micro Infusion System are devices because they are intended to affect the structure or any function of the body. The AQUAGOLD® fine touch and A.S.A.P! Micro Infusion System include microchannels (needles) that are 0.6mm and 0.2mm in length, respectively. Thus, these penetrate well beyond the stratum corneum (which is typically 0.02-0.04mm thick5). Based on the design and technology of these products, the entire microchannel is inserted into the skin and there is no mechanism that would prevent the user from inserting the entire microchannel into the skin. Therefore, your devices result in needle penetration beyond the stratum corneum and into the living layers of the skin (epidermis and dermis), showing that they are “intended to affect the structure or any function of the body” under section 201(h) of the FD&C Act.\n\nMicroneedling devices for aesthetic use are Class II devices regulated under 21 CFR 878.4430 and require premarket notification [510(k)]. At this time, no microneedling device has been cleared for over-the-counter (OTC) or home use. Additionally, devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biological products are not included in this classification and may need to be evaluated by the Center for Biologics Evaluation and Research (CBER) and\u002For the Center for Drug Evaluation and Research (CDER).\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at: http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\n\nWe note that your firm is also marketing other products that are drugs, biological products and\u002For combination products, which are subject to additional\u002Fdifferent requirements than those discussed above. For example, you are marketing the SKINWORKOUT® U.R. (Ultimate Radiance) and the SKINWORKOUT® T.T. (Targeted Toning) as serums that are intended to be injected into the human body for various medical purposes. On your firm’s website (https:\u002F\u002Fskinworkout.com), you state that the SKINWORKOUT® U.R. (Ultimate Radiance) is a serum containing hyaluronic acid, “growth factors,” polydeoxyribonucleotide, and tri-peptides, among other things, and that it promotes the formation of collagen and elastin, stimulates cellular renewal, and helps regenerate damaged skin. You also state that the SKINWORKOUT® T.T. (Targeted Toning) is a serum containing hyaluronic acid, glutathione, and niacinamide, among other things, and that it activates a metabolic process to brighten the skin and reduces inflammation. You also are marketing the A.S.A.P! + Two Serums Skin Care Gift Set, which is a set that includes the Ultimate Radiance Serum, Targeted Toning Serum, A.S.A.P! Microinfusion System, and a cap.\n\nWe note that for combination products (see 21 CFR 3.2(e)), the regulations at 21 CFR Part 4 also apply. The appropriate marketing application for a combination product generally depends on which agency component (i.e., CBER, CDER or the Center for Devices and Radiological Health) has the lead responsibility for the premarket review and regulation of the combination product. Your firm may obtain formal or informal determinations regarding the assignment (the agency component with the lead regulatory responsibility), as well as the classification, of products by submitting RFDs or pre-RFDs, respectively, with the FDA’s Office of Combination Products (OCP). For further information about the RFD and pre-RFD processes, you may visit OCP’s website at http:\u002F\u002Fwww.fda.gov\u002FCombinationProducts\u002Fdefault.htm or contact OCP at 301-796-8930 or combination@fda.gov. You should also review the following guidances for additional information: How to Write a Request for Designation (RFD): Guidance for Industry (fda.gov) and How to Prepare a Pre-Request for Designation (Pre-RFD) (fda.gov).\n\nYour firm should take prompt action to address the violations described in this letter. Failure to adequately address any violations may lead to regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nAlso, other federal agencies may take your compliance history into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that you have complied with the Act and FDA regulations, please provide your reasoning and any supporting information for our consideration as part of your response to FDA within fifteen business days.\n\nIf you have any questions about the contents of this letter, please contact Compliance Officer, Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA.\n\nSincerely,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1 – East\n\n\u002FS\u002F\n\nBinita S. Ashar, M.D., M.B.A., F.A.C.S.\n\nDirector\n\nOHT4: Office of Surgical\n\nand Infection Control Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc: Aquavit Life Sciences, Inc.\n\n145 W 57th Street, Floor 15\n\nNew York, NY 10019\n\n______________________________\n\n1 FDA has had previous interactions with your firm regarding these products, including in correspondence related to: (1) It Has Come To Our Attention (IHCTOA) letters sent to your firm on May 10, 2016 and July 18, 2016, (2) a Request For Designation (RFD) your firm submitted to FDA on April 10, 2017, and (3) FDA’s inspection of your firm from October 23, 2019 to December 19, 2019.\n\n2 As discussed further below, your firm is also marketing other products that are drugs, biological products, and\u002For combination products, which are subject to additional\u002Fdifferent requirements from those discussed in this letter. Please refer to page 4 of this letter for additional information on these issues.\n\n3 The AQUAGOLD® fine touch has been listed with product code GAA (Needle, Aspiration And Injection, Disposable) under 21 CFR 878.4800. Based on the claims discussed further below, the device does not fall under that product code or regulation. We note that the A.S.A.P! Micro Infusion System has not been listed. Under section 502(o) of the Act, 21 U.S.C. § 352(o), a device that is not listed as required by section 510(j) is deemed to be misbranded.\n\n4 We note that FDA issued the Regulatory Considerations for Microneedling Products - Guidance for Industry and Food and Drug Administration Staff (fda.gov) (November 2020) to assist industry in understanding when a microneedling product is a device as defined in section 201(h) of the Act. The guidance discusses a firm’s claims and statements associated with a microneedling product that FDA believes would generally cause the product to meet the device definition (e.g., it treats scars, treats wrinkles and deep facial lines, treats acne, treats alopecia, stimulates collagen production, and promotes wound healing). The guidance also states that FDA may consider the design and technological characteristics\u002Ffeatures of a microneedling product in determining whether it is a device under the Act. As noted in the guidance, microneedling products that are combination products are outside the scope of the guidance.\n\n5 Haftek M. (2017) Stratum Corneum Histopathology. In: Humbert P., Fanian F., Maibach H., Agache P. (eds) Agache's Measuring the Skin. Springer, Cham. https:\u002F\u002Fdoi.org\u002F10.1007\u002F978-3-319-32383-1_23.","Aquavit Pharmaceuticals, Inc","aquavit-pharmaceuticals-inc-607150-06172021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faquavit-pharmaceuticals-inc-607150-06172021","2026-10-26T08:07:57.152127+00:00","2021-06-29","607150","Medical Devices","Sobin Chang","2026-08-20T03:02:31.064+00:00","United Parcel Service","2021-06-17",{"id":352,"raw":353,"subject":12,"body_html":357,"body_text":358,"firm_name":359,"letter_id":360,"created_at":361,"fei_number":19,"letter_url":362,"updated_at":363,"action_type":22,"case_status":23,"posted_date":364,"marcs_cms_no":365,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":366,"body_fetched_at":367,"delivery_method":151,"recipient_title":19,"reference_number":368,"action_taken_date":369,"medical_device_id":19,"response_letter_date":19},204,[354,355,356,11,12,13,13,13],"\u003Ctime datetime=\"2026-04-28T04:00:00Z\">04\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-30T04:00:00Z\">03\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-721151-03302026\">Intas Pharmaceuticals Limited \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-57\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kirti Maheshwari\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Intas Pharmaceuticals Limited \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 255, Magnet Corporate Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nr. Sola Bridge, S. G. Highway, Thaltej\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-57\u003C\u002Fp>\u003Cp>March 30, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Maheshwari:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3005890633, located at Camp Road, Selaqui, Dehradun, from September 8 to 17, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 8, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into out-of-specification (OOS) assay results were inadequate. Your corrective and preventive actions (CAPAs) to address your persistent OOS assay results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets were not robust, as evidenced by the continued trend of subpotent assay stability failures and multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong> to drug product expiry period.\u003C\u002Fp>\u003Cp>For example, since 2023, your testing has shown multiple confirmed stability OOS results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches. You \u003Cstrong>(b)(4)\u003C\u002Fstrong> your expiry period from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and then further \u003Cstrong>(b)(4)\u003C\u002Fstrong> it to the current \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We acknowledge your decision to recall \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets in response to stability OOS results since 2024.\u003C\u002Fp>\u003Cp>Multiple CAPAs included changes to batch processing to prevent further degradation of the active pharmaceutical ingredient. You also implemented modifications to your assay sample preparation procedures. However, you still experienced OOS assay results. For example, you tested 12-month long term stability batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and had a confirmed OOS result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (specification is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%). Your investigation of this 12-month stability failure was inadequate.\u003C\u002Fp>\u003Cp>You identified the root cause as “product behavior” and recalled this batch. You did not adequately evaluate the reserves of all distributed batches or reserve batches using the same API lot to determine if market action is warranted, as required.\u003C\u002Fp>\u003Cp>After the initial OOS result, you proceeded to test samples from the same batch and other previously OOS batches, using a revised analytical method with a different sample preparation and obtained different results. Despite using the revised analytical method, two batches (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg and \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg) remained out of specification. Your investigation failed to evaluate why these batches still failed or assess whether the analytical method itself contributes to result variability. Attributing a failure to inherent drug product behaviors is not scientifically sound when a change in the test method yields a different outcome.\u003C\u002Fp>\u003Cp>Additionally, after you implemented your revised method in July 2025 you continued to experience low assay results. For example, you invalidated an assay result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for a sample batch (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) used as a control due to “solution preparation error” without conclusive supporting evidence, despite the sample preparation analysis being deemed “satisfactory” during the laboratory Phase I investigation. You did not issue a CAPA plan for analyst training. You also discarded the initial OOS with insufficient supporting documentation and did not include it in your final reporting of the assay result.\u003C\u002Fp>\u003Cp>In your response, you attribute the low assay values to the analytical limitation in the assay method, specifically incomplete extraction of the active pharmaceutical ingredient. You state it is not “totally due to actual product degradation.” You discuss your submission of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the Agency to address the assay OOS results. Using the revised method, your new assay results appeared to be closer to the lower specification end. The variability in the new results does not clearly explain why these results are outside of the target assay value.\u003C\u002Fp>\u003Cp>Additionally, you initiated testing of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> distributed batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP (all strengths) within their approved shelf-life for the U.S. market. All batches met the specification criteria.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your response does not address why the extraction limitation was not identified during the original method validation or explain what failures in your method validation process allowed this critical deficiency. In addition, your impact assessment of the evaluation of the extraction method did not extend to all assay values specifically which were on the higher end of the specification. Your response does not review or correlate market complaints or adverse events with low assay batches, which would be critical for a patient safety assessment.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>An impact assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablet batches within expiry that showed assay results below your target assay. This assessment can coincide with your protocol for impact assessment for batches in the U.S. market that have stability testing assay results below \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Identify any common variables leading to the low assay values. Provide the OOS investigations for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and all OOS assay failures for \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets since the FDA inspection.\u003C\u002Fli>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality assurance decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks controls to assure the integrity of electronic batch record data. Your quality assurance employee instructed your software vendor to make changes to your electronic batch record which were not captured in the audit trail or managed through your quality system.\u003C\u002Fp>\u003Cp>During the inspection, you provided written communication from a quality assurance employee to the software vendor that discussed multiple changes and modifications made to the electronic batch record. One of the changes included the replacement of an employee identification number with another employee number for “Dispensed by” in \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg batch record \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The change was not recorded in the audit trail, nor was it noted in the electronic batch record. Additionally, your firm lacked detailed procedural controls to assure the integrity of electronic batch record data when modifications are made after completion of the batch record.\u003C\u002Fp>\u003Cp>In your response, you indicate that the changes the software vendor made in the electronic batch record corrected inaccuracies only. You state your requests to software vendors to modify data have been terminated. You commit to conducting formal interviews with employees who contacted the vendors to request the data changes and to initiating deviation investigations. You commit to performing a retrospective review of all group and individual email messages sent to the software vendor to determine which email messages contained CGMP instructions. You also commit to conducting a review of the audit trails of all U.S. batches.\u003C\u002Fp>\u003Cp>Your response is inadequate. You fail to provide documentation of the deviations, interview transcripts, or discussion held with the employees who requested changes to electronic batch record data. You fail to explain why Quality Assurance did not initiate a deviation upon finding discrepancies or why the batch record contained no comments or remarks about the employee identification change. Additionally, your retrospective review of email requests to software vendors for data changes did not include an assessment of communications with other software vendors such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective review of all software related communications and correlated audit trail between your Intas Dehradun facility and software support vendors. Provide any updated deviations and related CAPA reports.\u003C\u002Fli>\u003Cli>A product impact assessment for identified communications related to changes in batch record data and process parameters.\u003C\u002Fli>\u003Cli>Effectiveness checks for the CAPAs implemented in your “Data Integrity Risk Assessment” of software applications, conducted by third party consultants in 2024.\u003C\u002Fli>\u003Cli>Performance qualification deviations for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling machine (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Model \u003Cstrong>(b)(4)\u003C\u002Fstrong>, equipment ID: DP-38). Include a report discussing the discrepancies in entries in the data sheet versus audit trail data, including maximum \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This equipment is related to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Intas Pharmaceuticals Limited located at Camp Road, Selaqui, Dehradun, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005890633 and ATTN: Erika V. Butler.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-57\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kirti Maheshwari\n\nRecipient Title\n\nChief Operating Officer\n\nIntas Pharmaceuticals Limited\n\nPlot No. 255, Magnet Corporate Park\n\nNr. Sola Bridge, S. G. Highway, Thaltej\n\nAhmedabad\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-57\nMarch 30, 2026\nDear Mr. Maheshwari:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3005890633, located at Camp Road, Selaqui, Dehradun, from September 8 to 17, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 8, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour investigations into out-of-specification (OOS) assay results were inadequate. Your corrective and preventive actions (CAPAs) to address your persistent OOS assay results for (b)(4) tablets were not robust, as evidenced by the continued trend of subpotent assay stability failures and multiple (b)(4) to drug product expiry period.\nFor example, since 2023, your testing has shown multiple confirmed stability OOS results for (b)(4) batches. You (b)(4) your expiry period from (b)(4) to (b)(4), and then further (b)(4) it to the current (b)(4). We acknowledge your decision to recall (b)(4) batches of (b)(4) tablets in response to stability OOS results since 2024.\nMultiple CAPAs included changes to batch processing to prevent further degradation of the active pharmaceutical ingredient. You also implemented modifications to your assay sample preparation procedures. However, you still experienced OOS assay results. For example, you tested 12-month long term stability batch (b)(4) and had a confirmed OOS result of (b)(4)% (specification is (b)(4)%). Your investigation of this 12-month stability failure was inadequate.\nYou identified the root cause as “product behavior” and recalled this batch. You did not adequately evaluate the reserves of all distributed batches or reserve batches using the same API lot to determine if market action is warranted, as required.\nAfter the initial OOS result, you proceeded to test samples from the same batch and other previously OOS batches, using a revised analytical method with a different sample preparation and obtained different results. Despite using the revised analytical method, two batches ((b)(4) and (b)(4), (b)(4) tablets USP (b)(4) mcg and (b)(4) mcg) remained out of specification. Your investigation failed to evaluate why these batches still failed or assess whether the analytical method itself contributes to result variability. Attributing a failure to inherent drug product behaviors is not scientifically sound when a change in the test method yields a different outcome.\nAdditionally, after you implemented your revised method in July 2025 you continued to experience low assay results. For example, you invalidated an assay result of (b)(4)% for a sample batch ((b)(4)) used as a control due to “solution preparation error” without conclusive supporting evidence, despite the sample preparation analysis being deemed “satisfactory” during the laboratory Phase I investigation. You did not issue a CAPA plan for analyst training. You also discarded the initial OOS with insufficient supporting documentation and did not include it in your final reporting of the assay result.\nIn your response, you attribute the low assay values to the analytical limitation in the assay method, specifically incomplete extraction of the active pharmaceutical ingredient. You state it is not “totally due to actual product degradation.” You discuss your submission of a (b)(4) to the Agency to address the assay OOS results. Using the revised method, your new assay results appeared to be closer to the lower specification end. The variability in the new results does not clearly explain why these results are outside of the target assay value.\nAdditionally, you initiated testing of all (b)(4) distributed batches of (b)(4) tablets USP (all strengths) within their approved shelf-life for the U.S. market. All batches met the specification criteria.\nYour response is inadequate. Your response does not address why the extraction limitation was not identified during the original method validation or explain what failures in your method validation process allowed this critical deficiency. In addition, your impact assessment of the evaluation of the extraction method did not extend to all assay values specifically which were on the higher end of the specification. Your response does not review or correlate market complaints or adverse events with low assay batches, which would be critical for a patient safety assessment.\nIn response to this letter, provide the following:\nAn impact assessment of (b)(4) tablet batches within expiry that showed assay results below your target assay. This assessment can coincide with your protocol for impact assessment for batches in the U.S. market that have stability testing assay results below (b)(4)%. Identify any common variables leading to the low assay values. Provide the OOS investigations for batch (b)(4) and all OOS assay failures for (b)(4) tablets since the FDA inspection.\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality assurance decisions, and is fully supported by executive management.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm lacks controls to assure the integrity of electronic batch record data. Your quality assurance employee instructed your software vendor to make changes to your electronic batch record which were not captured in the audit trail or managed through your quality system.\nDuring the inspection, you provided written communication from a quality assurance employee to the software vendor that discussed multiple changes and modifications made to the electronic batch record. One of the changes included the replacement of an employee identification number with another employee number for “Dispensed by” in (b)(4) tablets USP (b)(4) mcg batch record (b)(4). The change was not recorded in the audit trail, nor was it noted in the electronic batch record. Additionally, your firm lacked detailed procedural controls to assure the integrity of electronic batch record data when modifications are made after completion of the batch record.\nIn your response, you indicate that the changes the software vendor made in the electronic batch record corrected inaccuracies only. You state your requests to software vendors to modify data have been terminated. You commit to conducting formal interviews with employees who contacted the vendors to request the data changes and to initiating deviation investigations. You commit to performing a retrospective review of all group and individual email messages sent to the software vendor to determine which email messages contained CGMP instructions. You also commit to conducting a review of the audit trails of all U.S. batches.\nYour response is inadequate. You fail to provide documentation of the deviations, interview transcripts, or discussion held with the employees who requested changes to electronic batch record data. You fail to explain why Quality Assurance did not initiate a deviation upon finding discrepancies or why the batch record contained no comments or remarks about the employee identification change. Additionally, your retrospective review of email requests to software vendors for data changes did not include an assessment of communications with other software vendors such as (b)(4).\nIn response to this letter, provide the following:\nA retrospective review of all software related communications and correlated audit trail between your Intas Dehradun facility and software support vendors. Provide any updated deviations and related CAPA reports.\nA product impact assessment for identified communications related to changes in batch record data and process parameters.\nEffectiveness checks for the CAPAs implemented in your “Data Integrity Risk Assessment” of software applications, conducted by third party consultants in 2024.\nPerformance qualification deviations for your (b)(4) filling machine ((b)(4), Model (b)(4), equipment ID: DP-38). Include a report discussing the discrepancies in entries in the data sheet versus audit trail data, including maximum (b)(4). This equipment is related to a (b)(4) for (b)(4) solution (b)(4).\nA comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Intas Pharmaceuticals Limited located at Camp Road, Selaqui, Dehradun, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005890633 and ATTN: Erika V. Butler.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Intas Pharmaceuticals Limited","intas-pharmaceuticals-limited-721151-03302026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-721151-03302026","2026-10-26T08:08:59.53451+00:00","2026-04-28","721151","Mr. Kirti Maheshwari","2026-08-19T04:45:36.862+00:00","320-26-57","2026-03-30",{"id":371,"raw":372,"subject":12,"body_html":376,"body_text":377,"firm_name":359,"letter_id":378,"created_at":183,"fei_number":19,"letter_url":379,"updated_at":380,"action_type":22,"case_status":23,"posted_date":381,"marcs_cms_no":382,"product_type":26,"closeout_date":19,"issuing_office":199,"recipient_name":383,"body_fetched_at":384,"delivery_method":328,"recipient_title":19,"reference_number":19,"action_taken_date":385,"medical_device_id":19,"response_letter_date":19},1722,[373,374,375,199,12,13,13,13],"\u003Ctime datetime=\"2023-11-28T14:20:00Z\">11\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-21T05:00:00Z\">11\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-662868-11212023\">Intas Pharmaceuticals Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nimish Chudgar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer &amp; Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Intas Pharmaceuticals Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thaltej, Ahmedabad\u003C\u002Fspan> \u003Cspan>380054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-24-12\u003C\u002Fp>\n\n\u003Cp>November 21, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chudgar:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3003157498, at Plot No. 457- 458 &amp; 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, from May 1 to May 12, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 05, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Quality Assurance (QA) and production departments failed to provide adequate oversight and ensure the reliability of data related to the quality of finished drug products manufactured at your facility. Since 2021, visual inspectors manipulated particle and other defect counts on manual visual inspection records in many instances, in order to keep the finished product batches within rejection limits. More specifically, the investigation found that operators manipulated the defect quantities “to keep the category wise rejections within limits to avoid a deviation and investigation.”\u003C\u002Fp>\n\n\u003Cp>In addition, multiple operators manipulated the reported defects, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> attributes and particle counts, on manual visual inspection records to have identical numbers. This practice was repeatedly performed by at least nine different manual visual inspectors on trays of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The records, filled out by multiple operators, had an identical number of defects listed for all drug product defect categories.\u003C\u002Fp>\n\n\u003Cp>Production managers including, but not limited to, front line supervisors failed to ensure reliable data, leading to significant data integrity deficiencies in your production records.\u003C\u002Fp>\n\n\u003Cp>In addition, there was a lack of QA department review and oversight of visual inspection records, and your firm continued this egregious pattern of recording and altering defect counts. These findings indicated that your QA department was not exercising its basic responsibilities including, but not limited to, oversight and control over the adequacy and reliability of all CGMP data at your facility.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the discrepancies found in the visual inspection records and identify the contributing factors to these deviations as “inadequate data management processes, inadequate training and procedures, and inadequate quality oversight of the visual inspection operation.” You state that “all the visual inspectors in this area have been disqualified” and “operators have been moved to the secondary packaging area and are not participating in GMP activities.”\u003C\u002Fp>\n\n\u003Cp>In addition, you also commit to working with a qualified consultant to perform a “data governance and integrity audit” and to establish a remediation plan. You commit to perform an assessment to evaluate injectable products that are within shelf life and are on the market to identify similar discrepancies in the visual inspection records.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your voluntary recall of batches of drug products due to particle contamination identified in product retain samples.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you have not conducted a comprehensive evaluation of other CGMP records in which data may have been reported inaccurately or otherwise manipulated by your employees. You do not provide a comprehensive corrective action and preventative action (CAPA) plan with a systematic approach to correct these oversight deficiencies. Furthermore, although you indicate that you have performed training for inspectors, QA, and managers, you fail to adequately address the managers’ failure to act on observed data integrity lapses. In particular, you lack a comprehensive review of the management of your operations, including but not limited to ineffective supervision and governance in your production department (i.e., encompassing frontline supervisors through top operations managers).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An explanation why disqualified visual inspectors relocated to secondary packaging operations were characterized as not being involved in CGMP activities. Secondary packaging functions in a production department are performed under good manufacturing practices.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QA disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Describe how top management supports QA and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>Describe your plans to prevent manipulation and enhance control of all CGMP records. Specifically, describe your reconciliation and integrity improvements for all CGMP records that may be in loose form or otherwise vulnerable to manipulation. Based on an independent review by a qualified consultant, provide a gap analysis and specific CAPA measures you will take to safeguard integrity of records (e.g., recording data in logbooks, pre-paginated documents, and validated electronic systems).\u003C\u002Fli>\n\t\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, operations management oversight of facilities and equipment. This plan should include, at a minimum:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Improved production management oversight that ensures prompt detection of equipment, facility, and process performance issues\u003Cbr>\n&nbsp; &nbsp; o Timely upgrades to equipment and facilities\u003Cbr>\n&nbsp; &nbsp; o Adherence to appropriate preventive maintenance schedules\u003Cbr>\n&nbsp; &nbsp; o Effective execution of repairs\u003Cbr>\n&nbsp; &nbsp; o Allocation of appropriate resources, staffing, and competencies\u003Cbr>\n&nbsp; &nbsp; o Appropriately qualified production supervisors and managers\u003Cbr>\n&nbsp; &nbsp; o Improved systems for ongoing management review\u003Cbr>\n&nbsp; &nbsp; o A provision(s) that appropriate actions are taken throughout the company network\u003Cbr>\n&nbsp; &nbsp; o A thorough evaluation and risk assessment that addresses the suitability of your equipment for its intended use. Include an evaluation whether equipment is of appropriate design and your ongoing control and maintenance program is effective.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to initiate or conduct adequate investigations into significant deviations in your aseptic processing manufacturing operations. You lacked investigations into visual inspection failures and non-viable particulates (NVP) exceeding your action levels. When investigations were conducted, they were often insufficient and lacked scientifically supported root cause(s).\u003C\u002Fp>\n\n\u003Cp>A. Several investigations were opened due to batches that failed visual inspection rejection rate limits. These investigations were closed without identifying the particles or their sources. There was no characterization of the particulates found in the batch to determine if they were intrinsic, extrinsic, or inherent to the product.\u003C\u002Fp>\n\n\u003Cp>For example, a deviation investigation was initiated for an \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection batch intended for the European market, filled on the same aseptic processing line as that used to produce \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches intended for the U.S. market. The batch exceeded the total rejection limit and the individual limits for white particles and glass particles. The investigation did not isolate or identify the white particles. In addition, there was no documented breakage of vials in the filling batch record. You closed the investigation without identifying the root cause or identifying the source of the white or glass particles.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge your deviation investigation failed to characterize the particulates when a batch failed to meet established limits. You commit to revise procedures for manual inspections of filled and sealed vials, to perform particle characterization, and to identify sources of particles during investigations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you commit to perform particle characterization to identify the source of particulates during investigations, you do not commit to ensure appropriate definition and categorization of observed intrinsic and extrinsic particulates, and to fully evaluate visible particulate contamination.\u003C\u002Fp>\n\n\u003Cp>It is important that any visible particulate contamination is appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your design and production controls. When categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Extrinsic or foreign particulate contamination should occur very infrequently, and be thoroughly investigated and appropriate CAPA implemented.\u003C\u002Fp>\n\n\u003Cp>B. During aseptic filling, non-viable particle (NVP) count limits were exceeded in ISO 5 aseptic processing areas and no investigations were conducted because these excursions did not persist for more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as stated in your procedure.\u003C\u002Fp>\n\n\u003Cp>You lacked an adequate system for handling NVP counts exceeding your action levels of NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles ≥ 0.5 μm\u002Fft\u003Csup>3\u003C\u002Fsup> during aseptic processing operations. Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> frequently failed to meet these ISO 5 limits. You routinely failed to investigate these high particulate levels in the ISO 5 aseptic processing operation.\u003C\u002Fp>\n\n\u003Cp>For example, while manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> product produced for the U.S. market, the NVP probe at the filling station, the probe at the infeed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the probe at the stoppering station failed the NVP count limit multiple times. In one instance, the filling machine automatically stopped as a result of these NVP alarms. There was no procedural requirement to clear any open product containers present at the time of the excursion. Your firm determined that no investigation would be done because the ISO 5 alarms did not individually persist for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Excessive particulates in the ISO 5 environment can lead to non-viable or biological contamination of sterile drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you state for NVP count excursions, removal of open containers will be added to the relevant SOP(s) to address this observation.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. There is no commitment to address the inappropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong> timeframe to initiate a NVP deviation. The use of any timeframe-based criteria to initiate a NVP deviation is unacceptable. Any excursion or result outside of the classification limits should be investigated, and the intensity of those investigations should be consistent with the magnitude or frequency of the excursions. You should also trend data to identify and assess hazards and implement effective CAPA. In addition, you do not commit to perform a retrospective review of all batches with NVP levels outside the ISO 5 limits, including individual occurrences, as well as instances in which alarms occurred or the machine stopped during aseptic processing.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>An independent, retrospective evaluation of all ISO 5 NVP deviations, root causes, and a relevant CAPA plan.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess (21 CFR 211.100 (a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your personnel qualification for the visual inspection of injectable products is deficient.\u003C\u002Fp>\n\n\u003Cp>A. Your firm failed to provide adequate challenge test set vials to qualify your operators to perform the visual inspection of your drug products. The challenge test kit used to qualify manual visual inspectors was created using good and rejected vials from a previous batch, with unknown sizes of particles present in the vials. Additionally, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> μm \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle was added to the challenge kit but it is not representative of the types of particles found in your operation. You lacked assurance the test kit with unknown particle sizes can adequately assess if your inspectors have the competencies required to identify the particles that may be present in the vials. In addition, quality unit personnel have not maintained a defect library for training purposes or reference.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to create a new visual inspection kit with known sizes of certified particle defects and revise procedures for kit preparation (e.g., to include particles with known particle sizes) and the inclusion of a reference defect library.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not state how including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle to your qualification kit is representative of your process to qualify visual inspectors.\u003C\u002Fp>\n\n\u003Cp>B. Your firm failed to adequately validate the manufacturing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. Specifically, your process validation lacked inter-batch and intra-batch evaluation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and process times for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During production, \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing times, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were left to operators’ discretion and variation of parameters were observed between batches.\u003C\u002Fp>\n\n\u003Cp>In addition, you lacked scientific justification for the sample sizes collected at the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;operations to analyze for percent \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dissolution, and appearance. Your firm has initiated deviations for OOS results of percent \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and rough surfaces were also observed during \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. The process validation study, and commercial manufacturing data, did not provide sufficient assurance of that process consistency is maintained throughout production batch operations.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge there is a lack of evaluation of inter- and intra-batch variability and insufficient guidance to the operators regarding process controls. You commit to performing an impact assessment on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets \u003Cstrong>(b)(4)\u003C\u002Fstrong> and other drug products containing a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also commit to revise your process validation procedures to ensure adequate samples are collected and performing statistical evaluations to understand the inter- and intra- batch variability with existing process validations. We acknowledge your firm’s commitment to perform process validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stage of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\u003Cbr>\n&nbsp; &nbsp; o A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing.\u003Cbr>\n&nbsp; &nbsp; o Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\u003Cbr>\n&nbsp; &nbsp;  Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\u003Cbr>\n&nbsp; &nbsp;  Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\u003Cbr>\n&nbsp; &nbsp;  Scrutiny of raw material variability from suppliers\u003Cbr>\n&nbsp; &nbsp;  Quality signals from both internal data and customers\u003Cbr>\n&nbsp; &nbsp;  How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\u003Cbr>\n&nbsp; &nbsp; o Based on this assessment, provide a CAPA to address any deficiencies in your process validation program.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Improved in-process testing and monitoring to enhance detection of variation during production of each batch (including for both individual and average test limits). Include remediated in-process quality standards, including but not limited to enhanced sampling, that will more robustly monitor upstream process control. Describe how the improvements will ensure early detection of process variation and manufacturing defects, and prevent consumer exposure to substandard quality drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113 (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A. Your procedures did not include a requirement for smoke studies to be performed in dynamic conditions in classified critical areas. There have been no smoke studies to determine whether the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF [laminar air flow]” can provide appropriate unidirectional air during dynamic activities, such as loading of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier systems (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS). The mobile LAF was not evaluated during the smoke studies under dynamic conditions. For example, the operator removes the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tub from the mobile LAF and carries them under the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF” (which is classified as an ISO 7 area) and then into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS.\u003C\u002Fp>\n\n\u003Cp>Thorough smoke studies are essential to evaluate and qualify your aseptic processing operations and ensure appropriate implementation of needed design remediations.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicate your procedures were revised to include instructions for conducting smoke studies under dynamic conditions. You state you have now performed smoke studies under dynamic conditions for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tub loading process including the mobile LAF and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF.” You commit to an assessment for all filling lines of parenteral drug products to evaluate execution of smoke studies in static and dynamic conditions.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not provide the smoke study video and report evaluating unidirectional airflow patterns under dynamic conditions for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tub loading process, including mobile LAF and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF.”\u003C\u002Fp>\n\n\u003Cp>B. The qualification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipped with transport ports failed to ensure adequate decontamination and worst-case locations in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in manufacturing. Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transport port \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to transport components to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not assessed with biological indicators at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the investigator observed an overlap and fold in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> near the area where the \u003Cstrong>(b)(4)\u003C\u002Fstrong> attaches to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for which the qualification failed to address if this area can be reproducibly decontaminated by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the observation that chemical and biological indicators were not placed at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer port and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We note a requalification was performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cited during the inspection and a report was provided. You commit to evaluating all \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for appropriate sample locations. You commit to reviewing the qualification protocols and reports for all remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> are adequately sampled. As a result of this inspection, you conducted a retrospective review and discovered five other \u003Cstrong>(b)(4)\u003C\u002Fstrong> that did not have chemical and biological indicators at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>-decontamination.\u003C\u002Fp>\n\n\u003Cp>As acknowledged in your response, further evaluations are needed to identify and assess the potential weak spots in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process. Your strategy appears to emphasize use of chemical indicators. However, biological indicators are essential to any evaluation to identify and evaluate locations that may lack assurance of sufficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>A. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003C\u002Fli>\n\t\u003Cli>Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>B. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>C. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\t\u003Cli>A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003C\u002Fli>\n\t\u003Cli>Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003C\u002Fli>\n\t\u003Cli>Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003C\u002Fli>\n\t\u003Cli>A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003C\u002Fli>\n\t\u003Cli>Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to investigate potential breaches.\u003C\u002Fli>\n\t\u003Cli>A status report for any of the above activities already underway or completed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection, including the inspection of July 22 to August 02, 2019, FDA cited similar CGMP observations. You proposed specific remediations for these observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on November 14, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at, Intas Pharmaceuticals Limited, at Plot No. 457- 458 &amp; 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003157498 and ATTN: Erika V. Butler.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nimish Chudgar\n\nRecipient Title\n\nChief Executive Officer & Managing Director\n\nIntas Pharmaceuticals Limited\n\nPlot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\n\nThaltej, Ahmedabad 380054\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-12\n\nNovember 21, 2023\n\nDear Mr. Chudgar:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3003157498, at Plot No. 457- 458 & 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, from May 1 to May 12, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your June 05, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour Quality Assurance (QA) and production departments failed to provide adequate oversight and ensure the reliability of data related to the quality of finished drug products manufactured at your facility. Since 2021, visual inspectors manipulated particle and other defect counts on manual visual inspection records in many instances, in order to keep the finished product batches within rejection limits. More specifically, the investigation found that operators manipulated the defect quantities “to keep the category wise rejections within limits to avoid a deviation and investigation.”\n\nIn addition, multiple operators manipulated the reported defects, including (b)(4) attributes and particle counts, on manual visual inspection records to have identical numbers. This practice was repeatedly performed by at least nine different manual visual inspectors on trays of (b)(4). The records, filled out by multiple operators, had an identical number of defects listed for all drug product defect categories.\n\nProduction managers including, but not limited to, front line supervisors failed to ensure reliable data, leading to significant data integrity deficiencies in your production records.\n\nIn addition, there was a lack of QA department review and oversight of visual inspection records, and your firm continued this egregious pattern of recording and altering defect counts. These findings indicated that your QA department was not exercising its basic responsibilities including, but not limited to, oversight and control over the adequacy and reliability of all CGMP data at your facility.\n\nIn your response, you acknowledge the discrepancies found in the visual inspection records and identify the contributing factors to these deviations as “inadequate data management processes, inadequate training and procedures, and inadequate quality oversight of the visual inspection operation.” You state that “all the visual inspectors in this area have been disqualified” and “operators have been moved to the secondary packaging area and are not participating in GMP activities.”\n\nIn addition, you also commit to working with a qualified consultant to perform a “data governance and integrity audit” and to establish a remediation plan. You commit to perform an assessment to evaluate injectable products that are within shelf life and are on the market to identify similar discrepancies in the visual inspection records.\n\nWe acknowledge your voluntary recall of batches of drug products due to particle contamination identified in product retain samples.\n\nYour response is inadequate because you have not conducted a comprehensive evaluation of other CGMP records in which data may have been reported inaccurately or otherwise manipulated by your employees. You do not provide a comprehensive corrective action and preventative action (CAPA) plan with a systematic approach to correct these oversight deficiencies. Furthermore, although you indicate that you have performed training for inspectors, QA, and managers, you fail to adequately address the managers’ failure to act on observed data integrity lapses. In particular, you lack a comprehensive review of the management of your operations, including but not limited to ineffective supervision and governance in your production department (i.e., encompassing frontline supervisors through top operations managers).\n\nIn response to this letter, provide:\n\nAn explanation why disqualified visual inspectors relocated to secondary packaging operations were characterized as not being involved in CGMP activities. Secondary packaging functions in a production department are performed under good manufacturing practices.\n\nA comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QA disposition decision\n\no Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products\n\nDescribe how top management supports QA and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\n\nDescribe your plans to prevent manipulation and enhance control of all CGMP records. Specifically, describe your reconciliation and integrity improvements for all CGMP records that may be in loose form or otherwise vulnerable to manipulation. Based on an independent review by a qualified consultant, provide a gap analysis and specific CAPA measures you will take to safeguard integrity of records (e.g., recording data in logbooks, pre-paginated documents, and validated electronic systems).\n\nYour corrective action and preventive action (CAPA) plan to implement routine, operations management oversight of facilities and equipment. This plan should include, at a minimum:\n\no Improved production management oversight that ensures prompt detection of equipment, facility, and process performance issues\n\no Timely upgrades to equipment and facilities\n\no Adherence to appropriate preventive maintenance schedules\n\no Effective execution of repairs\n\no Allocation of appropriate resources, staffing, and competencies\n\no Appropriately qualified production supervisors and managers\n\no Improved systems for ongoing management review\n\no A provision(s) that appropriate actions are taken throughout the company network\n\no A thorough evaluation and risk assessment that addresses the suitability of your equipment for its intended use. Include an evaluation whether equipment is of appropriate design and your ongoing control and maintenance program is effective.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to initiate or conduct adequate investigations into significant deviations in your aseptic processing manufacturing operations. You lacked investigations into visual inspection failures and non-viable particulates (NVP) exceeding your action levels. When investigations were conducted, they were often insufficient and lacked scientifically supported root cause(s).\n\nA. Several investigations were opened due to batches that failed visual inspection rejection rate limits. These investigations were closed without identifying the particles or their sources. There was no characterization of the particulates found in the batch to determine if they were intrinsic, extrinsic, or inherent to the product.\n\nFor example, a deviation investigation was initiated for an (b)(4) injection batch intended for the European market, filled on the same aseptic processing line as that used to produce (b)(4) batches intended for the U.S. market. The batch exceeded the total rejection limit and the individual limits for white particles and glass particles. The investigation did not isolate or identify the white particles. In addition, there was no documented breakage of vials in the filling batch record. You closed the investigation without identifying the root cause or identifying the source of the white or glass particles.\n\nIn your response, you acknowledge your deviation investigation failed to characterize the particulates when a batch failed to meet established limits. You commit to revise procedures for manual inspections of filled and sealed vials, to perform particle characterization, and to identify sources of particles during investigations.\n\nYour response is inadequate. Although you commit to perform particle characterization to identify the source of particulates during investigations, you do not commit to ensure appropriate definition and categorization of observed intrinsic and extrinsic particulates, and to fully evaluate visible particulate contamination.\n\nIt is important that any visible particulate contamination is appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your design and production controls. When categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Extrinsic or foreign particulate contamination should occur very infrequently, and be thoroughly investigated and appropriate CAPA implemented.\n\nB. During aseptic filling, non-viable particle (NVP) count limits were exceeded in ISO 5 aseptic processing areas and no investigations were conducted because these excursions did not persist for more than (b)(4), as stated in your procedure.\n\nYou lacked an adequate system for handling NVP counts exceeding your action levels of NMT (b)(4) particles ≥ 0.5 μm\u002Fft3 during aseptic processing operations. Line (b)(4) frequently failed to meet these ISO 5 limits. You routinely failed to investigate these high particulate levels in the ISO 5 aseptic processing operation.\n\nFor example, while manufacturing (b)(4) injection, a (b)(4) product produced for the U.S. market, the NVP probe at the filling station, the probe at the infeed (b)(4), and the probe at the stoppering station failed the NVP count limit multiple times. In one instance, the filling machine automatically stopped as a result of these NVP alarms. There was no procedural requirement to clear any open product containers present at the time of the excursion. Your firm determined that no investigation would be done because the ISO 5 alarms did not individually persist for (b)(4).\n\nExcessive particulates in the ISO 5 environment can lead to non-viable or biological contamination of sterile drug products.\n\nIn your response, you state for NVP count excursions, removal of open containers will be added to the relevant SOP(s) to address this observation.\n\nYour response is inadequate. There is no commitment to address the inappropriate (b)(4) timeframe to initiate a NVP deviation. The use of any timeframe-based criteria to initiate a NVP deviation is unacceptable. Any excursion or result outside of the classification limits should be investigated, and the intensity of those investigations should be consistent with the magnitude or frequency of the excursions. You should also trend data to identify and assess hazards and implement effective CAPA. In addition, you do not commit to perform a retrospective review of all batches with NVP levels outside the ISO 5 limits, including individual occurrences, as well as instances in which alarms occurred or the machine stopped during aseptic processing.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nAn independent, retrospective evaluation of all ISO 5 NVP deviations, root causes, and a relevant CAPA plan.\n\n3. Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess (21 CFR 211.100 (a)).\n\nYour personnel qualification for the visual inspection of injectable products is deficient.\n\nA. Your firm failed to provide adequate challenge test set vials to qualify your operators to perform the visual inspection of your drug products. The challenge test kit used to qualify manual visual inspectors was created using good and rejected vials from a previous batch, with unknown sizes of particles present in the vials. Additionally, a (b)(4) μm (b)(4) particle was added to the challenge kit but it is not representative of the types of particles found in your operation. You lacked assurance the test kit with unknown particle sizes can adequately assess if your inspectors have the competencies required to identify the particles that may be present in the vials. In addition, quality unit personnel have not maintained a defect library for training purposes or reference.\n\nIn your response, you commit to create a new visual inspection kit with known sizes of certified particle defects and revise procedures for kit preparation (e.g., to include particles with known particle sizes) and the inclusion of a reference defect library.\n\nYour response is inadequate. You do not state how including the (b)(4) particle to your qualification kit is representative of your process to qualify visual inspectors.\n\nB. Your firm failed to adequately validate the manufacturing process for (b)(4) mg (b)(4) tablets. Specifically, your process validation lacked inter-batch and intra-batch evaluation of (b)(4), and process times for the (b)(4). During production, (b)(4) processing times, (b)(4), and (b)(4) were left to operators’ discretion and variation of parameters were observed between batches.\n\nIn addition, you lacked scientific justification for the sample sizes collected at the (b)(4) operations to analyze for percent (b)(4), dissolution, and appearance. Your firm has initiated deviations for OOS results of percent (b)(4), and rough surfaces were also observed during (b)(4) of (b)(4)mg (b)(4) tablets. The process validation study, and commercial manufacturing data, did not provide sufficient assurance of that process consistency is maintained throughout production batch operations.\n\nIn your response, you acknowledge there is a lack of evaluation of inter- and intra-batch variability and insufficient guidance to the operators regarding process controls. You commit to performing an impact assessment on the (b)(4) on (b)(4) mg (b)(4) tablets (b)(4) and other drug products containing a (b)(4). You also commit to revise your process validation procedures to ensure adequate samples are collected and performing statistical evaluations to understand the inter- and intra- batch variability with existing process validations. We acknowledge your firm’s commitment to perform process validation for the (b)(4) stage of (b)(4) mg (b)(4) tablets.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nIn response to this letter, provide:\n\nProvide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\n\no A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\n\no A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing.\n\no Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\n\n Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\n\n Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\n\n Scrutiny of raw material variability from suppliers\n\n Quality signals from both internal data and customers\n\n How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\n\no Based on this assessment, provide a CAPA to address any deficiencies in your process validation program.\n\nImproved in-process testing and monitoring to enhance detection of variation during production of each batch (including for both individual and average test limits). Include remediated in-process quality standards, including but not limited to enhanced sampling, that will more robustly monitor upstream process control. Describe how the improvements will ensure early detection of process variation and manufacturing defects, and prevent consumer exposure to substandard quality drug products.\n\n4. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113 (b)).\n\nA. Your procedures did not include a requirement for smoke studies to be performed in dynamic conditions in classified critical areas. There have been no smoke studies to determine whether the “(b)(4) LAF [laminar air flow]” can provide appropriate unidirectional air during dynamic activities, such as loading of the (b)(4) into the (b)(4) restricted access barrier systems ((b)(4)RABS). The mobile LAF was not evaluated during the smoke studies under dynamic conditions. For example, the operator removes the (b)(4) tub from the mobile LAF and carries them under the “(b)(4) LAF” (which is classified as an ISO 7 area) and then into the (b)(4)RABS.\n\nThorough smoke studies are essential to evaluate and qualify your aseptic processing operations and ensure appropriate implementation of needed design remediations.\n\nIn your response, you indicate your procedures were revised to include instructions for conducting smoke studies under dynamic conditions. You state you have now performed smoke studies under dynamic conditions for the (b)(4) tub loading process including the mobile LAF and “(b)(4) LAF.” You commit to an assessment for all filling lines of parenteral drug products to evaluate execution of smoke studies in static and dynamic conditions.\n\nYour response is inadequate. You do not provide the smoke study video and report evaluating unidirectional airflow patterns under dynamic conditions for the (b)(4) tub loading process, including mobile LAF and “(b)(4) LAF.”\n\nB. The qualification of the (b)(4) cycle of the (b)(4) equipped with transport ports failed to ensure adequate decontamination and worst-case locations in the (b)(4) used in manufacturing. Specifically, the (b)(4) transport port (b)(4) used to transport components to the (b)(4) was not assessed with biological indicators at the (b)(4) of the (b)(4). In addition, the investigator observed an overlap and fold in the (b)(4) of the (b)(4) near the area where the (b)(4) attaches to the (b)(4) for which the qualification failed to address if this area can be reproducibly decontaminated by (b)(4).\n\nIn your response, you acknowledge the observation that chemical and biological indicators were not placed at the (b)(4) of the (b)(4) transfer port and (b)(4) for (b)(4). We note a requalification was performed on the (b)(4) cited during the inspection and a report was provided. You commit to evaluating all (b)(4) and (b)(4) for appropriate sample locations. You commit to reviewing the qualification protocols and reports for all remaining (b)(4) to ensure the (b)(4) are adequately sampled. As a result of this inspection, you conducted a retrospective review and discovered five other (b)(4) that did not have chemical and biological indicators at the (b)(4) of the (b)(4) for (b)(4)-decontamination.\n\nAs acknowledged in your response, further evaluations are needed to identify and assess the potential weak spots in your (b)(4) decontamination process. Your strategy appears to emphasize use of chemical indicators. However, biological indicators are essential to any evaluation to identify and evaluate locations that may lack assurance of sufficient (b)(4) exposure.\n\nIn response to this letter, provide:\n\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\n\nWe acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\n\nA. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\nA detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\nInterviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nA comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nB. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nC. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\n\nA detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\nA comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\nInterim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\nLong-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\nA commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\nInform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to investigate potential breaches.\n\nA status report for any of the above activities already underway or completed.\n\nRepeat Observations at Facility\n\nIn a previous inspection, including the inspection of July 22 to August 02, 2019, FDA cited similar CGMP observations. You proposed specific remediations for these observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nFDA placed your firm on Import Alert 66-40 on November 14, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at, Intas Pharmaceuticals Limited, at Plot No. 457- 458 & 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nWe request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003157498 and ATTN: Erika V. Butler.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n___________________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","intas-pharmaceuticals-limited-662868-11212023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-662868-11212023","2026-10-26T08:08:59.489025+00:00","2023-11-28","662868","Mr. Nimish Chudgar","2026-08-20T00:28:57.09+00:00","2023-11-21",{"id":387,"raw":388,"subject":12,"body_html":392,"body_text":393,"firm_name":359,"letter_id":394,"created_at":183,"fei_number":19,"letter_url":395,"updated_at":396,"action_type":22,"case_status":23,"posted_date":397,"marcs_cms_no":398,"product_type":26,"closeout_date":19,"issuing_office":199,"recipient_name":383,"body_fetched_at":399,"delivery_method":328,"recipient_title":19,"reference_number":19,"action_taken_date":400,"medical_device_id":19,"response_letter_date":19},1959,[389,390,391,199,12,13,13,13],"\u003Ctime datetime=\"2023-08-01T14:31:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-28T04:00:00Z\">07\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-652067-07282023\">Intas Pharmaceuticals Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nimish Chudgar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer &amp; Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Intas Pharmaceuticals Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thaltej, Ahmedabad\u003C\u002Fspan> \u003Cspan>382213\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-20\u003C\u002Fp>\n\n\u003Cp>July 28, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chudgar:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3004011473, at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India, from November 22 to December 02, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 27, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure reliability of data relating to the quality of medicines produced at your facility. Our inspection revealed serious deviations, including but not limited to, inadequate oversight of original CGMP documents, deficient controls over computerized systems, insufficient laboratory investigations, and aborted chromatographic sequences.\u003C\u002Fp>\n\n\u003Cp>Senior facility managers failed to exercise their authority and responsibility to ensure reliable data, leading to severe data integrity deficiencies in your production and laboratory departments. These findings also indicate that your quality assurance function is not exercising its responsibilities, including but not limited to, oversight and control over the adequacy and reliability of CGMP data used throughout your operation.\u003C\u002Fp>\n\n\u003Cp>A. You failed to assure integrity of analytical testing data. Some examples include:\u003C\u002Fp>\n\n\u003Cp>1. Our investigators observed plastic bags filled with torn and discarded original CGMP documents in your quality control (QC) scrap area under a stairwell, in your general parenteral scrap room, and on a truck outside your facility. Among these CGMP documents were engineering checklists associated with the Environmental Monitoring System (EMS), torn Karl Fischer (KF) analytical test reports, auto titration curves, and analytical balance weight slips for finished drug products.\u003C\u002Fp>\n\n\u003Cp>2. An analyst destroyed CGMP records by pouring acetic acid in a trash bin containing analytical balance slips for testing the standardization of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A QC employee stated he observed the same analyst destroy KF titration curves and balance printouts. The employee reported the incident to QC laboratory management on November 22, 2022. An investigation into the destruction of the torn CGMP documents and the impact to your drug product quality was not initiated until November 28, 2022.\u003C\u002Fp>\n\n\u003Cp>3. An analyst weighed out the same samples of amitriptyline hydrochloride tablets USP 100 mg batches multiple times for \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong> test. The analyst stated to our investigator that he did not report all the test results, further stating that in some instances balance printouts were discarded in the trash. In addition, the time stamp on each of the analytical balance and \u003Cstrong>(b)(4)\u003C\u002Fstrong> printouts did not match your Laboratory Information Management System (LIMS) records.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to working with a qualified consultant to perform an overall baseline assessment of data integrity and governance controls, and to establish a remediation plan.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate in that it did not fully evaluate the scope of this deficiency and the impact to product quality. You did not adequately address the major failure of laboratory, operations, and quality assurance management to conduct proper oversight over documentation and prevent data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>B. Your department failed to exercise appropriate controls over computerized systems. For example:\u003C\u002Fp>\n\n\u003Cp>1. Your electronic batch records allowed changes to be made to manual entries prior to saving. Our inspector observed a production employee manually alter the reported time that an operation was performed. QA did not review audit trails as part of their batch record review to identify discrepancies and compare the reported date and time against that which was originally logged.\u003C\u002Fp>\n\n\u003Cp>2. Analysts manually reprocessed chromatograms by adding integration events that were not approved by QC management. In addition, you lacked appropriate procedures describing when the analyst can manually input integration events, how these events should be used, or how they should be reviewed.\u003C\u002Fp>\n\n\u003Cp>3. Destroyed KF raw data paper printouts associated with drug products were discovered by our inspection team in a trash bag. The KF instrument used for water content testing and assay testing is capable of storing electronic data; however, this capacity was not utilized, and you did not save this data electronically.\u003C\u002Fp>\n\n\u003Cp>4. Your 2018 Process Equipment Assessment Report identified numerous gaps and deficiencies for electronic manufacturing equipment needing upgrades in access controls, audit trails, saving electronic data and preventing clock alterations. You had not documented closures of these corrective action and preventive action (CAPA) measures to support data integrity in your computerized systems. Your QA department had not performed a similar assessment in your QC laboratories.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the inspection findings and you reference your standard operating procedure titled, “Data Integrity,” which stipulates the individuals permitted to make changes in an electronic record and requires audit trails to capture those actions. You also commit to obtaining expertise from a qualified consultant to systematically address the deviations, as part of the baseline assessment.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you established procedures, you did not explain the critical failure of laboratory and operations management in not providing adequate oversight of data integrity of computer systems. You also did not address the failure of the QA department to fully exercise its authority and responsibilities to ensure integrity of all data related to manufacturing and quality.\u003C\u002Fp>\n\n\u003Cp>C. You failed to have adequate oversight of laboratory investigations and to implement a systemic CAPA to address the high number of aborted chromatographic sequences. For example:\u003C\u002Fp>\n\n\u003Cp>1. You invalidated multiple out-of-specification (OOS) results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP without adequate scientific justification. You then prepared new samples and reported passing results. You concluded the OOS results may be due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination during initial sample preparation. However, the laboratory investigation, which was approved by QA, did not discuss why other samples in the same analysis of lots, from the same material, prepared by the same analyst, under the same test conditions, were not affected by such contamination.\u003C\u002Fp>\n\n\u003Cp>2. You aborted hundreds of chromatographic sequences in your QC laboratories between January 2020 to November 2022. Each of the incidents were investigated by the quality control laboratory; however, you lacked adequate trending and CAPA systems to evaluate and identify recurring issues that should be targeted for laboratory improvements.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the need to enhance your processes and practices for investigating laboratory deviations, applying CAPAs, and checking their effectiveness. In addition, you acknowledge the current trending procedures lack systematic tools for conducting evaluations and implementing effective corrective actions.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response did not adequately address how you will implement systems to identify and address adverse laboratory incident trends, or provide an overall management strategy for improving all phases of your laboratory investigations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QA disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>\n&nbsp; &nbsp; o Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products irrespective of whether the batch was ultimately distributed in the United States for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; &nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\u003Cbr>\n&nbsp; &nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems (e.g., PLC).\u003Cbr>\n&nbsp; &nbsp; o A list of all software configurations (both equipment software and LIMS) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; &nbsp; o System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; &nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; &nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; &nbsp; o In addition to interim data retention measures, also provide more comprehensive and sustainable CAPA for retention of all CGMP data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>\n&nbsp; &nbsp; o Technological improvements to increase the integration of data generated through electronic systems from standalone equipment (e.g., balances, pH meters, water content testing) into the LIMS network.\u003Cbr>\n&nbsp; &nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; &nbsp; o Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; &nbsp; o Provisions for oversight from QA managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A. Your laboratory records lacked complete and accurate data to support the analysis performed. Colony forming units (CFU) were not counted accurately in the laboratory's environmental monitoring (EM) data. Our investigators observed colony counts shortly after being read by your analyst for environmental and personnel monitoring that did not match your official records.\u003C\u002Fp>\n\n\u003Cp>Your analyst undercounted carboplatin injection batch EM data by recording two merged colonies as one CFU, despite your procedure stating, “If merged colonies are observed, count it as a separate colony.” Your laboratory identification instrument subsequently identified the joined colonies as two different species.\u003C\u002Fp>\n\n\u003Cp>Notably, you firm indicated no EM results were outside of action limits for Grade A (ISO 5) sample locations from January 2020 until our inspection in November 2022.\u003C\u002Fp>\n\n\u003Cp>B. Laboratory raw data was missing and could not be provided during the inspection. For example, analysts did not consistently include \u003Cstrong>(b)(4)\u003C\u002Fstrong> printout raw data in laboratory records. Paper printouts for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> determinations and pH printouts could not be reconciled for \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, process validation batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Because the \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument lacked audit trail capabilities, unreported raw data could not be detected during the QA review process.\u003C\u002Fp>\n\n\u003Cp>Failing to maintain complete records of the data and testing conditions associated with all tests significantly compromises the reliability of data and your QA’s ability to perform its obligation to assure quality through conformance with CGMP.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge EM samples are not counted accurately and that “laboratory practice was to count colonies that merge together with similar morphology, as one colony.” You opened EM investigations for action and alert samples and commit to working with an independent third-party consultant. We also acknowledge you provided modular training for microbiologists and revised standard operating procedures (SOPs).\u003C\u002Fp>\n\n\u003Cp>You also state you investigated the missing \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument print-outs but were unable to definitively determine the root cause of the missing laboratory data. You commit to improvements to the SOPs related to reconciliation of reported results with raw data.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide the opened investigations or updates to the investigations regarding the EM data or missing laboratory data. You did not commit to a retrospective review and risk assessment of personnel and environmental monitoring data. You did not commit to investigate the impact of missing laboratory data on the process validation batches.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow required laboratory control mechanisms (21 CFR 211.160(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to have appropriate procedures for the integration of chromatographic peaks and for the review of chromatographic data.\u003C\u002Fp>\n\n\u003Cp>Our inspection team identified examples of your analysts entering manual integration events that yielded passing results without adequate procedural controls or justification.\u003C\u002Fp>\n\n\u003Cp>In addition, your chromatographic data integration procedure is inadequate because it does not identify when it is appropriate for an analyst to input manual integration events. Your procedure lacked a requirement for supervisory approval and other controls such as data review and justification to consistently document when and why an analyst manually performs integration events.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the observation and states you misunderstood the regulatory expectation of controls for manual integration. You commit to software upgrades which will maintain all processing parameters and methods. And you commit to working with a qualified third-party consultant to perform an overall baseline audit of the QC laboratories.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not commit to performing a retrospective review of all chromatographic data associated with manual integration. We acknowledge your commitment to work with a third-party to audit your QC laboratories; however, you did not provide details such as the scope of this audit or ongoing third-party laboratory activities. You also did not adequately address oversight of the QC laboratory by your QA department and any additional controls to be added to improve consistency of chromatographic practices.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Include an assessment of all test methods and procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and have been appropriately validated to determine whether they are fit for purpose. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A comprehensive review and remediation plan for your out-of-specification (OOS) result investigation systems. The corrective action and preventive action (CAPA) should include, but not be limited to, addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequate scoping of each investigation and its CAPA\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately validate the manufacturing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. Specifically, your process validation lacked an evaluation of inter-batch and intra-batch variability observed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurities and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>A fourth process validation batch for \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg was initiated to evaluate related substances from different positions within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to the incomplete impurity testing. This fourth process validation batch yielded a high OOS result for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurity. This OOS and failure of the fourth process validation batch was not referenced or discussed in the validation summary report or addendum. A fifth process validation batch was manufactured and included in the addendum report. You subsequently rejected a commercial batch for the U.S. market, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to a high OOS result for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurity.\u003C\u002Fp>\n\n\u003Cp>In your response you acknowledge the validation program does not evaluate inter-batch and intra-batch variability. You commit to revising your validation program to establish a process to analyze test data within and across batches and to consistently assess the variability of the production process. In addition, you state you will review equipment qualification to evaluate capabilities of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response did not address the omission of the failed fourth process validation batch for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurity in the approved QA validation report and addendum. Furthermore, your CAPA did not include evaluation of other drug product process validation studies that may be similarly deficient to ensure processes and equipment have adequate data to support their capabilities.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\u003Cbr>\n&nbsp; &nbsp; o A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing\u003Cbr>\n&nbsp; &nbsp; o Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Scrutiny of raw material variability from suppliers\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Quality signals from both internal data and customers\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\u003Cbr>\n&nbsp; &nbsp; o Based on this assessment, provide a CAPA to address any deficiencies in your process validation program\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your QA department did not ensure raw materials used in the manufacture of drug products were appropriately tested. Your firm failed to perform method validation (or verification, as appropriate) of test methods to ensure that they were suitable for their intended use. You provided a list of multiple in-house methods and compendial methods which have not been validated or verified, including for raw materials such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Method validation and verification is necessary to support reliable determination of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that your laboratory data accurately reflects drug product quality.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge all materials used for manufacturing need to be tested using methods that have been validated or verified. You commit to reviewing the procedures governing method validation and method verification as well as technical transfer to ensure that the procedures comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed, independent assessment of all test methods to evaluate if they include sufficiently specific instructions to ensure repeatability, are supported by adequate validation (or verification, for United States Pharmacopeia (USP) compendial methods) studies, and are appropriate for their intended use. The assessment should also determine whether test methods used in the stability program are stability-indicating. The scope of the assessment should encompass any tests conducted by your firm or its contract laboratories.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Other Inspectional Findings\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your plan to conduct new smoke studies under dynamic conditions to improve your evaluation of the effect of interventions and interactions (i.e., mobile cart transfers, other material transfers) on airflow within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Restricted Access Barrier System (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS). In your response to this letter, provide updated static and dynamic smoke studies, or a commitment to provide these studies upon their completion.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>A. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003C\u002Fli>\n\t\u003Cli>Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>B. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>C. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\t\u003Cli>A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003C\u002Fli>\n\t\u003Cli>Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003C\u002Fli>\n\t\u003Cli>Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003C\u002Fli>\n\t\u003Cli>A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003C\u002Fli>\n\t\u003Cli>Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to ensure any potential breach is investigated.\u003C\u002Fli>\n\t\u003Cli>A status report for any of the above activities already underway or completed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In previous inspections, including the inspection of May 20-28, 2019 FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Test Results Out-of-Specification\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision. A possible laboratory error is insufficient to close an investigation at Phase 1. Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Validation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on June 1, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Intas Pharmaceutical Limited at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004011473 and ATTN: Erika V. Butler.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nimish Chudgar\n\nRecipient Title\n\nChief Executive Officer & Managing Director\n\nIntas Pharmaceuticals Limited\n\nPlot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\n\nThaltej, Ahmedabad 382213\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-20\n\nJuly 28, 2023\n\nDear Mr. Chudgar:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3004011473, at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India, from November 22 to December 02, 2022.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 27, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYou failed to ensure reliability of data relating to the quality of medicines produced at your facility. Our inspection revealed serious deviations, including but not limited to, inadequate oversight of original CGMP documents, deficient controls over computerized systems, insufficient laboratory investigations, and aborted chromatographic sequences.\n\nSenior facility managers failed to exercise their authority and responsibility to ensure reliable data, leading to severe data integrity deficiencies in your production and laboratory departments. These findings also indicate that your quality assurance function is not exercising its responsibilities, including but not limited to, oversight and control over the adequacy and reliability of CGMP data used throughout your operation.\n\nA. You failed to assure integrity of analytical testing data. Some examples include:\n\n1. Our investigators observed plastic bags filled with torn and discarded original CGMP documents in your quality control (QC) scrap area under a stairwell, in your general parenteral scrap room, and on a truck outside your facility. Among these CGMP documents were engineering checklists associated with the Environmental Monitoring System (EMS), torn Karl Fischer (KF) analytical test reports, auto titration curves, and analytical balance weight slips for finished drug products.\n\n2. An analyst destroyed CGMP records by pouring acetic acid in a trash bin containing analytical balance slips for testing the standardization of (b)(4). A QC employee stated he observed the same analyst destroy KF titration curves and balance printouts. The employee reported the incident to QC laboratory management on November 22, 2022. An investigation into the destruction of the torn CGMP documents and the impact to your drug product quality was not initiated until November 28, 2022.\n\n3. An analyst weighed out the same samples of amitriptyline hydrochloride tablets USP 100 mg batches multiple times for (b)(4) by (b)(4) test. The analyst stated to our investigator that he did not report all the test results, further stating that in some instances balance printouts were discarded in the trash. In addition, the time stamp on each of the analytical balance and (b)(4) printouts did not match your Laboratory Information Management System (LIMS) records.\n\nIn your response, you commit to working with a qualified consultant to perform an overall baseline assessment of data integrity and governance controls, and to establish a remediation plan.\n\nYour response is inadequate in that it did not fully evaluate the scope of this deficiency and the impact to product quality. You did not adequately address the major failure of laboratory, operations, and quality assurance management to conduct proper oversight over documentation and prevent data integrity lapses.\n\nB. Your department failed to exercise appropriate controls over computerized systems. For example:\n\n1. Your electronic batch records allowed changes to be made to manual entries prior to saving. Our inspector observed a production employee manually alter the reported time that an operation was performed. QA did not review audit trails as part of their batch record review to identify discrepancies and compare the reported date and time against that which was originally logged.\n\n2. Analysts manually reprocessed chromatograms by adding integration events that were not approved by QC management. In addition, you lacked appropriate procedures describing when the analyst can manually input integration events, how these events should be used, or how they should be reviewed.\n\n3. Destroyed KF raw data paper printouts associated with drug products were discovered by our inspection team in a trash bag. The KF instrument used for water content testing and assay testing is capable of storing electronic data; however, this capacity was not utilized, and you did not save this data electronically.\n\n4. Your 2018 Process Equipment Assessment Report identified numerous gaps and deficiencies for electronic manufacturing equipment needing upgrades in access controls, audit trails, saving electronic data and preventing clock alterations. You had not documented closures of these corrective action and preventive action (CAPA) measures to support data integrity in your computerized systems. Your QA department had not performed a similar assessment in your QC laboratories.\n\nIn your response, you acknowledge the inspection findings and you reference your standard operating procedure titled, “Data Integrity,” which stipulates the individuals permitted to make changes in an electronic record and requires audit trails to capture those actions. You also commit to obtaining expertise from a qualified consultant to systematically address the deviations, as part of the baseline assessment.\n\nYour response is inadequate. Although you established procedures, you did not explain the critical failure of laboratory and operations management in not providing adequate oversight of data integrity of computer systems. You also did not address the failure of the QA department to fully exercise its authority and responsibilities to ensure integrity of all data related to manufacturing and quality.\n\nC. You failed to have adequate oversight of laboratory investigations and to implement a systemic CAPA to address the high number of aborted chromatographic sequences. For example:\n\n1. You invalidated multiple out-of-specification (OOS) results for (b)(4) USP without adequate scientific justification. You then prepared new samples and reported passing results. You concluded the OOS results may be due to (b)(4) contamination during initial sample preparation. However, the laboratory investigation, which was approved by QA, did not discuss why other samples in the same analysis of lots, from the same material, prepared by the same analyst, under the same test conditions, were not affected by such contamination.\n\n2. You aborted hundreds of chromatographic sequences in your QC laboratories between January 2020 to November 2022. Each of the incidents were investigated by the quality control laboratory; however, you lacked adequate trending and CAPA systems to evaluate and identify recurring issues that should be targeted for laboratory improvements.\n\nIn your response, you acknowledge the need to enhance your processes and practices for investigating laboratory deviations, applying CAPAs, and checking their effectiveness. In addition, you acknowledge the current trending procedures lack systematic tools for conducting evaluations and implementing effective corrective actions.\n\nYour response is inadequate. Your response did not adequately address how you will implement systems to identify and address adverse laboratory incident trends, or provide an overall management strategy for improving all phases of your laboratory investigations.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QA disposition decision.\n\no Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products.\n\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products irrespective of whether the batch was ultimately distributed in the United States for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but not be limited to:\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems (e.g., PLC).\n\no A list of all software configurations (both equipment software and LIMS) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no In addition to interim data retention measures, also provide more comprehensive and sustainable CAPA for retention of all CGMP data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\n\no Technological improvements to increase the integration of data generated through electronic systems from standalone equipment (e.g., balances, pH meters, water content testing) into the LIMS network.\n\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\n\no Provisions for oversight from QA managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\n\n2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nA. Your laboratory records lacked complete and accurate data to support the analysis performed. Colony forming units (CFU) were not counted accurately in the laboratory's environmental monitoring (EM) data. Our investigators observed colony counts shortly after being read by your analyst for environmental and personnel monitoring that did not match your official records.\n\nYour analyst undercounted carboplatin injection batch EM data by recording two merged colonies as one CFU, despite your procedure stating, “If merged colonies are observed, count it as a separate colony.” Your laboratory identification instrument subsequently identified the joined colonies as two different species.\n\nNotably, you firm indicated no EM results were outside of action limits for Grade A (ISO 5) sample locations from January 2020 until our inspection in November 2022.\n\nB. Laboratory raw data was missing and could not be provided during the inspection. For example, analysts did not consistently include (b)(4) printout raw data in laboratory records. Paper printouts for the (b)(4) determinations and pH printouts could not be reconciled for (b)(4) injection, (b)(4) mg, process validation batch (b)(4).\n\nBecause the (b)(4) instrument lacked audit trail capabilities, unreported raw data could not be detected during the QA review process.\n\nFailing to maintain complete records of the data and testing conditions associated with all tests significantly compromises the reliability of data and your QA’s ability to perform its obligation to assure quality through conformance with CGMP.\n\nIn your response, you acknowledge EM samples are not counted accurately and that “laboratory practice was to count colonies that merge together with similar morphology, as one colony.” You opened EM investigations for action and alert samples and commit to working with an independent third-party consultant. We also acknowledge you provided modular training for microbiologists and revised standard operating procedures (SOPs).\n\nYou also state you investigated the missing (b)(4) instrument print-outs but were unable to definitively determine the root cause of the missing laboratory data. You commit to improvements to the SOPs related to reconciliation of reported results with raw data.\n\nYour response is inadequate. You did not provide the opened investigations or updates to the investigations regarding the EM data or missing laboratory data. You did not commit to a retrospective review and risk assessment of personnel and environmental monitoring data. You did not commit to investigate the impact of missing laboratory data on the process validation batches.\n\nIn response to this letter, provide:\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n3. Your firm failed to establish and follow required laboratory control mechanisms (21 CFR 211.160(a)).\n\nYour firm failed to have appropriate procedures for the integration of chromatographic peaks and for the review of chromatographic data.\n\nOur inspection team identified examples of your analysts entering manual integration events that yielded passing results without adequate procedural controls or justification.\n\nIn addition, your chromatographic data integration procedure is inadequate because it does not identify when it is appropriate for an analyst to input manual integration events. Your procedure lacked a requirement for supervisory approval and other controls such as data review and justification to consistently document when and why an analyst manually performs integration events.\n\nIn your response, you acknowledge the observation and states you misunderstood the regulatory expectation of controls for manual integration. You commit to software upgrades which will maintain all processing parameters and methods. And you commit to working with a qualified third-party consultant to perform an overall baseline audit of the QC laboratories.\n\nYour response is inadequate. You did not commit to performing a retrospective review of all chromatographic data associated with manual integration. We acknowledge your commitment to work with a third-party to audit your QC laboratories; however, you did not provide details such as the scope of this audit or ongoing third-party laboratory activities. You also did not adequately address oversight of the QC laboratory by your QA department and any additional controls to be added to improve consistency of chromatographic practices.\n\nIn response to this letter, provide:\n\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Include an assessment of all test methods and procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and have been appropriately validated to determine whether they are fit for purpose. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA comprehensive review and remediation plan for your out-of-specification (OOS) result investigation systems. The corrective action and preventive action (CAPA) should include, but not be limited to, addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequate scoping of each investigation and its CAPA\n\nRevised OOS investigation procedures with these and other remediations\n\n4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to adequately validate the manufacturing process for (b)(4) injection (b)(4) mg. Specifically, your process validation lacked an evaluation of inter-batch and intra-batch variability observed for (b)(4) impurities and (b)(4).\n\nA fourth process validation batch for (b)(4) injection (b)(4) mg was initiated to evaluate related substances from different positions within the (b)(4) due to the incomplete impurity testing. This fourth process validation batch yielded a high OOS result for the (b)(4) impurity. This OOS and failure of the fourth process validation batch was not referenced or discussed in the validation summary report or addendum. A fifth process validation batch was manufactured and included in the addendum report. You subsequently rejected a commercial batch for the U.S. market, (b)(4), due to a high OOS result for the (b)(4) impurity.\n\nIn your response you acknowledge the validation program does not evaluate inter-batch and intra-batch variability. You commit to revising your validation program to establish a process to analyze test data within and across batches and to consistently assess the variability of the production process. In addition, you state you will review equipment qualification to evaluate capabilities of the (b)(4).\n\nYour response is inadequate. Your response did not address the omission of the failed fourth process validation batch for the (b)(4) impurity in the approved QA validation report and addendum. Furthermore, your CAPA did not include evaluation of other drug product process validation studies that may be similarly deficient to ensure processes and equipment have adequate data to support their capabilities.\n\nIn response to this letter, provide:\n\nProvide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\n\no A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\n\no A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing\n\no Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\n\n Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\n\n Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\n\n Scrutiny of raw material variability from suppliers\n\n Quality signals from both internal data and customers\n\n How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\n\no Based on this assessment, provide a CAPA to address any deficiencies in your process validation program\n\n5. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYour QA department did not ensure raw materials used in the manufacture of drug products were appropriately tested. Your firm failed to perform method validation (or verification, as appropriate) of test methods to ensure that they were suitable for their intended use. You provided a list of multiple in-house methods and compendial methods which have not been validated or verified, including for raw materials such as (b)(4).\n\nMethod validation and verification is necessary to support reliable determination of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that your laboratory data accurately reflects drug product quality.\n\nIn your response, you acknowledge all materials used for manufacturing need to be tested using methods that have been validated or verified. You commit to reviewing the procedures governing method validation and method verification as well as technical transfer to ensure that the procedures comply with FDA regulations.\n\nIn response to this letter, provide:\n\nA detailed, independent assessment of all test methods to evaluate if they include sufficiently specific instructions to ensure repeatability, are supported by adequate validation (or verification, for United States Pharmacopeia (USP) compendial methods) studies, and are appropriate for their intended use. The assessment should also determine whether test methods used in the stability program are stability-indicating. The scope of the assessment should encompass any tests conducted by your firm or its contract laboratories.\n\nOther Inspectional Findings\n\nWe acknowledge your plan to conduct new smoke studies under dynamic conditions to improve your evaluation of the effect of interventions and interactions (i.e., mobile cart transfers, other material transfers) on airflow within the (b)(4) Restricted Access Barrier System ((b)(4)RABS). In your response to this letter, provide updated static and dynamic smoke studies, or a commitment to provide these studies upon their completion.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\n\nWe acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\n\nA. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\nA detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\nInterviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nA comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nB. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nC. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\n\nA detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\nA comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\nInterim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\nLong-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\nA commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\nInform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to ensure any potential breach is investigated.\n\nA status report for any of the above activities already underway or completed.\n\nRepeat Observations at Facility\n\nIn previous inspections, including the inspection of May 20-28, 2019 FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nTest Results Out-of-Specification\n\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision. A possible laboratory error is insufficient to close an investigation at Phase 1. Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\n\nProcess Validation\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nFDA placed your firm on Import Alert 66-40 on June 1, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Intas Pharmaceutical Limited at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004011473 and ATTN: Erika V. Butler.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n__________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","intas-pharmaceuticals-limited-652067-07282023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-652067-07282023","2026-10-26T08:08:59.43293+00:00","2023-08-01","652067","2026-08-20T00:49:55.281+00:00","2023-07-28",88,{"510k":403,"classification":404,"enforcement":405,"event":406,"event_backfill":407,"pma":408,"warning_letter":409},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]